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Abstract
Nitric oxide (NO) is an important signalling molecule of the central nervous system 
(CNS), immune system and vascular endothelium. In the vascular system NO acts as a 
vasodilator as well as having anti-thrombotic and atheroprotective functions. The 
development of cardiovascular disease (CVD) is a complex multifactorial process 
known to have a heritable component. The aim of this study therefore was to 
investigate the role of three candidate genes involved in regulation of NO synthesis and 
susceptibility to CVD.
This study investigated the association between cardiovascular risk factors and 
polymorphisms in the p22phox subunit of NADPH oxidase, GTPCH1 and DDAH2. 
This study showed the previously identified C242T polymorphism in p22phox was 
associated with endothelium-dependent vasodilation in healthy subjects. Individuals 
homozygous for the T allele exhibited increased endothelium-dependent vasodilation 
compared to C allele carriers. Single strand conformational polymorphism analysis 
(SSCP) identified four polymorphisms within the GCH1 gene, three in the promoter (- 
577G/A, -741T/C and -796G/A) and one in intron 1 (599C/G). Genotyping of 2390 
healthy men revealed an association between the -796 and -577 polymorphisms and 
circulating levels of neopterin. An association was also found between -796 genotype 
and endothelial function in a second cohort of 246 healthy subjects. SSCP of the 
DDAH2 gene identified six polymorphisms. Five in the promoter region at position - 
1415G/A, -1151C/A, -1020C/G, -871 6G/7G and -449C/G and the sixth at position 
618C/T within intron 4. No significant associations were identified between DDAH2
genotype and ADMA, SDMA ADMA/SDMA ratio or other cardiovascular disease risk 
factors in healthy subjects, renal failure patients or diabetics.
In conclusion, this study has identified common polymorphisms in enzymes affecting 
NO synthesis or inactivation. Polymorphisms in the p22phox gene and GTPCH1 gene 
were associated with risk factors for cardiovascular disease including endothelium- 
dependent vasodilation and plasma neopterin (a marker of BH4).
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CHAPTER 1 
INTRODUCTION
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1.1 Cardiovascular diseases and endothelial function
1.1.1 Background
Atherosclerosis leads to stroke, coronary heart disease (CHD) and peripheral vascular 
disease and is a major cause of death and morbidity. In the developed world it accounts 
for over four million deaths every year in Europe (British Heart Foundation, 
www.dphpc.ox.ac.uk), and as a disease it is assuming greater importance in the 
developing world (Perret et al., 2000). Atherosclerosis is characterized by the 
development of atherosclerotic plaques in large and medium sized arteries. Early 
plaques are evident by the second decade of life (McGill et al., 2000) and their 
development is initiated and accelerated by damage to the endothelium. Atherosclerotic 
plaques consist of a core rich in cholesterol and other lipids, which are surrounded by 
smooth muscle cells and fibrous tissue (Figure 1.1). The formation of plaques is 
preceded initially by damage to the endothelium mediated by factors such as increased 
blood pressure, products of cigarette smoke, high levels of cholesterol, circulating 
oxidized low density lipoprotein (oxLDL) cholesterol and inflammatory cytokines 
(Ross et al., 1993). This leads to the adhesion of leukocytes to the vessel wall, their 
migration into the sub-endothelial space and the uptake of cholesterol rich lipid particles 
by macrophages (Libby, 2000). Proliferation of the underlying smooth muscle cells 
triggered by the release of growth factors eventually leads to a decrease in the size of 
the vessel lumen. Plaque fissure or rupture results in the exposure of plaque contents to 
the circulating blood, thrombus formation and occlusion of the vessel, which is 
responsible for myocardial infarction and some forms of stroke. The risk of developing 
vascular disease is highly increased in the presence of renal failure (Foley, 1998a;
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Foley, 1998b) and diabetes (Ginsberg, 2000; Haffner et al., 1999), however onset 
cannot always be solely attributed to environmental factors. The genetic makeup of an 
individual is now being recognized as having a vital role in vascular disease risk 
(Boerwinkle et al., 1996). The past 20 years have seen huge developments in the field 
of genetics and molecular biology, in particular the advance of the human genome 
project (International Human Genome Sequencing Consortium, 2001), which has made 
possible the identification, isolation and characterization of a multitude of genes 
implicated in medical disorders including cardiovascular disease (CVD).
Adventitia Vessel lumen
Endothelium
Lipid rich 
plaque
Media
Thrombus
Fissure
Figure 1.1. Schematic illustration of an atherosclerotic plaque within an artery. The
lumen of the vessel is narrowed by the presence of the plaque, which contains cholesterol and 
other lipids. Rupture of the fibrous cap results in thrombus formation leading ultimately to 
occlusion of the vessel.
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1.1.2 Maintenance of a healthy vasculature-role of the endothelium
The endothelium consists of a monolayer of cells lining all blood vessels. It serves as a 
permeability barrier between the circulating blood and the vessel wall. However, its 
role is not simply that of an inert barrier. Receptors on the endothelial cell surface act 
as sensors of the biochemical and physical environment of the blood, responding to 
chemical signals such as serotonin, bradykinin, and shear stress, which prompts this 
single layer of cells to release anti-adhesive, anti-thrombotic, vasoconstrictor and 
vasorelaxant mediators, thereby ensuring a state of vascular homeostasis.
The involvement of the endothelium in the process of atherosclerotic disease had been 
suggested as early as the 1800s (Virchow, 1856), but the mechanisms involved have 
only recently been identified. The essential role of the endothelium for vascular 
relaxation was first discovered by Furchgott and Zawadski in a series of experiments in 
which they demonstrated that removal of the endothelium completely inhibited 
relaxation of rabbit thoracic aorta to acetylcholine (Furchgott and Zawadski, 1980). 
This observation led to the discovery of a highly potent vasodilator originally named 
endothelium-derived relaxant factor (EDRF). EDRF was subsequently identified as 
nitric oxide (NO) (Ignarro et al., 1987), which is capable of exerting many athero- 
protective, anti-thrombotic and anti-inflammatory actions upon the vasculature and is 
discussed in more detail in section 1.2. The endothelium also releases other vasodilator 
molecules, for example prostacyclin and endothelium-derived hyperpolarizing factor 
(EDHF) as well as vasoconstrictors such as endothelin and angiotensin II (Figure 1.2). 
Production of these mediators is stimulated by physical factors (e.g. increased flow at 
the endothelial surface) as well as the binding of agonists including acetylcholine (ACh)
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and bradykinin (Bk) to receptors on the endothelial cell surface. However, in the 
presence of a dysfunctional endothelium some of these agonists (e.g. ACh) are also 
capable of inducing vasoconstriction by binding to receptors on underlying vascular 
smooth muscle cells (VSMC).
Atherosclerotic plaques form predominantly at the sites of arterial branch points where 
there is disturbed laminar flow (Comhill et al., 1976). This led to the theory that 
external forces upon endothelial cells such as shear stress (generated by the flow of 
blood over the endothelium) play a part in regulating endothelial cell function. 
Subsequent studies revealed that a number of genes expressed by the endothelium 
(including the gene encoding the enzyme for NO synthesis), are upregulated by shear 
stress (Resnick et al., 1995), suggesting that the hemodynamic forces generated by 
blood flow can indeed direct endothelial function.
Vascular homeostasis is therefore maintained through the balanced production of a 
range of vasoactive substances. Dysfunction of the endothelium caused by elevated 
blood cholesterol, hyperglycemia and hypertension are known to increase endothelial 
cell permeability, the expression of adhesion molecules and restrict the release of 
vasodilators such as NO. This ultimately manifests in the development of 
atherosclerosis and vascular disease.
Endothelial function in humans in vivo is often measured using one of two techniques- 
venous occlusion plethysmography which measures endothelial function in small 
resistance vessels and flow mediated dilatation (FMD) which measures endothelial 
function in the brachial artery, a conduit vessel. Venous occlusion plethysmography
24
measures the change in blood flow in the forearm in response to endothelium-dependent 
agonists. A cuff is placed on the upper arm and periodically inflated to prevent venous 
return. A strain-gauge placed around the forearm measures the change in forearm 
circumference in millimetres per minute which is proportional to arterial blood inflow 
during the period of occlusion (Benjamin et al., 1995). Insertion of a needle into the 
brachial artery allows administration of endothelium-dependent vasodilators such as 
ACh or Bk, and endothelium-independent control dilators such as GTN. FMD 
measures brachial artery diameter in response to increased blood flow. A cuff placed 
around the forearm is inflated to suprasystolic pressure to make the arm ischemic. 
When the cuff is deflated, the flow of blood into the ischemic arm and the resulting 
shear stress produced in the brachial artery causes NO release and dilatation. This 
dilatation is endothelium-dependent and can be measured using an ultrasound device 
(Celermajer et al., 1992). Endothelial dysfunction determined by venous occlusion 
plethysmography or FMD correlates with coronary endothelial dysfunction and is 
indicative of vascular disease (Vita et al., 1990). Endothelial dysfunction also correlates 
with cardiovascular risk factors as assessed by the Framingham risk score (Chan et al., 
2001) and predicts cardiovascular outcome (Suwaidi et al., 2000; Schachinger et al., 
2000).
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Figure 1.2. Diagrammatic representation of the vascular endothelium and 
underlying smooth muscle cells. A. The endothelium produces substances such as 
nitric oxide, which has anti-atherogenic and vasorelaxant properties essential for 
maintaining a healthy vasculature. B. In the presence of risk factors for CVD such as 
hypercholesterolaemia, hypertension and diabetes there is increased endothelial cell 
adhesiveness and permeability. Nitric oxide availability is decreased and consequently 
its anti-atherogenic and relaxant properties are attenuated.
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1.1.3 Heritability of vascular disease
Common complex diseases such as atherosclerosis, hypertension, diabetes, and cancer 
are believed to be caused through the interaction of an individuals genes and the 
environment. Such diseases tend to be of late onset, have no clear pattern of inheritance 
and as a result the causative genes and risk factors have been difficult to identify. 
However, rare monogenic forms of these diseases such as autosomal dominant Familial 
hypercholesterolaemia (FH), autosomal dominant hypertension due to Liddle’s 
syndrome, familial breast cancer and monogenic forms of type II diabetes have helped 
us to understand the pathophysiological basis of the complex disease state.
Table 1.1 gives three examples of monogenic diseases resulting in elevated LDL or 
blood pressure, which are risk factors for CVD development. FH is caused by 
mutations in the low-density lipoprotein receptor (LDLR) gene (Hobbs et al., 1992), and 
is one of the most common autosomal inherited disorders, with 1 out of every 500 
individuals affected (Smilde et al., 2001). Individuals who carry the mutant gene are 
characterized by elevated LDL cholesterol, due to the fact that it cannot be removed 
from the circulation. To date more than 500 mutations have been reported in the LDL 
receptor gene, resulting in a decrease in the number of receptors (in the case of 
heterozygote individuals) or a complete absence of receptors (homozygote individuals) 
on the liver cell surface. This directly results in elevated circulating LDL leading to 
vascular disease.
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Disease Mutant Gene Inheritance Effect
Familial
hypercholesterolaemia (FH) LDLR AD t  LDL
Liddle’s syndrome ENaC AD T blood pressure
Glucocorticoid-remedial
aldosteronism (GRA) Aldosterone synthase AD T blood pressure
Table 1.1 Monogenic diseases. Three examples of monogenic diseases, which 
result in the development of premature CVD, and their respective mutant genes are 
shown. The study of such disorders and the identification of the causative genes, has 
helped improve our understanding of the more complex cardiovascular diseases
Advances in molecular biology have also enabled the identification of a vast number of 
candidate genes implicated in the development of common forms of atherosclerosis. 
CVD is therefore thought to be polygenic (caused by several genes) with a major 
contribution coming from environmental factors e.g. smoking. The Apolipoprotein E 
gene (.ApoE) is another gene known to be involved in the development of vascular 
disease (Eichner et al., 2002). This gene encodes a protein, which acts as a ligand 
expressed on the surface of LDL particles, via which, LDL particles are cleared from 
the circulation by binding to the LDL receptor. Three variants of this gene are known to 
exist-E2, E3 and E4. The E2 isoform has the lowest affinity for the LDL-receptor and 
E4 the highest affinity. Individuals homozygous for the E2 isoform are predisposed to 
develop elevated cholesterol and triglyceride levels leading to premature atherosclerosis 
but, unlike FH, disease progression is also influenced strongly by environmental factors 
such as diet, obesity and diabetes. ApoE genotype is therefore classed as a risk factor
for CVD.
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1.1.3.1 Evidence for a heritable basis for atherosclerosis
Studies of the offspring of patients with premature cardiovascular disease show that 
structural and functional changes are present in arteries even before the onset of disease 
and such individuals may be at increased risk of developing atherosclerosis (Gaeta et 
al., 2000). Impaired endothelium dependent flow mediated dilatation (FMD) has been 
reported in individuals with a positive family history of coronary artery disease (CAD), 
and was most pronounced in those individuals who both themselves and also their 
affected first degree relative were free from conventional risk factors such as smoking 
and diabetes (Clarkson et al., 1997; Gaeta et al., 2000). Some of the most convincing 
evidence for a genetic contribution to common forms of cardiovascular diseases comes 
from studies of twins. In a follow-up study of 21,000 twins Marenberg et al in 1994 
and Zdravkovic et al in 2002 found that in twin pairs, the risk of a CHD event in the 
second twin of a monozygotic pair (who share 1 0 0 % of their genes) was 2 -fold higher 
than that for a second twin of a dizygotic pair, (who share only 50% of their genes). 
This evidence suggests that both atherosclerosis and the endothelial dysfunction that 
may underlie it are at least in part heritable disorders. Screening of populations at high 
risk of developing CVD is an important strategy for preventing disease onset and 
progression, and genetic association studies have been used extensively to try and locate 
and identify genes that could influence susceptibility to vascular diseases.
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1.1.4 Candidate genes for CVD
The process of atherosclerosis development, plaque formation and eventual rupture 
involves many proteins and pathways. Each protein is encoded by its own gene, and 
variation in the coding sequence of these genes due to polymorphisms or mutation may 
result in individual differences in protein expression or function and predisposition to 
disease. Both polymorphisms and mutations refer to alteration in the nucleotide 
sequence of a gene such as base substitutions or insertion/deletion of a nucleotide. Rare 
mutations usually occurring in less than 1 % of the population are well known causes of 
monogenic disorders such as cystic fibrosis or sickle cell disease. Conventionally, 
polymorphisms are classed as more common sequence changes occurring throughout 
the genome. Common polymorphisms may be silent but some may increase the risk of 
developing common disorders such as atherosclerosis. Additional polymorphisms or 
environmental factors may modulate this risk. Both polymorphisms and mutations may 
result in a change in the protein sequence with the consequence of altered protein 
function or, if  the change lies within the promoter, a change in gene expression. 
Changes in protein function may be the result of nucleotide alterations such as missense 
mutations (causing a change in amino acid), nonsense mutations (resulting in a stop 
codon and therefore premature termination of translation) or frameshift mutations 
(causing a change in the reading frame). It has been reported that approximately 1.42 
million single nucleotide polymorphisms (SNP) exist throughout the human genome, 
with on average one SNP every 1300bp (The International SNP Map Working Group,
2001). Single nucleotide polymorphisms may lie within the coding regions of genes (c- 
SNPs), within promoters (p-SNPs) or in introns. Although, many c-SNPs may be 
‘silent’ (fail to alter the amino acid sequence of the protein), others alter amino acid
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sequence and, consequently, protein activity. P-SNPs may influence protein function 
through regulation of protein expression. In each case, it is envisaged that carriage of 
the variant is entirely compatible with health, but in the presence of adverse 
environmental factors or additional risk alleles in other genes, disease develops.
Like all multi-factorial diseases, the identification of a causative gene (or genes) is 
proving to be a difficult task for CVD. Association analysis of polymorphisms in 
candidate genes has led to the study of hundreds of possible genes including those 
encoding cytokines, adhesion molecules, growth factors and coagulation-fibrinolysis 
mediators. In addition, genes encoding enzymes involved in the regulation of blood 
pressure such as the renin-angiotensin system, lipid metabolism and also the nitric oxide 
system have been included in this search. A few of these genes and their 
polymorphisms, which have been investigated for association with risk of CVD are 
shown in table 1.2. A recent study in which 4152 Japanese individuals were genotyped 
for 112 polymorphisms in 71 candidate genes for myocardial infarction (MI), identified 
the 1019C/T polymorphism in the connexin 37 gene and the p22phox 242C/T 
polymorphism to be associated with increased risk of MI in men, and the - 6 8 8  4G/5G 
plasminogen activator inhibitor (PAI) polymorphism and -1171 5A/6A stromelysin 1 
polymorphism to be associated with increased risk of MI in women (Yamada et al., 
2002). The endothelial nitric oxide synthase gene (NOS 3) has also been the focus of 
several association studies for CVD. In particular, the -786T/C and Glu298Asp 
polymorphisms have been associated with increased risk of vascular disease (Nakayama 
et al., 1999; Hingorani et al., 1999; Miyamoto et al., 1998; Yoshimura et al., 1998). 
Such large-scale association studies between candidate genes and CVD have been aided 
by the completion of the first draft of the human genome sequence (International
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Human Genome Sequencing Consortium, 2001) and subsequent generation of a 
comprehensive single nucleotide polymorphism (SNP) database. Improved high 
throughput genotyping techniques have also revolutionized the speed at which 
association studies can be performed with hundreds of individuals genotyped for 
multiple polymorphisms each day.
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Gene Gene symbol Polymorphism Amino acid change
Nitric oxide system
Nitric oxide synthase 3 NOS 3 894G-»T Glu298Asp
-786T->C -
Renin-Angiotensin system
Angiotensin AGT 803T->C Met235Thr
Angiotensin receptor 1 AGTR1 1166A->C -
Lipid metabolism
Apolipoprotein E ApoE 388T-»C Cysll2Arg
Low density lipoprotein Receptor LDLR IVS12+2T->C -
Cytokines & adhesion molecules
Interleukin 1-beta IL1B -581C->T ’ -
Tumor necrosis factor receptor superfamily CD40L 420C—»G Trpl40Cys
Intercellular adhesion molecule 1 ICAM1 167A-»T Lys29Met
Coagulation factors
Plasminogen activator inhibitor 1 P A I1 (SERPINE1) -1965 del G -
Fibrinogen FGA 116T-»A Val20Asp
Table 1.2. Examples of some of the genes investigated for association with CVD. The corresponding gene symbols and 
polymorphisms are shown, and where appropriate the amino acid change.
1.2 The L-Arginme->NO system
1.2.1 Discovery of Nitric Oxide
In 1980 Furchgott and Zawadzki observed that the endothelium was necessary for 
vascular relaxation induced by acetylcholine (Furchgott and Zawadski, 1980). If the 
endothelium was removed this relaxation was abolished. They postulated that this 
endothelium-dependent relaxation was mediated by an unstable diffusible factor, with a 
biological half-life of only a few seconds. It was subsequently named endothelium- 
derived relaxant factor (EDRF). In 1986 it was proposed that EDRF was in fact nitric 
oxide (NO) (Ignarro et al., 1987). This hypothesis was later confirmed when several 
investigators showed that vascular endothelial cells synthesize NO, and that 
administration of exogenous NO reproduced the biological effects of EDRF (Palmer et 
al., 1987; Ignarro et al., 1987; Radomski et al., 1987a).
1.2.2 Different isoforms of NO exist
NO is synthesized by the enzyme nitric oxide synthase (NOS), of which three isoforms 
have been identified; neuronal nitric oxide synthase (nNOS), inducible nitric oxide 
synthase (iNOS) and endothelial nitric oxide synthase (eNOS), named after the tissues 
in which the genes were first cloned and characterized (Fostermann et al., 1994). All 
three isoforms have since been found in a variety of different tissues, and undergo 
complex regulation. The binding of calmodulin (CaM) was found to be pre-requisite 
for all isoforms of NOS activity, and is regulated by intracellular calcium (Ca2+) levels. 
The requirement for Ca2+ differs between the three isoforms. nNOS and eNOS require
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greater concentrations of intracellular Ca2+ for activity, whereas it has been suggested 
that CaM is very tightly bound to the iNOS enzyme and therefore only low levels of 
Ca2+ are needed for activation. nNOS and eNOS were formerly considered to be 
constitutive enzymes, but their expression is now known to be subject to up or down 
regulation for example during pregnancy and exercise (Dotsch, 2001; Tatchum-Talom 
et al., 2000). eNOS released by the endothelium induces vascular relaxation and inhibits 
many processes involved in atherosclerosis development, whereas nNOS is the major 
isoform found in the brain where it acts as a neurotransmitter (Dawson et al., 1996). 
iNOS is expressed in cells such as macrophages and vascular smooth muscle cells 
(VMSC) after exposure to cytokines and lipopolysaccharide (Chester, 1998), and 
through its potent cytotoxic actions is one mechanism by which macrophages kill 
invading pathogens (Bogdan et al., 2000).
The three nitric oxide synthases are similar in structure, each comprising a reductase 
and an oxygenase domain. The active enzyme is in the form of a dimer as illustrated for 
eNOS in figure 1.3. Each reductase domain has recognition sites for the cofactors 
nicotinamide adenine dinucleotide phosphate (NADPH), flavine adenine dinucleotide 
(FAD), flavine mononucleotide (FMN) and CaM. Electrons are shuttled form NADPH 
to FAD and then FMN and ultimately to the iron protoporphyrin DC (haem) within the 
oxygenase domain, which harbors the catalytic active site for the reaction L- 
arginine+02-»NO+citrulline. The oxygenase domain also binds tetrahydrobiopterin 
(BH4 ), which is thought to have multiple roles in NOS function (section 1.3.3).
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Figure 1.3. Diagrammatic representation of endothelial nitric oxide synthase
(eNOS). The protein comprises a homodimer in its active state. Each monomer has an 
oxygenase domain (highlighted in red) and a reductase domain (highlighted in blue). 
Electrons are passed from NADPH to FAD and FMN within the reductase domain and 
then to haem within the oxygenase domain. The oxygenase domain binds BH4, which 
could be involved in stabilization of the NOS dimer.
The corresponding three human NOS genes have each been characterized (Marsden et 
al., 1992; Charles et al., 1993; Hall et al., 1994). The genes encoding nNOS and eNOS 
(termed NOS 1 and NOS 3) are located on chromosomes 12q24.2 and 7q35-36 
respectively, and the gene encoding iNOS (NOS 2) is located on chromosome 17cen- 
q l 1.2. Each isoform exhibits an 80-90% homology between species, which is 
indicative of their high evolutionary conservation, and each isoform bears a 50-60% 
homology to each other within a species, suggesting a common ancestral NOS gene
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(Alderton et al., 2001). The eNOS and iNOS genes are similar in structure, each 
composed of 26 exons. The iNOS gene is 37kb and encodes a protein of 1153 amino 
acids (131kDa), while the eNOS gene is smaller-21-22kb but encodes a protein 1203 
amino acids (133kDa). In contrast the nNOS gene is much larger comprising 29 exons 
and has a complex structural organization over a distance of more than 2 0 0 kb resulting 
in a protein of 1434 amino acids (161kDa). It is highly regulated by alternate splicing, 
which could be important for tissue specific NOS activity (Brenman et al., 1997). 
Splice variants have also been detected for iNOS, but not eNOS.
1.2.3 Physiological actions of eNOS
Endothelial NO is the most potent vasodilator known. It is synthesized from L-arginine 
and molecular oxygen with citrulline as the co-product (Moncada et al., 1993). 
Endothelial NO exerts its effects by diffusing into sub-adjacent vascular smooth muscle 
cells, where it activates soluble guanylate cyclase (sGC), which in turn stimulates the 
conversion of guanosine triphosphate to cyclic GMP (Rapoport et al., 1983). Increased 
levels of cyclic GMP lead to vascular smooth muscle cell relaxation and consequently 
vasodilation (Rapoport et al., 1983; Murad, 1986; Murad, 1990.). Other intrinsic 
properties of NO include: inhibition of platelet aggregation (Radomski et al., 1987b), 
inhibition of smooth muscle cell growth and migration (Nakiki et al., 1990; Sarkar et 
al., 1996) and anti-inflammatory properties such as inhibition of endothelial adhesion 
molecule expression and leukocyte adhesion (Bath et al., 1991; Bath et al., 1993). Thus 
physiological levels of NO are considered to confer atheroprotective and 
thromboresistant properties to the endothelium.
37
1.3 Decreased NO availability, endothelial dysfunction and 
cardiovascular disease
The onset of atherosclerosis is preceded by attenuation in functions of the endothelium, 
caused by environmental influences, genetic factors or both. The underlying causes of 
endothelial dysfunction are as yet not fully understood, however it is likely, given the 
key anti-atherogenic and anti-thrombotic properties of NO, that a reduction in its 
synthesis or action is an important part of this process. Studies of normal NO synthesis 
and regulation are providing a number of possible mechanisms to account for decreased 
availability of NO that underlies vascular disease. Some of the factors and pathways 
that might be involved are illustrated in figure 1.4. Decreased NO bioavailability that 
predates/predicts atherosclerotic events might result from reduced eNOS expression, 
increased ADMA (inhibitor of NOS), decreased BH4  (co-factor for NOS) or increased 
inactivation of NO by reactive oxygen species. The evidence for these will be discussed 
in detail.
Arginine
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Figure 1.4 Regulation of NO synthesis. NO is synthesized by the enzyme NOS which 
requires BH4 as a cofactor and is inhibited by asymmetric dimethylarginine (ADMA). NO has 
vasodilator and antiatherogenic properties but can be inactivated by oxidation to ONOO*.
1.3.1 Decreased NOS expression or activity-studies of the eNOS gene (NOS 3)
The human eNOS gene, NOS 3, located on chromosome 7q35-36, comprises 26 exons 
and spans a distance of 21kb (Marsden et al., 1993). The 5’ regulatory region exhibits a 
structure that is consistent with a constitutively expressed gene- it is TATA-less and 
harbours consensus sequences for transcription factors Spl and GATA. Decreased 
expression or activity of NOS3 would be expected to result in decreased NO synthesis 
predisposing to endothelial dysfunction and vascular disease. It is not surprising 
therefore that the NOS 3 gene has been the focus of intensive research to identify any 
polymorphisms or mutations, which could affect NO synthesis through differences in 
expression or activity. To date more than 100 polymorphisms have been identified in 
the NOS 3 gene (NCBI SNP database, http//www.ncbi.nlm.nih.gov/SNP/), and at least 
four of these investigated as risk factors for atherosclerosis (Bonnardeaux et al., 1995; 
Wang et al., 1996; Yoshimura et al., 1998; Nakayama et al., 1999).
Decreased expression of NOS 3 leading to reduced NO synthesis has been demonstrated 
in human atherosclerotic arteries (Oemar et al., 1998). To date more than 15 
polymorphisms in the NOS3 promoter have been described (NCBI SNP database, 
http//www.ncbi.nlm.nih.gov/SNP/) that might influence transcription. The -786T/C, - 
922A/G and -1468T/A polymorphisms were found to be associated with coronary 
spasm (Nakayama et al., 1999). In addition the -786T/C polymorphism has been 
associated with increased risk of CAD (Rossi et al., 2003) and influenced promoter 
activity in a luciferase/reporter assay system (Nakayama et al., 1999).
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Polymorphisms within the coding region of the NOS 3 gene could alter NOS enzymatic 
activity. One of the most studied eNOS polymorphisms (894G-»T) within exon 7, is 
the only polymorphism identified that encodes an amino acid change- Glu298Asp 
(Glutamate to Aspartate at position 298). Individuals carrying the Asp variant have 
been reported as having an increased risk of developing IHD (Hingorani et al., 1999; 
Miyamoto et al., 1998; Yoshimura et al., 1998). These observations are supported by a 
recent meta-analysis in which data was available in 9867 cases and 13161 controls from 
26 previous studies. The authors concluded that individuals homozygous for the 
298Asp allele had a moderately increased risk of IHD (Casas et al, unpublished data 
reproduced with permission o f  authors). Expression studies have revealed that the Asp 
variant maybe more susceptible to proteolytic cleavage (Tesauro et al., 2000), and 
carriers of the Asp298 allele have been shown to have reduced endothelium-dependent 
vasodilation of the brachial artery during pregnancy (Sawidou et al., 2 0 0 1 ).
1.3.2 Decreased L-arginine availability
Despite the fact that its concentration in cells/blood is greater than the Km (l-4pM) of 
NOS for arginine (Charles et al., 1996; Bredt and Snyder, 1990), the availability of 
arginine may, in some circumstances become one of the rate limiting factors for the 
synthesis of NO. This observation has become known as the “arginine paradox”. 
Several human in vivo studies have demonstrated that endothelial function can be 
improved by administration of arginine to both healthy (Bode-Boger et al., 1994; Mehta 
et al., 1996; frnaizumi et al., 1992) and atherosclerotic coronary arteries (Boger et al., 
1998a; Tousoulis et al., 1998), but to date the reason for this phenomenon is still 
unexplained. Three possible theories have been put forward, the first suggests that
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cellular arginine concentrations available to the NOS enzyme are somehow limited, for 
example if arginine is sequestered within storage pools inaccessible to NOS (McDonald 
et al., 1997). The second theory proposes that binding of arginine to the active site of 
NOS may be hindered by the presence of an inhibitor (Vallance et al., 1992), and the 
third that the transport of arginine into the cell via specific transporters may be down 
regulated (Kaye et al., 2002). The large oral dose of L-arginine that is required to 
improve endothelial function, has, however limited its use as a potential therapeutic 
agent.
1.3.3 Limited availability of BH4 for NOS enzyme activity
It has been hypothesized that a deficiency in BH4, either caused by a reduction in its 
synthesis or increased oxidative inactivation could lead to reduced NO availability and 
endothelial dysfunction. When BH4 is limiting, NOS generates 02‘ rather than NO from 
oxygen and NADPH (Pou et al., 1992), but the reason why has continued to elude 
scientists possibly because the precise role of BH4 in the synthesis of NO is still unclear 
(Vasquez-Vivar et al., 1999; Wever et al., 1997; Xia et al., 1998). Administration of 
low dose BH4 to smokers, hypertensives, hypercholesterolemics and diabetics -  all 
states in which endothelium-dependent vasodilation is attenuated can reinstate normal 
endothelial function, whereas BH4 has no effect on healthy vessels at the same dose 
(Ueda et al., 2000; Stroes et al., 1997; Pieper, 1997). This observation is consistent with 
the theory that BH4 availability may be limited in diseased vessels. Insufficient BH4 
availability maybe caused by reduced synthesis or oxidative inactivation. 
GTPcyclohydrolase 1 is the first and rate-limiting enzyme in the synthesis pathway of 
BH4 (Duch and Smith, 1991). However, to date, no studies have investigated any
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differences in expression of GTPCH-1 between atherosclerotic and non-atherosclerotic 
vessels. However, agents that improve endothelial function such as HMG-CoA 
reductase inhibitors (statins) also upregulate GTPCH-1 mRNA (Hattori et al., 2003). 
Oxidative inactivation of BH4  is supported by studies in which endothelial function can 
be improved by vitamin C and folic acid supplementation and by the observation that in 
diseased tissues the BH4 /BH2 ratio is reduced (Heller et al., 1999; Heitzer et al., 1996; 
Stroes et al., 2000). The beneficial effects of these anti-oxidants maybe due to direct 
scavenging of oxygen-derived free radicals. However it has also been proposed that 
vitamin C and folic acid may increase availability of BH4 , increase the affinity of BH4  
for eNOS or could facilitate the 1-electron oxidation of BH4  to the BPLj radical (Baker et 
al., 2001; Stroes et al., 2000).
1.3.3.1 Multiple functions of BH^-essential NOS cofactor
The NOS enzymes depend on the cofactor BH4, which binds to the haem-containing 
domain of the enzyme and forms part of the dimer interface. Its position within the 
NOS enzyme has led to the hypothesis that BH4 is involved in stabilization of the NOS 
dimer (Klatt et al., 1995; Ghosh et al., 1996). However, the amount of BIT* required for 
each isoform of NOS has been reported to differ, the iNOS isoform relying on more 
BH4 for activity compared to eNOS and nNOS (reviewed in Stuehr et al., 1999). Other 
studies have proposed functions such as: promoting coupling of NADPH oxidation to 
NO synthesis (Vasques-Vivar et al., 1999), allosteric binding effects (Giovanelli et al., 
1991; Klatt et al., 1994; Alderton et al., 1998) and modification of the haem 
environment (Wang et al., 1993; Wang et al., 1995). BR4 is also an essential cofactor 
for the phenylalanine, tryptophan and tyrosine hydroxylases. These enzymes are
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essential for the synthesis of hormones and neurotransmitters such as dopamine, 
noradrenaline, adrenaline and serotonin.
1.3.3.2 Synthesis of BH4
Reduced synthesis of BH4 could be one reason for decreased NOS activity leading to 
endothelial dysfunction, but this has not been systematically investigated. The pathway 
of synthesis of BH4 is illustrated in figure 1.5. The initial step is the conversion of GTP 
to dihydroneopterin triphosphate by GTP cyclohydrolase 1 (GTPCH-1), which is the 
first and rate-limiting enzyme in this pathway (Duch and Smith, 1991). In man, but not 
rodents, a proportion of the dihydroneopterin triphosphate is converted to neopterin, 
which serves as a marker of pterin pathway activity. The majority of dihydroneopterin 
triphosphate is converted to 6 -pyruvoyl tetrahydropterin by 6 -pyruvoyl tetrahydropterin 
synthase (PTPS) and finally to BH4 by sepiapterin reductase (SR). Mutations in 
GTPCH-1 and PTPS result in decreased BH4 leading to hyperphenylalanaemia and a 
neurological disorder L-DOPA responsive dystonia (DRD) (Thony et al., 1997). 
However, the effects of polymorphisms or mutations in GTPCH-1 on endothelial 
function and risk of vascular disease have not yet been studied.
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GTP: Guanosine triphosphate
GTP-CH-I: GTP-Cyclohydrolase I
7, 8-NH2-TP: 7, 8-Dihvdroneopterin- 
triphosphate
7, 8-NH2: 7, 8-Dihydroneopterin
OH OH PTPS: 6-Pyruvoyl-tetrahydropterin- 
synthaseGTP
SR: Sepiapterin-reductase
G T P - CH I
5, 6 , 7, 8-BH4: 5, 6 , 7, 8-Tetrahydro- 
biopterin
OH OH
Oxidation
PTPS; SR
OH OH
OH OH
NEOPTERIN
Figure 1.5. Synthesis of BH4. BH4 is synthesized from GTP via GTPCH-1 (the rate 
limiting enzyme), 6-pyruvoyl -tetrahydropterin- synthase and sepiapterin reductase. In 
man, but not rodents, a proportion of the dihydroneopterin triphosphate is converted to 
neopterin, which serves as a marker o f pterin pathway activity.
Adapted from Brahms Diagnostica.
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1.3.4 Inhibitors of nitric oxide synthase
Endogenous asymmetric methylarginines might have a profound effect on NO synthesis 
by inhibiting the NOS enzyme. Protein methylation occurs via a group of enzymes 
known as protein arginine methyltransferases (PRMT) and the breakdown of these 
proteins results in the release of free methylarginines including NG-monomethyl-L- 
arginine (L-NMMA), asymmetric dimethyl-L-arginine (ADMA) and symmetric 
dimethylaginine (SDMA) (Kakimoto et al., 1970), which are cleared from the body via 
the kidneys. In addition L-NMMA and ADMA (but not SDMA) are also metabolized 
by dimethylaginine dimethylaminohydrolase (DDAH). It is interesting to note that 
SDMA, which is not metabolized by DDAH is also not capable of inhibiting the NOS 
enzyme (Figure 1.6). L-NMMA and ADMA are analogues of L-arginine and are 
elevated in various disease states in which vascular disease is a clinical manifestation 
such as hypertension (Goonasekera et al., 1997; Fujiwara et al., 2000), renal failure 
(Vallance et al., 1989; Vallance et al., 1992; Rees et al., 1989), preeclampsia (Pettersson 
et al., 1998) and peripheral arterial occlusive disease (Boger et al., 1997). 
Normalization of ADMA levels in renal failure patients by dialysis has been shown to 
associated with improved endothelium-dependent vasodilation (Cross et al., 2001). In a 
recent study, administration of ADMA to twelve healthy volunteers reduced heart rate 
and cardiac output, and increased blood pressure and systemic vascular resistance 
(Achan et al., 2003). Increased circulating levels of ADMA may therefore be a 
contributing factor of endothelial dysfunction. Sufficient concentrations of these 
methylarginines to “out compete” arginine for NOS has been put forward as an 
explanation for the arginine paradox (section 1.3.2).
45
i „ Proteins
4 n o
*  w w \
\  p rm t
ADMA SDMA
citrulline
DDAH \
Excreted by the 
kidneys
Figure 1.6 Synthesis and metabolism of ADMA. The methylarginines ADMA and 
SDMA are synthesized from the proteolysis of arginine methylated proteins, which 
involves protein arginine methyltransferases (PRMT). ADMA is a competitive 
inhibitor o f NOS. Both ADMA and SDMA are eliminated from the body via the 
kidneys, however ADMA is also metabolized by DDAH.
L-NMMA has been utilized as a tool for research into the role of NO and endothelial 
relaxation for the past 10-15 years, however circulating concentrations of ADMA 
(0.5pm-lpM) are up to 10 times higher than L-NMMA in healthy individuals, and for 
this reason ADMA has attracted most interest as a possible endogenous inhibitor of 
NOS. The underlying cause of elevated ADMA in patients at risk o f vascular disease 
development in unknown, but at present two potential mechanisms have been proposed:
(1) Upregulation of PRMTs resulting in increased protein methylation and 
subsequent breakdown would lead to elevated circulating methylarginines. 
Studies have shown that release of ADMA by endothelial cells is upregulated by
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LDL cholesterol and this may be due to enhanced PRMT gene expression 
(Boger et al., 2000).
(2) Failure of ADMA to be cleared from the body. In addition to being excreted via 
the kidneys, ADMA is also metabolized by the enzymes dimethylarginine 
dimethylaminohydrolases (DDAH I + II). A decrease in metabolism or 
excretion would lead to an increase in circulating ADMA and inhibition of NO 
synthesis (MacAllister et al., 1996; Ito et al., 1999).
1.3.4.1 Reduced DDAH expression or activity could account for elevated ADMA
The observation that ADMA but not SDMA levels are elevated in patients at risk of 
developing CVD suggests that down-regulation or dysfunction of DDAH could be 
implicated in the pathogenesis of disease. DDAH has two isoforms named DDAH1 and 
DDAH2 (Leiper et al., 1999). Both enzymes are found in a variety of tissues, but the 
DDAH1 isoform is found predominantly in tissues expressing nNOS such as the brain, 
whereas DDAH2 is found in tissues expressing eNOS such as the heart and placenta 
(Tran et al., 2000). This may suggest isoform specific regulation of NOS enzymes, with 
DDAH2 possibly being the major functional variant within the vasculature.
The DDAH2 gene is located on chromosome 6  within the major histocompatibility 
complex (MHC) class IE region (Ribas et al., 1999). This region contains a number of 
genes, which are involved in autoimmune diseases such as insulin dependent diabetes 
mellitus, ankylosing spondylitis and celiac disease (Thomson et al., 1988; Benjamin et 
al., 1990; McManus et al., 1996). The DDAH2 gene comprises 8  exons that span a
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distance of 3kb and encodes a protein of 35kDa. To date a detailed analysis of the 
DDAH2 gene has not been attempted, but it is possible that polymorphisms or mutations 
could alter expression or activity resulting in elevated ADMA.
1.3.5 Inactivation of NO by superoxide (0 2‘)
The production of reactive oxygen species (ROS) such as superoxide (0 2), hydrogen 
peroxide (H2 O2 ), and peroxynitrite (ONOO-) in the vasculature, have long been 
suspected as being implicated in the development of vascular disease. 0 2‘ levels are 
elevated in hypertension, heart failure, hypercholesterolemia, diabetes, preeclampsia 
and renal failure and could prove to be a common cause of endothelial dysfunction 
among these patients (Mehta et al., 1994; Keith et al., 1998; Ohara et al., 1993; 
Langenstroer et al., 1992; Sikkema et al., 2001; Canaud et al., 1999). The precise 
source of increased 0 2" in individuals at risk of CVD is unknown, but a number of 
enzymes expressed in the vasculature, are potential sources. These include xanthine 
oxidase, cyclooxygenase, NADH/NADPH oxidase (Griendling et al., 2000) and the 
mitochondrial electron transport chain. Decreased inactivation by antioxidant enzymes 
such as superoxide dismutases (SOD) of which there are three isoforms (Noor et al.,
2002) may also contribute to increased 0 2‘ effects. It has been shown that endothelial 
function can be markedly improved after administration of anti-oxidants in individuals 
where endothelial function was previously impaired (Heller et al., 1999; Heitzer et al., 
1996) and in cholesterol fed rabbits (Mugge et al., 1991), suggesting that 0 2-may inhibit 
the vasodilator properties of NO. Inactivation of NO may be caused by the rapid 
reaction of NO with 0 2"to produce ONOO- (Goldstein and Czapski, 1995), which can 
itself act as a potent oxidant (Beckman and Crow, 1993). In addition to oxidative
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inactivation of NO, ROS species may also inactivate cofactors for NOS such as BH4 
(discussed in section 1.3.3). ROS species not only function as molecules able to 
inactivate many important proteins, but are known to be involved in many intracellular 
signaling pathways, which lead to regulation of gene transcription, smooth muscle cell 
proliferation and induction of adhesion molecule expression (Konishi et al., 1997; Fei et 
al., 2000; Weber et al., 1994). These diverse properties have made ROS, in particular 
0 2", prime suspects in the development of vascular disease.
1.3.5.1 NADPH oxidase is a major source of ROS in the vasculature
One of the main sources of ROS are the NADH/NADPH oxidases. Phagocytes use this 
enzyme system to produce bursts of 0 2‘ to kill invading pathogens, and it was 
subsequently found that endothelial cells and fibroblasts express their own 
NADH/NADPH oxidases, which are a major source of ROS in blood vessels. NADPH 
oxidase (in both phagocytic and non-phagocytic cells) is composed of five subunits: 
Gp91phox (the catalytic subunit), p22phox, p47phox, p67phox and p40phox (Figure 
1.7), however the catalytic Gp91phox is both genetically and structurally different 
between phagocytic and non-phagocytic cells. Animal and human in vitro studies have 
demonstrated that production of ROS can be increased upon activation of NADPH 
oxidase (Gorlach et al., 2000; Heinloth et al., 2000). ROS generation is also enhanced 
through mechanical stress, inflammatory mediators such as TNF-a, angiotensin II and 
coagulation factors, possibly by induction of NADPH oxidase (Hishikawa et al., 1997; 
De Keulenaer et al., 1998; Bhunia et al., 1998; Griendling et al., 1994; Zhang et al., 
1999; Patterson et al., 1999). The genes encoding each of the NADPH oxidase subunits 
are also attracting interest, as polymorphisms or mutations could have effects upon ROS
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production and consequences for vascular disease. Currently eleven variants have been 
identified within the p22phox gene (CYB A) and most of these are associated with 
chronic granulomatous disease (Dinauer et al., 1990; Dinauer et al., 1991; de Boer et al., 
1992; Yamada et al., 2000; Stasia et al., 2002). The C242T polymorphism which 
results in a histidine to tyrosine substitution at position 72 of the protein, has been the 
focus of most interest to date in relation to CVD (Parkos et al., 1988). This 
polymorphism has been associated with atherosclerosis, coronary artery disease (CAD) 
and cerebrovascular disease (Guzik et al., 2000a; Cahilly et al., 2000; Ito et al., 2000).
Extra cellular
heme heme
Intra cellular
NADP NADPH
Figure 1.7 NADPH oxidase enzyme complex. The NADPH oxidase enzyme is 
composed of a membrane-spanning catalytic subunit called gp91phox, which is 
genetically and structurally different between phagocytic and non-phagocytic cell types. 
The gp91phox subunit interacts with p22phox to form the stable complex 
flavocytochrome bsss- Upon stimulation, the cytosolic components p47phox, p67phox 
and p40phox translocate to the flavocytochrome bssg complex to form the active 
enzyme.
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1.4 Hypothesis
NO is a potent anti-atherogenic molecule produced in the endothelium by eNOS. A 
decrease in expression or activity of NO has been suggested as a causative agent in the 
development of vascular disease, which has a heritable basis. NOS requires the 
essential cofactor BH4 which is synthesized from GTP via GTPCH-1 (which is the rate- 
limiting enzyme for this process). Reduced availability of BH4 has been shown to result 
in increased production of 0 2* from eNOS, which can cause vascular damage. NOS can 
be inhibited by the endogenous L-arginine analogue ADMA. Plasma ADMA 
accumulates in hypercholesterolemics, hypertensives and in renal failure possibly 
resulting in endothelial dysfunction. The increase in ADMA may be attributed to a 
decrease in DDAH activity.
Based on the above, the central hypothesis explored in the studies of this thesis, is that 
common genetic variation (polymorphism) in the genes encoding enzymes regulating 
ADMA, BH4 and 0 2' availability in the endothelium, influence NO availability and 
endothelial function and through this, might alter susceptibility to cardiovascular 
disease.
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1.5 Aims
The aims of the work reported in this thesis were to:
1. identify common polymorphisms in the GCHl and DDAH2 genes that 
might influence expression or activity.
2 . relate any polymorphisms found to indices of gene expression or 
activity.
3. investigate associations between these polymorphisms and previously 
identified polymorphisms in the p22phox gene (CYBA) and NO synthesis 
and vascular function in healthy individuals and disease groups.
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CHAPTER 2 
MATERIALS AND METHODS
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2.1 Materials
2.1.1 General reagents
All general purpose chemicals and reagents were supplied by Sigma Aldrich Company Ltd 
(Poole, Dorset, UK), BDH (Merck, Dorset, UK) or Invitrogen (Paisley, UK) unless 
otherwise stated.
2.1.2 Enzymes used for PCR and restriction digests
DNA polymerase was obtained from Invitrogen, (Paisley, UK). Restriction endonucleases 
were supplied by New England Biolabs (Hertfordshire, UK) and are listed in table 2.1.
Restriction enzyme Recognition sequence
BsmFl 5’ GGGAC(N)1<4 3’
BsrDl 5’ GCAATGNNi 3’
BstUl 5’ CGiCG 3’
Mwol 5’ GCNNNNNiNNGC 3’
Rsal 5’ GTiAC 3’
Table 2.1 Restriction endonucleases used for PCR-RFLP analysis, i  indicates the 
cutting site of each enzyme.
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2.1.3 Oligonucleotides
Oligonucleotides were purchased from Sigma Aldrich Company Ltd (Poole, Dorset, UK). 
All oligonucleotides were synthesized at 0.2pM scale and desalted.
2.1.4 DNA ladders for agarose gel electrophoresis and genescan
lOObp, lkb and lkb plus DNA ladders for sizing PCR products on agarose gels were 
obtained from Invitrogen (Paisley, UK). Genescan TAMRA-350 DNA ladder for sizing 
fluorescent-labeled PCR products was from Perkin Elmer, Applied Biosystems 
(Warrington, UK).
2.1.5 Gel loading buffers
Agarose gel loading buffer (6 x concentrated) was purchased from Sigma Aldrich Company 
Ltd (Poole, Dorset, UK).
Polyacrylamide gel loading buffer (for SSCP) was made up as follows: 96% formamide, 
2.5% bromophenol blue, 2.5% xylene cyanol, 0.5M EDTA.
Polyacrylamide gel loading buffer (for DNA sequencing) was made up as follows: 83% 
deionised formamide, 4.2mM EDTA (pH 8.0), 5% blue dextran.
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TE buffer (for re-suspending DNA) was made up as follows: 0.01M Tris, ImM EDTA 
(Ethylenediaminetetraacetic acid) adjusted to Ph 7.6 with concentrated hydrochloric acid 
(HCL).
2.1.6 Cell culture reagents
E.coli strain DH5a for cloning experiments was purchased from Invitrogen (Paisley, UK). 
Human umbilical vein endothelial cells (HUVEC) for transfection studies were from 
PromoCell (Heidelberg, Germany). HUVEC were cultured in EGM media (Biowhittaker, 
Cambrex Bioscience, Wokingham Ltd).
2.1.7 Kits
A list of kits (and their contents) used during this study are summarized below:
DNA miniprep kit (Qiagen, Boundary Court, UK):
Spin columns, 2ml collection tubes, buffers; PI, P2, N3, PB, PE, EB, RNaseA.
DNA midiprep kit (Qiagen, Boundary Court, UK):
Qiagen tips 100, QiaFilter cartridges, buffers; PI, P2, P3, QBT, QC,QF, RNaseA.
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dRhodamine sequencing kit (Perkin Elmer, Warrington, UK):
Terminator ready reaction mix: A-Dye terminator labeled with dichloro[R6 G], C-Dye 
terminator labeled with dichloro[TAMRA], G-Dye terminator labeled with dichloro[Rl 10], 
T-Dye terminator labeled with dichloro[ROX], AmpliTaq FS, MgCl2, Tris-HCL buffer.
Dual light luciferase reporter assay kit {Promega, Madison, UK):
Luciferase assay buffer II, Luciferase assay substrate, Stop and Glow® buffer, Stop and 
Glow substrate, Stop and Glow substrate solvent, 5x passive lysis buffer.
Neopterin ELItest® competitive enzyme immunoassay kit (B.R.A.H.M.S diagnostica 
GMBH):
96 well microtitre plate coated with anti-neopterin antibodies, uncoated plate, 
neopterin/alkaline phosphatase conjugate, enzyme conjugate buffer, substrate (4- 
nitrophenylphosphate), substrate buffer, stop solution (2M sodium hydroxide), wash 
solution, human serum neopterin standards, control sera.
Phastgel silverstain kit (Amersham, UK):
Formaldehyde 37%, fixing solution (0.7% benzene sulphonic acid, 24% ethanol), staining 
solution (0.2% silver nitrare, 0.7% benzene sulphonic acid), sodium carbonate 2.5%, 
stopper/preserver solution (1% acetic acid, 5% sodium acetate, 10% glycerol), sodium 
thiosulphate 2 %.
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QIAamp® DNA Blood mini kit (Qiagen, Boundary Court, UK):
Spin columns, 2ml collection tubes, Buffers; AL, AW1, AW2, AE, Proteinase K.
QIAquick gel extraction kit (Qiagen, Boundary Court, UK):
Spin columns, 2ml collection tubes, buffers: QC, PE, EB
QIAquick PCR purification kit {Qiagen, Boundary Court, UK):
Spin columns, 2ml collection tubes, buffers; PB, PE, EB.
TOPO TA cloning kit {Invitrogen, UK):
PCR®2.1-TOPO: lOng/jil plasmid (in 50% glycerol, 50Mm Tris-HCL, IMm EDTA, IMm 
DTT, 0.1% Triton X-100, lOOpg/ml BSA, phenol red), salt solution (1.2M NaCl), sterile 
water.
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2.2 Methods
2.2.1 Extraction of DNA from whole blood samples
Two methods of DNA extraction were used during this study.
2.2.1.1 Salting out method
This method was originally described by Miller et al, 1988. Cell lysis was achieved by the 
addition of 10ml reagent A (109.54g sucrose dissolved in 10ml of 1M Tris pH7.5, 5ml of 
1M MgCl2 and 10ml Triton-X-100, made up to 1L with deionised water) followed by 
mixing and then centrifugation. The supernatant was discarded and the pellet re-suspended 
in a further 10ml of reagent A. This step was repeated to obtain a clean pellet. 2 ml of 
reagent B (2.34g NaCl and 1ml Tris-HCl (1M), 0.4ml Na-EDTA (0.5M), 90ml deionised 
water and 10ml of 10% SDS) was added to the pellet to complete nuclear lysis followed by 
lml of 5M sodium perchlorate for deproteinisation. Separation of protein was performed 
by the addition of 2ml chloroform and the samples mixed thoroughly. After centrifugation 
the upper aqueous phase containing the DNA was transferred to a fresh propylene tube and 
the lower phase containing protein discarded. 1 0 0 ml of ice-cold ethanol was added to the 
samples for DNA precipitation. The DNA was removed by inserting and swirling a sterile 
pasteur pipette into the solution (the DNA adheres to the outside of the pipette) and 
washing the pipette in 70% ethanol to remove salt and organic molecules. DNA was re­
suspended in TE buffer.
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2.2.1.2 DNA purification kit method {QiAmp blood minikit)
Cell lysis was achieved by adding proteinase K to 200pl of whole blood. The lysate was 
then pipetted into a 1.5ml tube containing a silica-gel membrane. During centrifugation 
DNA adsorbs to the membrane whilst protein and other contaminants pass through. The 
membrane was then washed with a series of salt solutions to remove all traces of 
contaminants. The genomic DNA was eluted off the membrane with elution buffer (lOmM 
Tris-Cl; 0.5Mm EDTA; pH9.0). An average of 6 fig of DNA is purified using this protocol.
All DNA samples were stored at -20°C.
2.2.2 DNA amplification by PCR
All PCR reactions were performed in 30jil volumes containing, 2jil DNA, lOx buffer 
(500mM KCL, lOOmM Tris (pH8.3), 0.01% Gelatin, 2mM each dNTP (dATP dGTP dTTP 
and dCTP), lOpmol of each oligonucleotide and 0.1U Taq DNA polymerase. The MgCh 
concentration and annealing temperature were optimised for each oligonucleotide pair. 
Reactions were performed in 96-well microtitre plates (Abgene, Epsom, Surrey, UK). 
Cycling conditions were 95°C for 5min, followed by 35 cycles of 95°C for 30sec, 
annealing temperature for 30sec, 72°C for 1 minute and a final extension at 72°C for 10 
mins on a (Techne-Genius, 96 well PCR machine). For each set of PCR reactions a 
negative control was carried out (by using sterile dH20  in place of DNA) to test for DNA 
contamination.
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2.2.3 Agarose gel electrophoresis
Molecular biology grade agarose (Invitrogen) was dissolved in lxTBE (Invitrogen) to 
prepare gels of between 1 and 2% depending on the application. Ethidium bromide 
(0.5pg/ml) was added to the gel before allowing it to set. Samples were mixed 5:1 with 6 x 
gel loading buffer to give a final concentration of lx gel loading buffer. In addition a DNA 
ladder was loaded as a size marker. Samples were electrophoresed in lxTBE running 
buffer at a constant voltage of 100V. After electrophoresis gels were visualized in a UV 
transilluminator (Syngene, UK).
2.2.4 Single-strand conformation polymorphism analysis (SSCP)
2.2.4.1 Radioactive SSCP
PCR was carried out in 30pl reaction volumes as described in section 2.2.2 with one 
modification- 90% dCTP was substituted with 0.2 mM a-32P dCTP. 7.5% acrylamide gels 
were prepared by mixing 7.5ml lOxTBE, 11.25ml 49% acrylamide:Bis, 3ml 0.5M EDTA, 
7.5ml glycerol and dH20  up to a final volume of 75ml. 115jnl of 25% APS and 115pl of 
TEMED were added prior to gel pouring into glass plates measuring 40cmx30cmx0.4mm. 
Gels were allowed to set at room temperature for a minimum of 2 hours. 3pi of 
radiolabelled PCR product was mixed with 6 pl of loading buffer and denatured at 95°C for 
3mins. Gels were run for 21 hours at 300 Volts. After electrophoresis gels were dried at 
80°C for 30 minutes on a BioRad 583 gel dryer, and exposed to film (Hyperfilm MP,
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Amersham, UK) for 1-2 days at -70°C. The films were developed by silver nitrate 
staining. Staining was stopped by acetic acid and background staining reduced with 
formaldehyde and sodium carbonate. Finally, films were washed with dH20 .
2.2.4.2 Non-radioactive SSCP (PhastSystem)
Genomic DNA was amplified by PCR as described in section 2.2.2 with no radioactive 
label. PCR products were mixed with an equal volume of gel loading buffer, denatured at 
95°C and immediately placed on ice to stabilize the structure of the single strands. The 
samples were loaded onto 12% or 20% ready prepared acrylamide gels and run at 4°C for 
approximately 700 average voltage hours (avh) on a PhastSystem electrophoresis apparatus 
(Amersham, UK) capable of running 2 gels simultaneously (total number of samples 16). 
The gels were visualised by silver staining with the PhastSystem silver stain kit as 
described by the manufacturers (Amersham, UK). Briefly the gels were fixed in a solution 
containing 0.7% benzene sulphonic acid and stained with 0.2% silver nitrate. The reaction 
was stopped with a stopper/preserver solution comprising 1% acetic acid, 5% sodium 
acetate and 10% glycerol. Sodium thiosulphate (2%) was used to reduce the background 
on the gels. Silver staining allows the detection of as little as 20-50pg/band of DNA.
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2.2.5 DNA sequencing
2.2.5.1 Template preparation
The genomic region to be sequenced was amplified by PCR as described in section 2.2.2 
and the PCR product used as a template. A total of 4 PCR reactions were carried out for 
each sample and combined to ensure adequate template was obtained after purification. All 
PCR products were purified using spin columns (Qiagen, UK) to remove excess primers 
and oligonucleotides. Briefly this process involved adding the PCR products to a tube 
containing a silica-membrane. The DNA adsorbs to the membrane under high salt 
concentrations, whilst contaminants pass through. The membrane was then washed with a 
low salt buffer to eliminate impurities such as unbound oligonucleotides (up to 40bp in 
length), and the DNA eluted with Tris buffer. This method allows the purification of up to 
lOpgof DNA.
2.2.5.2 Sequencing reaction
Sequencing was performed in 20j l i1 reaction volumes containing 8 pi dRhodamine dye 
terminator mix (Applied Biosystems,Warrington,UK), 3.2pmol of primer and lpl of 
purified PCR product. Both forward and reverse reactions were performed on each PCR 
template to accurately verify sequencing in both directions. Cycling conditions used were: 
25cyCles of 95°C for 30sec, 55°C for 18sec, 60°C for 4mins on a (Techne-Genius, 96 well 
PCR machine). Sequencing products were precipitated with 95% ethanol and 3M sodium
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acetate pH5.2 to remove any unincorporated nucleotides and primers and left to dry at room 
temperature. Samples were stored at -20°C until loading.
2.2.5.3 Gel loading and electrophoresis of sequencing products
5% polyacrylamide gels were prepared for DNA sequencing as follows: 18g urea, 27ml 
dH20, 5.2ml 40% acrylamide (Anachem Ltd, Bedfordshire, UK) and 0.5g amberlite resin 
to de-ionise the solution were mixed thoroughly until all urea was dissolved and then 
filtered through 0.2pm sterile filter units. 5ml of lOxTBE was then filtered into the mix 
and the gel solution de-gassed for 5 minutes. 250pl of 10% ammonium persulphate and 
3 5pi of TEMED were added immediately prior to gel pouring. The gels were cast in 36cm 
plates with 0 .2 mm thick spacers and left to set at room temperature for at least 2  hours. 
Four pi of loading buffer was added to each sequencing product and the samples denatured 
by heating at 95°C for approximately 3 minutes to separate the single strands. Denatured 
samples were placed immediately on ice and loaded without delay. Gels were run for 7 
hours on an ABI377 DNA sequencer (Applied Biosystems, Warrington,UK) and data 
collected on an Apple Macintosh computer.
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2.2.6 Genotyping
2.2.6 .1 Genotyping by PCR-RFLP analysis
The genomic region of interest was amplified by PCR as described in section 2.2.2. 
Restriction sites either created or abolished by the presence of a polymorphism were 
identified by Webcutter software (http://www.firstmarket.com/cutter/cut2.html). 
Restriction digests were undertaken in 15pi reaction volumes comprising lOpl of PCR 
product, 2units of restriction enzyme, dH20  and lx appropriate buffer supplied by the 
manufacturers (final concentration). Digestion was carried out in 96 well plates by 
incubation for 16 hours at the optimum temperature for each particular enzyme on a Techne 
Genius 96 well PCR machine.
2.2.6.2 Genotyping by Genescan analysis
PCR was carried out as described in section 2.2.2. The forward reading oligonucleotide 
was labeled with the fluorescent dye 6 -FAM (6 -carboxyfluorescein). All PCR products 
were purified by spin column to remove any surplus oligonucleotides, which could interfere 
with the results. Samples were stored at -20°C until required.
4% polyacrylamide gels were prepared and cast in the same manner as for DNA sequencing 
(section 2.2.5.3), the gel mix comprising 18g urea, 25ml dH20, 5ml 40% acrylamide 
(Anachem Ltd, Bedfordshire, UK) and 0.5g amberlite resin to de-ionise the solution. Prior
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to gel loading the samples were diluted 1 in 20 with sterile dH20  to reduce fluorescence 
produced by the labelled oligonucleotides. Four pi of loading buffer was added to lpl of 
diluted sample and the samples denatured at 95°C for 3 minutes. Gels were 
electrophoresed in lxTBE running buffer for 2.5 hours at on an ABI 377 DNA sequencer 
(Perkin Elmer, Warrington, UK). The data was collected on an Apple Macintosh computer 
using Genescan software.
2.2.7 Search of the National Center for Biotechnology Information (NCBI) SNP 
database for polymorphisms
The NCBI SNP database (http://www.ncbi.nlm.nih.gov/SNP/) was established in 1988 and 
is a resource of freely available molecular biology information compiled by genome 
sequencing consortiums worldwide. The database was searched by entering the genomic 
DNA accession number or gene symbol of interest and viewing the sequence in graphical 
format. All previously identified polymorphisms are listed and information regarding the 
flanking sequence, location, heterozygosity and identification numbers are shown. This 
information was used to compare polymorphisms in the database with polymorphisms 
identified by SSCP during this study.
66
2.2.8 Search of the Matlnspector database for putative transcription factor 
binding sites
Genomatix software (http://www.genomatix.de/free_login.html) comprises tools and 
databases for the analysis of genomic sequences. The Matlnspector database was used 
during this study to identify transcription factor binding sites within the promoter 
sequences of the GCHl and DDAH2 genes. The software scans the sequence against a 
library of matrix descriptions for transcription factor binding sites to find sequence 
matches. All potential transcription factor binding sites are listed including the core 
binding sequence and its matrix similarity (a measure of how conserved each base in the 
core binding sequence is compared to the matrix).
2.2.9 Measurement of plasma nitrite and nitrate (NOx).
Plasma NOx was measured using a modification of the Griess reaction as described 
previously (Jeerooburkhan et al., 2001). All plasma samples were filtered through 
Ultrafree microcentrifuge filter units (Biomax-5, Millipore) prior to analysis to remove any 
proteins such as haemoglobin (Hb) which may interfere with the reaction. Plasma nitrate 
(NO3 ') was reduced to nitrite (NO2’) by nitrate reductase and quantified by the addition of 
1% sulphanilamide in 5% phosphoric acid and 0.1% N-(-naphthyl)ethylenediamine. All 
measurements were carried out in duplicate and the mean value of each sample taken as the 
reading. 40jil of plasma was added to lOpl of phosphate buffered saline (PBS) in a 96 well 
microtitre plate (Beckton Dickinson). To each sample well was added lpM nicotinamide
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adenine dinucleotide phosphate dehydrogenase (NADPH), followed by a master mix 
containing 500pM glucose-6 -phosphate, 80U/L nitrate reductase and 160U/L glucose-6 - 
phosphate dehydrogenase. The plates were then incubated in the dark for 1 hour at room 
temperature. 1% sulphanilamide in 5% phosphoric acid was then added to each well along 
with an equal volume of 0.1% N-(naphthyl)ethylenediamine and the plates incubated for 15 
minutes at room temperature. To quantify N 02' produced, the absorbance was measured by 
UV visible spectroscopy on a Spectra Max 250, using SOFTmax Pro software (Molecular 
devices, Menlo Park, CA, USA).
2.2.10 Measurement of plasma neopterin
Neopterin was measured using the ELItest® competitive enzyme immunoassay kit 
(B.R.A.H.M.S diagnostica GMBH). Briefly, plasma samples were analysed in 96 well 
microtitre plates, which were coated with polyclonal sheep anti-neopterin antibody. 
Standards were made by adding 150pl of enzyme conjugate (consisting of neopterin- 
alkaline phosphatase conjugate) and 50pl neopterin standards (2-250nmol/L). Reactions 
were carried out by adding 50pl of patient plasma and 150pl enzyme conjugate to the pre­
coated wells. The neopterin in the patient samples competes with the neopterin-enzyme 
conjugate for the active site of the sheep polyclonal antibodies. lOOpl of 4- 
nitrophenylphosphate was added to the samples and standards which catalyses the removal 
of the phosphate from 4-nitrophenylphosphate resulting in a yellow colour (4-nitrophenole) 
forming in the reaction wells. Results were obtained by measuring the OD^nm on a 
spectrophotometer using Softmax Pro software.
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2.2.11 Luciferase reporter gene assay
2.2.11.1 Cell culture and transfection
HUVEC (Promocell, Germany) were cultured as monolayers in EGM media supplied by 
Biowhittaker at 37°C, 5% C02. Cells were seeded ~18hours prior to transfection at a 
density of 5xl04 cells/well into 12 well culture plates and were deemed suitable for 
transfection when approximately 70% confluent. Solution A containing Lipofectin 
(Invitrogen, Paisley, UK) (5.125pi for each well transfected) and Optimem 1 (Invitrogen, 
Paisley, UK) (82pl for each well to transfected) was mixed and left to warm to room 
temperature for 45 minutes. Solution B was made by mixing 0.6pg/well of plasmid 
construct, ~3ng/well renilla expression vector and 82pl/well optimem 1. A transfection 
mix was prepared by adding 87.125pl of solution A to solution B and left at room 
temperature for 15 minutes. Cells were washed with Optimem 1 to discard traces of growth 
media, which could interfere with transfection, and 330pl of Optimem 1 was added to each 
well. 168 pi of transfection mix was then added to each well and the cells incubated at 
37°C, 5%C02 for four hours. After incubation the spent media/transfection mix was 
discarded and 1ml of EGM media added to each well. Cells were cultured for a further 48 
hours.
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2 .2 .11.2 Cell lysis and luciferase assay
Cell lysis and luciferase measurements were performed using the dual light luciferase 
reporter assay kit (Promega, Madison, USA). Cells were lysed by the passive lysis method. 
250pl of passive lysis buffer was added to each well and mixed for 20 minutes to ensure 
complete lysis. Cell lysates were transferred to 1.5ml Eppendorf tubes and stored at -20°C 
until required, but for no longer than 48 hours. For luciferase measurement 20|ul of cell 
lysate was transferred to a 96 well opti-plate (Packard Bioscience, Netherlands) and placed 
in a Tropix TR717 dual injection microplate luminometer (Applied Biosystems). The 
luminometer was programmed to inject 50pl of LARI followed by 50pl of Stop and Glow. 
For each experiment transfections were performed in triplicate for each construct and 
luciferase activity was normalised to renilla activity.
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2.2.12 Populations collected for vascular phenotyping/disease studies
DNA from seven populations was collected for genotype/phenotype studies. Each of these 
cohorts had been developed with differing/complementary phenotypic measures.
2.2.12.1 Healthy Subjects
A) Prospective cohort study-NPHSII
Subjects were selected from the NPHSII cohort for analysis. This cohort comprises 
approximately 3000 healthy men recruited from 9 primary care practices in the UK (Table 
2.2). The study was originally setup to test the hypothesis that prior to myocardial 
infarction there is a hypercoagulable state within the body (Meade et al., 1986). 
Demographic characteristics of the study cohort are summarized in table 2.3. The men 
were aged between 50 and 61 years and were healthy at the time of recruitment. All 
subjects were reviewed annually and asked to avoid heavy meals, refrain from smoking and 
vigorous exercise from the midnight before the examination. Smoking status, blood 
pressure, BMI, serum cholesterol, trigycerides, fibrinogen, factor VII coagulant activity 
(FVIIc % standard) and HDL cholesterol were measured at the time of recruitment and 
during follow-up visits over the following 9 years. Serum cholesterol and triglyceride 
levels were measured by automated enzymatic methods (Sigma, UK and Wako Chemicals, 
Alpha Laboratories, UK). Venous blood was taken at time of recruitment and the plasma
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separated and stored at -80°C. All IHD events have been recorded over the time of the 
study.
Clinic Number of men recruited
Aston Clinton 1 1 1
Camberley 416
Carnoustie 408
Chesterfield 261
Halesworth 435
Harefield 291
North Mymms 291
Parkstone 413
St. Andrews 386
Table 2.2. Number of men recruited from each of the 9 UK clinics for the 
NPHSH study cohort.
Characteristic Mean (SD)
N 2965
Age (years) 56.1 (3.5)
BMI (kg/m2) 26.5 (3.5)
SBP (mmHg) 138.1 (19.2)
DBP (mmHg) 84.5(11.4)
Cholesterol (mmol/1) 5.7(1.02)
Triglycerides (mmol/1) 1.79 (0.95)
FVIIc (% standard) 109.1 (28.9)
Fibrinogen (pmol/1) 0.08 (0 .0 2 )
ApoAl (mmol/1) 1.63 (0.32)
Table 2.3 Demographic characteristics of the NPHSII study cohort.
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B) German population screen
Blood was collected from 128 healthy German individuals by Professor Rainer Boger 
(Department of Clinical Pharmacology, University of Hamburg). ADMA and SDMA 
measurements were collected by HPLC. Measurements of age, height, weight, blood 
pressure, heart rate, triglycerides and cholesterol were recorded and entered into an excel 
database. Of the 128 individuals studied, 3 were hypercholesterolemic, 2 were 
hypertensive, and no individuals were recorded as diabetic. Demographic characteristics of 
this cohort are summarized in table 2.4
Characteristic Mean (SD)
N 128
Age (years) 36.03 (11.16)
Height (cm) 177.0 (9.05)
Weight (kg) 75.85 (12.71)
SBP (mmHg) 127.9 (12.96)
DBP (mmHg) 79.30(7.31)
Heart rate (bpm) 73.14(8.10)
ADMA (pmol/1) 0.78 (0.40)
SDMA (pmol/l) 0.59 (0.29)
Table 2.4 Demographic characteristics of the German population screen cohort.
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C) Cambridge Young Adults Study
This cohort was originally recruited by Dr. John Deanfield (University College London) to 
investigate associations between eNOS genotype and vascular function (Leeson et al., 
2002). Healthy individuals bom in the Cambridge Maternity Hospital between 1969 and 
1975 (in whom early growth measures had been recorded) were invited to attend a clinic 
for cardiovascular risk profile evaluation. A total of 264 subjects aged 20-28 years were 
recruited. Blood was collected by venepuncture and personal and family medical history 
(including details of heart disease and risk factors) assessed by questionnaire. In each 
subject a fasting venous blood sample was analysed for insulin, glucose, total cholesterol, 
HDL, LDL and triglycerides. Individuals were classed as smokers if one of more cigarette 
was smoked per day for the previous six months. Blood pressure, weight (to +/-0.1kg) and 
height (+/-0.1mm) were also recorded. Measurement of endothelial dependent and 
independent vascular responses of the brachial artery were performed using high resolution 
ultrasound imaging (Acuson 128XP/10. 7MHz probe and automated vessel diameter 
measurement) as described in section 2.2.13.2. All FMD measurements were carried out 
by Dr. Paul Leeson. Phenotypic characteristics of this cohort are shown in table 2.5.
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Characteristic Mean (SD)
N 264
Age (years) 23.49(1.837)
Height (cm) 168.4(10.42)
Weight (kg) 68.42 (12.54)
SBP (mmHg) 127.3 (13.98)
DBP (mmHg) 70.34 (8.75)
Total cholesterol (mmol/1) 4.58(1.01)
LDL cholesterol (mmol/1) 2.84 (0.91)
HDL cholesterol (mmol/1) 1.2 (0.3)
Table 2.5 Demographic characteristics of the Cambridge Young Adults Study.
2.2.12.2 Renal Failure patients
A) London renal failure patients
A cohort of individuals comprising 130 renal failure patients of different ethnicity, 53% 
males and 47% females, were recruited from the Middlesex Hospital, London by Dr. Jenny 
Cross. Endothelial function was assessed in vivo by the measurement of conduit artery in 
response to increased blood flow (flow mediated dilatation; FMD) (section 2.2.13.2). 
Systolic and diastolic blood pressure measurements were taken using a 
sphygmomanometer. ADMA and SDMA measurements were made by Miss Rachel 
Jackson (University College London), using reverse phase high-pressure liquid 
chromatography (HPLC) as described by Vallance et al., 1992. Demographic 
characteristics of the study cohort are summarised in table 2 .6 .
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Characteristic Mean (SD)
N 130
Age (years) 53.4(17.59)
SBP (mmHg) 144.8 (32.02)
DBP (mmHg) 85.16(52.83)
FMD (% change) 4.64 (4.45)
ADMA (pmol/1) 1.57(1.16)
SDMA (pmol/1) 3.71 (2.05)
Table 2.6 Demographic characteristics of the London Renal Failure cohort.
B) Italian renal failure patients (CREED)
DNA from 277 renal failure patients was kindly donated by Dr Carmine Zoccali (IBIM- 
CNR, Italy). Subjects were originally recruited for the CREED (Cardiovascular Risk 
Extended Evaluation in Dialysis) study, in which a total of 278 dialysis patients were 
followed up over a 4 year period to determine risk markers for CVD among patients with 
advanced renal disease (Malatino et al., 1999). Demographic characteristics of the study 
cohort are summarised in table 2.7. Measures of cardiovascular risk factors such as 
ADMA, SDMA, fibrinogen, homocysteine, cholesterol, C-reactive protein and age were 
recorded as well as time of death (all cause and CVD related).
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Characteristic Mean (SD)
N 277
Age (years) 61.02(15.38)
SBP (mmHg) 132.2 (22.64)
DBP (mmHg) 74.36(12.16)
Total cholesterol (mmol/1) 5.39(1.46)
HDL (mmol/1) 1.06 (0.3)
LDL (mmol/1) 3.41 (1.26)
Triglycerides (mmol/1) 2 .0 ( 1 .0 2 )
BMI (kg/m2) 24.89 (4.37)
Fibrinogen (pmol/1) 13.39 (6.16)
ADMA (pmol/1) 3.26 (2.04)
SDMA (pmol/1) 3.71 (2.18)
Table 2.7 Demographic characteristics of the Italian Renal Failure cohort 
(CREED).
2.2.12.3 Diabetic patients and controls (EBCT cohort)
A cohort of 385 individuals comprising 188 type I diabetic patients and 197 control 
subjects was collected by Dr. H Colhoun (University College London) initially to measure 
the effect of diabetes on coronary artery calcification (CAC) (Colhoun et al., 2000). 
Diabetic patients were recruited form five London hospitals and defined by age of onset 
<25years. Control subjects were drawn from two London general practices and were 
included regardless of heart disease. All participants gave informed written consent. The 
health status of all subjects was assessed by questionnaire, which noted alcohol 
consumption, smoking status and amount of exercise taken weekly. Blood pressure was
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measured in triplicate and the mean of the second and third reading used. CAC was 
measured by electron beam computerised tomography (EBCT), using an Ultrafast CT 
scanner (IMATRON C-150XL). In vivo vascular function studies were performed by 
venous occlusion plethysmography as described previously (Chan et al., 2003) (section 
2.2.13.1). Briefly, forearm blood flow was measured in response to intra-brachial artery 
infusion of acetylcholine (ACh) at doses 25, 50 and 100 nmol/min each dose for 3 minutes, 
bradykinin (BK) at doses 10, 30 and lOOpmol/min each dose for 3 minutes, glyceryl 
trinitrate (GTN) at doses 4, 8  and 16 nmol/min each dose for 5 minutes, N^-monomethyl- 
Larginine (LNMMA) at doses 1, 2 and 4pmol/min each dose for 5 minutes and 
noradrenaline (NA) at doses 60, 120 and 240pmol/min each dose for 5 minutes. Total 
cholesterol, HDL, LDL, triglycerides and C-reactive protein (CRP) were also recorded.
Total cohort Diabetics Non-Diabetics
Characteristic Mean (SD) Mean (SD) Mean (SD)
N 385 197 188
Age (years) 37.9 (3.9) 37.9(3.9) 37.9(3.9)
SBP (mmHg) 121.1 (14.24) 124.9(13.47) 117.5(14.1)
DBP (mmHg) 73.4 (9.2) 73.92 (8 .6 ) 72.79 (9.75)
Cholesterol (mmol/1) 5.42(1.16) 5.34(1.09) 5.5 (1.22)
HDL (mmol/1) 1.77 (0.44) 1.84 (0.47) 1.7 (0.41)
Table 2.8 Demographic characteristics of the Diabetic patients and controls. 
The mean (SD) of CVD risk factors are shown for the total cohort, diabetics and 
non-diabetics.
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2.2.12.4 Pregnant Females
139 unrelated Caucasian women with normal singleton pregnancies were previously 
recruited from the Harris Birthright Centre antenatal clinic by Dr Makrina Sawidou (Kings 
College London) to study the association of the Glu298Asp eNOS polymorphism with 
FMD during pregnancy (Sawidou et al., 2001). All were healthy and had no history of 
cardiovascular disease. Age, smoking status, blood pressure, FMD, gestational age, parity 
and heart rate were recorded. Demographic characteristics of this study cohort are 
summarised in table 2.9.
Characteristic Mean (SD)
N 139
Age (years) 33 (30-35)
BMI (kg/m2) 22.94 (21.11-25.21)
Smokers 24% r
SBP (mmHg) 115.4(10.17)
DBP (mmHg) 6 8 . 8  (10.33)
Cholesterol (mmol/1) 5.11 (0.80)
FMD (% max) 9.33 (3.29)
Gestational age (weeks) 12.4 (12.3-12.9)
Heart rate (bpm) 75 (9.0)
Table 2.9 Demographic characteristics of the pregnancy cohort.
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2.2.13 Measures of vascular function
2.2.13.1 Venous occlusion plethysmography
Forearm blood flow was measured by venous occlusion plethysmography as described 
previously (Benjamin et al., 1995). All studies were carried out by the individual who 
recruited the patient cohort. Briefly, the subject lay supine in a quiet temperature controlled 
laboratory and the brachial artery of the non-dominant arm was cannulated with a 27-gauge 
needle inserted under local anaesthesia (2mL of 1% lidocaine). A strain-gauge (mercury in 
silastic) was placed around the forearm to measure the change in forearm circumference in 
millimetres per minute, which is proportional to arterial blood inflow. Resting blood flow 
was allowed to normalise for 30 minutes following needle insertion prior to the infusion of 
vasoactive drugs. Drugs (ACh, BK, LNMMA, NA and GTN) or normal saline (sodium 
chloride 0.9% wt/vol) were infused continuously ■ at 0.5mL/min. During periods of 
recording, the hands were excluded from the circulation by inflating wrist cuffs to 2 0 0  
mmHg. The needle was removed at the end of each study period.
2.2.13.2 Flow mediated dilatation (FMD)
Measurement of endothelial dependent and independent vascular responses of the brachial 
artery were performed using high resolution ultrasound imaging. All studies were carried 
out by the individual who recruited the patient cohort. Each subject lay supine in a quiet 
temperature controlled laboratory and, after ten minutes brachial artery diameter and blood
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flow were recorded at baseline. A pneumatic cuff was then inflated to suprasystolic 
pressure on the forearm for four and a half minutes. Deflation of the cuff resulted in 
reactive hypereamia causing increased flow through the brachial artery stimulating 
endothelium dependent flow mediated dilation (FMD). The change in brachial artery 
diameter was measured one minute after cuff deflation (maximal response). Measurements 
were then repeated after a ten minute rest, and between three and four minutes after a single 
sublingual spray of glyceryl trinitrate (GTN) to measure endothelium-independent 
response.
2.2.14 Statistical analysis
All statistical analyses were carried out using Graphpad Prism software (version 3.0), or 
STATA. Phenotypic measures are described by the mean and standard deviation (SD). 
Observed numbers of each genotype were compared with those expected under the 
assumption of Hardy-Weinberg equilibrium by %2 analysis (see appendix I). Allele 
frequencies were deduced from genotype frequencies. Pairwise linkage disequilibrium 
coefficients between polymorphisms were estimated by log linear analysis (Chakravarti et 
al., 1984) (Appendix II). Allelic associations were tested by One-Way Analysis of 
Variance (ANOVA) or student t test where appropriate. A P value of <0.05 was taken to be 
statistically significant. The Bonferroni test was used where necessary to correct for 
multiple comparisons.
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CHAPTER 3
ASSOCIATION STUDIES OF THE NADPH OXIDASE 
p22PHOX C242T POLYMORPHISM AND ENDOTHELIAL
FUNCTION
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3.1 Aim
To investigate the association between the p22phox (CYBA) C242T polymorphism and 
endothelial function in healthy subjects.
3.2 Background
The possible role of ROS in the development of vascular diseases such as atherosclerosis 
has attracted widespread interest over recent years. ROS mediate oxidation of LDL 
particles, which accumulate causing damage to the endothelium, and contribute to 
atherosclerotic plaque development (Witztum et al., 1991). In addition ROS have been 
implicated in the promotion of smooth muscle cell growth, migration and apoptosis 
(Griendling et al., 2000) all of which occur during the atherogenic process. The reactions 
between ROS and NO may also have implications for vascular disease development. For 
example, NO reacts rapidly with 0 2* to produce ONOO', which can lead to protein and 
DNA damage, but perhaps most importantly results in ‘quenching’ of the vasodilator and 
numerous athero-protective functions of NO, leading, potentially to endothelial dysfunction 
(Beckman et al., 1990). Several studies have indicated that 0 2‘ is indeed elevated in disease 
states such as hypertension, heart failure, hypercholesterolemia, diabetes, preeclampsia and 
renal failure, and could be contributing to the endothelial dysfunction seen in these 
disorders (Mehta et al., 1994; Keith et al., 1998; Ohara et al., 1993; Langenstroer et al., 
1992; Sikkema et al., 2001; Canaud et al., 1999). Diverse sources for the increased 0 2' in 
the vessel wall have been proposed including enzymes such as the NADPH oxidases,
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xanthine oxidase, cyclooxygenase or, under some circumstances, NOS. Decreased 
inactivation of 0 2‘ for example by SOD might also contribute (Kodja et al., 1999; Fukai et 
al., 2002). 0 2' production by the NADPH oxidase enzyme in the vasculature has attracted a 
vast amount of interest to date, and is the main focus of this chapter.
3.2.1 NADPH oxidase generates 0 2~ in both phagocytic and non-phagocytic cells
Release of 0 2’ by cells of the immune system (primarily macrophages) is part of an innate 
defense mechanism against bacterial pathogens. The production of 0 2' is mediated by the 
enzyme NADPH oxidase which utilizes either NADH or NADPH as an electron donor to 
reduce molecular oxygen (0 2) to 0 2' in the reaction: NAD(P)H + 2 0 2 -» NAD(P)+ + 202\  
A functional NADPH oxidase in non-phagocytic cells was proposed when patients with the 
X-linked form of the immunodeficiency syndrome-chronic granulatomous disease (CGD, 
which is caused by a dysfunctional or absent gp91phox subunit of the NADPH oxidase), 
were found to have normal 0 2' production in fibroblasts (Meier et al., 1993). Subsequently 
mRNA and protein for NADPH oxidase subunits have been identified in a variety of cell 
types including human and animal endothelial cells and vascular smooth muscle cells (Van 
Heerebeek et al., 2002), leading to the theory that NADPH oxidase may represent a major 
source of 0 2' in the human vasculature. This theory is supported by evidence that the 
vascular wall is a site of 0 2' generation (Barbacanne et al., 2000), and the finding of an 
association between 0 2* generated from NADPH oxidase in the vascular wall and risk 
factors for atherosclerosis (Guzik et al., 2000a). In addition, a number of studies have 
recently demonstrated evidence for increased NADPH oxidase subunit expression in
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diseased vessels. For example Morawietz et al., 2001 demonstrated a 10 fold increase in 
expression of gp91phox mRNA in aortic rings of spontaneously hypertensive rats which 
correlated with a 3 fold increase in production of 0 2' (although this might also reflect the 
recruitment of macrophages in diseased vessels). p22phox mRNA expression was shown 
to be elevated in aortic VSMC of hypertensive rats (Fukui et al., 1997), and also in human 
atherosclerotic coronary arteries compared to non-atherosclerotic arteries (Azumi et al., 
1999). Also, studies of smooth muscle cells from genetically modified mice (p47phox'A) 
demonstrated reduced 0 2‘ production and proliferation compared to wild type mice. 
Smooth muscle cells from mice lacking the gp91phox subunit (gp91phox"/‘) however were 
indistinguishable from smooth muscle cells from wild type mice. Comparison of aortic 
atherosclerotic lesions of ApoE knockout mice (ApoE7', a model of atherosclerosis) with 
ApoE and p47phox double knockout mice (ApoE*/7p47phox*/‘) demonstrated reduced 
lesion size in the ApoE*/7p47phox'/' mice, suggesting a role for NADPH oxidase in the 
development of atherosclerosis (Barry-Lane et al., 2001).
3.2.2 Vasculature NADPH oxidase is distinct from phagocytic NADPH oxidase
Both phagocytic and vascular NADPH oxidases are transmembrane proteins comprising 
five subunits-gp91phox, p22phox, p47phox, p67phox and p40phox (Chapter 1.3.5.1). The 
gp91phox and p22phox subunits associate with each other to form the active 
flavocytochrome b558, whereas the three other phox proteins are cytosolic and associate with 
the flavocytochrome b558 to modulate its function. In contrast to the phagocytic NADPH 
oxidase, which releases 0 2‘ almost instantaneously, the vascular enzyme releases 0 2’ more
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slowly and it has been estimated that its capacity is one third that of the phagocytic enzyme 
(Griendling et al., 1998).
Recent research indicates that in non-phagocytic cells the gp91phox subunit of phagocytic 
NADPH oxidase is replaced by homologous proteins designated Noxl, Nox3, Nox4 and 
Nox5, depending on the cell type in which it is expressed. These differences account for the 
reduced enzyme activities in phagocytic versus non-phagocytic cells. Noxl mRNA has 
been detected in colon, prostate, uterus and vascular smooth muscle cells (Suh et al., 1999; 
Kikuchi et al., 2000), Nox3 is expressed by fetal kidney tissue, and Nox4 and 5 by renal 
epithelial cells (Geiszt et al., 2000; Shiose et al., 2001). The phagocytic NADPH oxidase 
contains the prototype gp91phox (also termed Nox2). Differential expression of gp91phox 
isoforms was first demonstrated by Sorescu et al., 2002. They reported gp91phox (Nox2) 
expression predominantly in the adventitia and intima of non-atherosclerotic arteries and in 
the plaque core of atherosclerotic arteries where macrophages are most active. In contrast 
the expression of the Nox4 isoform was complementary to that of gp91phox (Nox2), being 
mainly expressed in the media of non-atherosclerotic arteries and again where gp91phox 
(Nox2) was absent in atherosclerotic arteries. Only one isoform of p22phox has been 
reported, and its expression correlates with regions of 0 2‘ production. Thus differences in 
the expression pattern of gp91phox (Nox2) isoforms maybe relevant in the progression of 
atherosclerosis. However, as yet no genetic analysis of the Nox subunits expressed in the 
vasculature has been reported other than gp91phox mutations causing the X-linked form of 
CGD (OMIM database, www.ncbi.nlm.nih.gov). In contrast the gene encoding p22phox 
(CYBA) has been studied in detail and, in addition to mutations causing an autosomal
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recessive form of CGD, several polymorphisms have also been identified (Parkos et al., 
1988; Dinauer et al., 1991; de Boer et al., 1992).
3.2.3 Common Genetic variation in p22phox
Conjugation of the p22phox subunit with any of the Nox isoform subunits is essential for 
NADPH oxidase enzyme activity, and p22phox expression has been shown to correlate 
primarily with regions of elevated 0 2' production (Sorescu et al., 2002). Polymorphisms in 
one or more of the NADPH oxidase subunits could either up or down regulate the 
generation of 0 2' and prove to be an important risk factor for vascular disease development. 
Several mutations in the p22phox gene (CYBA) are known to cause autosomal recessive 
CGD (Dinauer et al., 1991; de Boer et al., 1992), but vascular function has not been 
systematically investigated in these individuals. To date two polymorphisms (C242T and 
A640G) have been described in the CYBA gene and investigated for association with 
atherogenesis (Guzik et al., 2000a; Cahilly et al., 2000; Cai et al., 1999; Gardemann et al., 
1999). The CYBA C242T polymorphism, which results in a His72-»Tyr substitution that 
lies in a potential heme-binding site within exon 4 of the protein (Parkos et al., 1988), has 
been the main focus of study. Several conflicting reports have been published as to the 
significance of this variant for vascular 0 2* production. For example, Guzik et al., 2000 
demonstrated that the 242T allele was associated with reduced NADPH oxidase activity in 
human blood vessels from patients with CAD. Carriage of the T allele was also associated 
with augmented FMD of the brachial artery in 93 patients, 30% of whom had evidence of 
CAD (Schachinger et al., 2001), suggesting that the 242T allele may exert a protective
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effect upon the vasculature by down-regulating 0 2' production. This data is supported by a 
case-control study in which the 242T allele was present at higher frequency in control 
subjects than individuals with CAD in a Japanese population (Inoue et al., 1998). In 
contrast, Cahilly et al., 2000, reported the 242T allele was associated with increased 
progression of CAD and decreased regression of disease upon treatment compared to CC 
homozygotes in a study of 313 individuals from the Lipoprotein and Coronary Artery 
Study. The C242T polymorphism was not associated with the occurrence or severity of 
CAD in a cohort of 689 Australian Caucasians, however in a small subset of 44 males the T 
allele was found to be more common amongst those with CAD (Cai et al., 1999). 
However, functional genetic studies in patients might be confounded by the presence of 
disease and/or drug treatment. The aim of this study therefore, was to genotype two 
cohorts (one comprising healthy individuals and one comprising 199 diabetics and 201 
controls) for the p22phox C242T polymorphism, and investigate the hypothesis that 
endothelium-dependent vaso-reactivity in healthy subjects would be dependent on genotype 
for the C242T polymorphism of p22phox.
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3.3 Subjects and Methods
3.3.1 Subjects
Two subject groups were investigated for association between p22phox genotype and 
vascular function during this study:
Cambridge Young Adults Study:
Individuals from the Cambridge Young Adults Study were selected for association studies 
between genotype and endothelium dependent and independent vascular response (Chapter 
2.2.12.1). Briefly, this cohort comprises 264 healthy individuals (127 males, 137 females) 
bom in the Cambridge Maternity Hospital between 1969 and 1975. A fasting venous blood 
sample was obtained form each participant and measures of various CVD risk factors such 
as cholesterol, blood pressure and glucose were recorded (detailed in Chapter 2.2.12.1). 
Subjects were classed as smokers (if 1 or more cigarette was smoked per day for the past 6  
months), previous smokers or non-smokers. Demographic characteristics of the study 
participants are outlined in table 2.5. Brachial artery diameter was measured in response to 
endothelium dependent (FMD) and independent (sublingual GTN) stimulus using high- 
resolution ultrasound imaging.
EBCT cohort:
Individuals from the EBCT cohort were investigated for associations between genotype and 
endothelial function. Briefly, this cohort consists of 385 individuals comprising 188 type 1
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diabetic patients and 197 control subjects (Chapter 2.2.12.3). Blood samples were collected 
from participants after an overnight fast and measures of total cholesterol, HDL cholesterol 
and triglycerides were recorded. Vascular function was assessed in vivo by forearm venous 
occlusion plethysmography (Chapter 2.2.13.1), which involves measuring forearm blood 
flow in response to intrabrachial infusion of the endothelium-dependent dilators 
acetylcholine (ACh) at doses 25, 50 and 100 nmol/min and bradykinin (BK) at doses 10, 30 
and 100 pmol/min, each dose for 3 min, and the endothelium-independent dilator glyceryl 
trinitrate (GTN) at doses 4, 8  and 16 nmol/min, each dose for 5 min. NG-monomethyl-L- 
arginine (L-NMMA) at doses 1, 2 and 4 pmol/min, each dose for 5 min, and noradrenaline 
(NA) at doses 60, 120 and 240 pmol/min, each dose for 5 min, were infused as 
endothelium-dependent and independent constrictors respectively.
3.3.2 DNA extraction
DNA was extracted from whole blood samples using the salting-out method as described in 
Chapter 2.2.1.1.
3.3.3 Genotyping by PCR-RFLP analysis
Exon 4 of the p22phox (CYBA) gene was amplified by PCR as described in Chapter 2.2.2 
with forward (5’ TGCTTGTGGGTAAACCAAGGCCGGTG 3’) and reverse (5’ 
AACACTGAGGTAAGTGGGGGT 3’) oligonucleotides described by Inoue et al., 1998. 
The optimum annealing temperature and MgCl2 concentration for the reaction were 60°C
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and 2mM respectively, and amplification resulted in a band of 348bp containing the 
p22phox C242T polymorphic site. The C-»T base substitution of the p22phox C242T 
polymorphism resulted in the creation of an Rsal restriction enzyme site. Genotyping was 
therefore carried out as described in Chapter 2.2.6.1 using restriction enzyme Rsal to 
distinguish between allelic variants. Digests were carried out overnight at 37°C. Upon 
digestion the 348bp PCR product was cleaved into fragments of 188bp and 160bp in the 
presence of the T allele. Products were electrophoresed on 1.5% agarose gels stained with 
ethidium bromide.
3.3.4 Data analysis
Genotype frequencies were compared to those expected under Hardy-Weinberg equilibrium 
by x2 analysis. Allelic associations were tested by One-Way Analysis of Variance 
(ANOVA) or Student t-test where appropriate. Multiple logistic regression was applied to 
analyse the relationship between genotype and endothelial function, and a linear regression 
model was used to look at the effect of risk factors on endothelial function using absolute 
FMD with resting vessel size as an independent factor. A p value of <0.05 was taken to be 
statistically significant.
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3.4 Results
3.4.1 Genotype and allele frequencies of the p22phox (CYBA) C242T polymorphism
Genotype and allele frequencies are summarized in table 3.1. A total of 249 out of 264 
individuals were genotyped successfully from the Cambridge Young Adults Study, and 332 
out of 385 from the EBCT study. PCR failed to amplify the remaining samples due to poor 
quality DNA. Genotype frequencies did not differ from those expected under Hardy- 
Weinberg equilibrium.
p22phox C242T
Cohort
CC
Genotype
N(%)
CT TT
Allele
%
C T
5C2 P
Cambridge 119(48.0) 107(43.0) 23 (9.0) 69.0 31.0 0.00 0.88
Young Adults
EBCT 151 (46.0) 149(44.0) 32 (10.0) 68.0 32.0 0.30 0.58
(Diabetics) 76 (45.0) 75 (44.0) 19(11.0) 67.0 33.0 0.00 0.94
(Controls) 75 (46.0) 74 (46.0) 13 (8.0) 69.0 31.0 0.80 0.37
Table 3.1 Genotype and allele frequencies of the p22phox C242T polymorphism.
Genotype frequencies did not differ from those expected by the Hardy-Weinberg equation 
calculated by Chi-squared analysis.
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3.4.2 p22phox genotype and CVD risk factors in the Cambridge Young Adults
cohort
Conventional cardiovascular risk factors and other demographic details are shown in table
3.2 according to p22phox genotype. TT homozygotes had significantly higher HDL 
cholesterol compared to C allele carriers (*P=0.03, students t-test, table 3.2), but no 
significant association was observed between genotype and other cardiovascular risk 
factors.
p22phox C242T
CC+CT 
Mean (SD) 
N=226
TT
Mean (SD) 
N=23
P
Age (years)
Weight (kg)
SBP (mmHg)
DBP (mmHg)
Total cholesterol (mmol/1) 
LDL cholesterol (mmol/1) 
HDL cholesterol (mmol/1) 
Glucose (mmol/1)
Fasting Insulin (IU)
23.4(1.89) 
68.7 (12.6) 
127(13.57) 
70.5 (8.29) 
4.58(1.01) 
2.84 (0.89) 
1.19(0.29)
5.01 (0.50)
9.1 (6.04)
23.83 (1.86) 
67.9 (12.94) 
126(17.26) 
68.43 (11.01) 
4.61 (0.81) 
2.7 (0.82) 
1.33 (0.28) 
5.1 (0.64) 
7.71 (4.39)
P=0.32
P=0.98
P=0.70
P=0.29
P=0.90
P=0.72
P=0.03 *
P=0.24
P=0.30
FMD (% change from baseline) 3.29 (2.6) . 4.51 (2.78) P=0.03*
GTN (% change from baseline) 21.65 (7.7) 24.31 (8.7) P=0.13
Table 3.2 Phenotypic characteristics of the Cambridge Young Adults cohort 
according to p22phox C242T genotype. C allele carriers were analysed against TT 
homozygotes. C allele carriers had lower FMD compared to TT homozygotes. Data is 
represented as mean (SD). *P=<0.05 (statistically significant). All data was analysed by 
students t test.
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3.4.3 Relationship between p22phox genotype and vascular function in the 
Cambridge Young Adults cohort.
A significant association was observed between genotype and endothelium dependent FMD 
(*P=0.03, One-way ANOVA). Mean (SD) FMD was 3.5±2.5 in CC homozygotes, 3.0±2.7 
in CT individuals and 4.51±2.78 in TT homozygotes. Post hoc comparison of FMD 
between all three genotypes by Tukey’s post-test, revealed the major significant difference 
in FMD was between CT and TT subjects (p<0.05). No significant difference in FMD was 
observed between CC and CT individuals (p>0.05). The data was therefore analysed 
according to a recessive genetic model where TT subjects were compared to C allele 
carriers. TT homozygotes had significantly increased FMD compared to C allele carriers 
(*P=0.03, figure 3.1 and table 3.2). No significant difference was observed for 
endothelium independent response (P=0.13, figure 3.2 and table 3.2). In a linear regression 
model the positive association between TT
homozygosity and endothelial function was independent of classical risk 
factors - systolic blood pressure, smoking, fasting glucose, LDL and HDL 
(regression coefficient for C242T alone = 0.0378 mm (95%CI: 0.00 to 0.08), 
p<0.05, r=0.13, and in a model including risk factors = 0.0399 mm (95%CI: 0.00 
to 0.08) p<0.05, r=0.26.
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CC+CT TT
p22phox genotype
Figure 3.1 FMD according to p22phox genotype in the Cambridge Young 
Adults Study. Individuals homozygous for the T allele has significantly higher 
FMD compared to CC+CT individuals *P=0.03 (students t test).
p22phox genotype
Figure 3.2 % change in brachial artery diameter in response to GTN
(endothelium-independent response) according to p2 2 phox genotype in the 
Cambridge Young Adults Study. No significant difference was observed between 
TT homozygotes and C allele carriers. P=0.13 (students t test).
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3.4.4 p22phox genotype and cardiovascular risk factors in the EBCT cohort
Phenotypic characteristics according to p22phox C242T genotype are shown in table 3.3. 
C allele carriers were grouped and analysed against TT homozygotes. No significant 
association was observed between p22phox genotype and total cholesterol, HDL 
cholesterol, systolic blood pressure or diastolic blood pressure in the whole cohort.
p22phox C242T
CC+CT
Mean (SD) 
N=300
TT
Mean (SD) 
N=32
P
Age (years) 38.1 (3.96) 36.7 (4.01) 0.07
SBP (mmHg) 121.5(14.23) 117.5(13.74) 0.13
DBP (mmHg) 73.4 (9.28) 72.0 (8.73) 0.43
Total cholesterol (mmol/1) 5.4(1.17) 5.3 (1.16) 0.59
HDL cholesterol (mmol/1) 1.8 (0.44) 1.7 (0.52) 0.72
Table 3.3 Phenotypic characteristics of individuals from the EBCT study 
according to p22phox C242T genotype. C allele carriers were analysed against TT 
homozygotes. Data is represented as mean (SD). All data was analysed by students t test.
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3.4.5 Relationship between p22phox genotype and vascular function in the EBCT
cohort.
Endothelial function according to p22phox genotype is shown in figure 3.3. No significant 
association was observed between p22phox genotype (TT versus CC+CT individuals) and 
endothelial function in this cohort (Figure 3.3). This was also the case after analyzing 
diabetics, non-diabetics, smokers and non-smokers separately (table 3.4).
Diabetics
P(P)
Non-diabetics
P(P)
Smokers
P(P)
Non-smokers
P(P)
Acetylcholine 0.03 (0.82) 0.16(0.39) 0.04 (0.86) 0.04 (0.71)
Bradykinin 0.02 (0.85) 0.17(0.17) 0.17(0.19) 0.05 (0.58)
GTN 0.04 (0.60) 0.06 (0.64) 0.07 (0.60) 0.01 (0.91)
Noradrenaline 0.05 (0.26) 0.02 (0.83) 0.08 (0.46) 0.03 (0.44)
L-NMMA 0.004 (0.89) -0.05 (0.25) 0.05 (0.36) -0.03 (0.37)
Table 3.4 Results of multiple regression analysis of endothelial function according to 
p22phox genotype in diabetics, non-diabetics, smokers and non-smokers. Effect of 
genotype on vascular function in response to acetylcholine (doses 25, 50 and 100 nmol/1), 
bradykinin (doses 10, 30 and 100 pmol/min, each dose for 3 min), GTN (doses 4, 8  and 16 
nmol/min, each dose for 5 min), noradrenaline (doses 60, 120 and 240 pmol/min, each dose 
for 5 min), L-NMMA (doses 1, 2 and 4 pmol/min, each dose for 5 min) was measured by 
venous occlusion plethysmography as described in chapter 2.2.13.1. Individuals were 
divided into diabetic/non-diabetic and smokers/non-smokers and analysed for a relationship 
between genotype (CC+CT versus TT) and endothelial function by multiple regression 
analysis, p coefficients and p value for the effect of genotype using a recessive model on 
forearm blood flow in response to drug infusion is reported.
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Figure 3.3 p22phox genotype and vascular function in the EBCT study cohort.
Graphs A-E show the fold change in forearm blood flow according to genotype (TT versus 
CC+CT individuals) after infusion with A-acetylcholine (25, 50 and 100 nmol/1), B- 
bradykinin (10, 30 and 100 pmol/min), C-glyceryl trinitrate (4, 8 and 16 nmol/min), D- L- 
NMMA (1,2 and 4 pmol/min) and E- noradrenaline (60, 120 and 240 pmol/min). No 
significant association was observed between genotype and forearm vascular reactivity.
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3.5 Discussion
During this study an association between the p22phox C242T polymorphism and FMD of 
the brachial artery was observed in a cohort of healthy subjects recruited from the 
Cambridge area. When analysed under a recessive model, individuals homozygous for the 
rare T allele exhibited significantly greater FMD compared to those individuals carrying the 
C allele. This difference was not confounded by differences in other cardiovascular risk 
factors including smoking, blood pressure, total and HDL cholesterol, since after 
adjustment for these in a multiple regression model, the relationship was preserved. No 
difference was observed for endothelium independent response between the two groups. In 
contrast no association was seen between p2 2 phox genotype and endothelial function in the 
forearm vasculature in a cohort of type I diabetics and controls.
Diminished FMD in healthy individuals is associated with a family history of IHD and, in 
patients with CVD, endothelial function is predictive of future events (Suwaidi et al., 2000; 
Schachinger et al., 2000). Down-regulation of NO synthesis or activity is a possible cause 
of such endothelial dysfunction (Gaeta et al., 2000). Endothelium-dependent vasodilation 
in response to flow is largely dependent on NO release (Joannides et al., 1995). The rapid 
reaction between ROS such as NO and 0 2' resulting in the formation of ONOO' is a 
plausible mechanism whereby the vasodilator actions of NO might be attenuated in this 
vessel. In addition, oxidative inactivation of the essential NOS cofactor BH4  could also 
lead to sub-optimal NOS activity resulting in decreased NO production and more 0 2‘ 
(Figure 3.4). If subjects homozygous for the 242T allele of p22phox produce less 0 2'
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basally as has been reported previously (Guzik et al., 2000), this might lead to increased 
NO availability and enhanced FMD. In contrast, no relationship was detected between 
endothelium-dependent dilatation in the forearm vessels of type 1 diabetics or controls and 
p22phox genotype. Endothelium-dependent vasodilation in the smaller forearm resistance 
vessels that are studied by plethysmography is dependent not only on the release of NO, but 
also on the release of EDHF (Garland et al., 1995). This might be a potential explanation 
for the failure to detect an effect of p22phox genotype on endothelial function in this vessel 
type.
NADP H oxidase
N T
1
Endothelial dysfunction
TONOO
Figure 3.4 Endothelial dysfunction as a manifestation of depleted NO caused by 
ROS generation. O2" production by NADPH oxidase can lead to inactivation of NO either 
directly resulting in the generation of ONOO' or by causing oxidative inactivation of BH4. 
At sub-optimum levels of BH 4 eNOS produces O2’ instead of NO. Reduced NO is thought 
to implicated in endothelial dysfunction.
1 0 0
The discovery of NADPH oxidases in cells of the vascular system has led to renewed 
interest in this family of enzymes as a possible source of constitutive 0 2* release (Van 
Heerebeek et al., 2002). Recent research has focused on the expression pattern of various 
isoforms of the active subunit gp91phox and its associated subunit p22phox, and 
demonstrated that while the gp91phox subunits are differentially expressed depending on 
the cell type, p22phox is exclusively expressed in regions of most 0 2* production (Sorescu 
et al., 2002). Discovery of several polymorphisms in p22phox led to speculation that 
common genetic variation in the p22phox gene (CYBA) may have subtle influences on 0 2' 
generation, which could influence endothelial function and alter susceptibility to CVD. 
Consequently p22phox polymorphisms have become a focus of investigation for 
association with CVD risk. This study revealed that healthy subjects who carry two copies 
of the rare T allele for the p22phox C242T polymorphism exhibited greater FMD compared 
to subjects who carried at least one C allele. This finding fits with previous reports that the 
T allele may exert a protective effect upon the vasculature by down-regulating NADPH 
oxidase activity (Guzik et al, 2000a). The position of the polymorphism at nucleotide 242 
gives a clue as to how enzyme activity may be modulated, as the resulting histidine to 
tyrosine substitution at position 72 of the protein lies in a heme binding domain which may 
be essential for optimal enzyme activity (Parkos et al., 1988). However, in vitro studies of 
isolated enzyme function will be needed to verify this hypothesis.
The risk of developing CVD such as atherosclerosis is greatly enhanced in the presence of 
diseases such as diabetes and renal failure (Bierman et al., 1992; Wheeler et al., 1996). 
Endothelial function in these individuals is reported to be attenuated by disruption of the L-
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arginine->NO system, but the precise mechanisms remain unknown. The discovery that 
vascular 0 2' production is elevated in such disease states has led to the hypothesis that NO 
is inactivated by reaction with 0 2‘ thereby predisposing to vascular disease. In the light of 
the findings of an association between the p22phox C242T polymorphism and FMD, this 
study also investigated the effect of p2 2 phox genotype on endothelial function assessed by 
venous occlusion plethysmography in a cohort of diabetic subjects. No association was 
seen between genotype and endothelial function in the resistance vasculature even when 
diabetics and non-diabetics and smokers and non-smokers were analysed separately. This 
data suggests that p22phox C242T genotype does not influence endothelial function in the 
resistance arteries of the forearm in either healthy subjects or in type 1 diabetics. The most 
likely explanation for this is that NO is a less important endothelium-dependent vasodilator 
in the small resistance arteries than it is in the larger conduit brachial artery. Alternatively, 
it is possible that the increased 0 2" reported in diabetic individuals originates from a 
different source other than NADPH oxidase, although the presence of other functional 
polymorphisms or mutations within the p22phox gene or indeed other NADPH oxidase 
subunits cannot be ruled out. During the time frame of the studies in this thesis, three new 
polymorphisms have been described within the coding region of CYBA resulting amino 
acid substitutions (NCBI SNP database, http//www.ncbi.nlm.nih.gov/SNP/). Two of these 
polymorphisms reside in exon 2 and confer a Thr—»Ala substitution at amino acid 29 and a 
Phe—>Ser at amino acid 38. The third is situated within exon 6  and results in a Val->Ala at 
amino acid 174. Further studies to investigate the role of these variants and endothelial 
function and indeed risk of vascular disease are now needed.
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In summary, these data demonstrate a significant association between p22phox genotype 
and endothelial function in the brachial artery of healthy individuals. Subjects who carry 
the TT genotype showed increased FMD in comparison to C allele carriers. This finding 
supports the hypothesis that the presence of the T allele may down-regulate NADPH 
oxidase generation of 0 {  thereby preserving the vasodilator properties of NO. No 
association was observed between genotype and endothelial function in smaller forearm 
resistance vessels in a cohort of diabetic subjects, suggesting that 0 2' generation from 
NADPH oxidase and NO availability are less important mediators of vasoreactivity in these 
vessels.
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CHAPTER 4
IDENTIFICATION OF POLYMORPHISMS IN THE HUMAN 
GTP-CYCLOHYDROLASE 1 GENE (GCH1)
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4.1 Aim
To scan the human GTP cyclohydrolase 1 gene (GCH1) for novel genetic variants, with the 
intension of investigating the role of any polymorphisms discovered in the regulation of 
endothelial dilator function, plasma neopterin and the susceptibility to CVD.
4.2 Background
Limited availability of the essential NOS cofactor BH4  has been proposed as one 
mechanism which may result in decreased NO production and susceptibility to CVD in 
some individuals. The amount of BH4 available to the NOS enzyme depends upon two 
factors: its rate of synthesis and rate of inactivation/breakdown. While inactivation of BH4 
is most probably subject to the presence of ROS within the microenvironment of the 
enzyme, generated from a variety of sources in the vessel wall, the de novo production of 
BH4 is reliant upon three enzymes -  GTPcyclohydrolase 1, 6 -pyruvoyl-tetrahydropterin 
synthase and sepiapterin reductase (Chapter 1.3.3.2). BH4 is also regenerated via a 
‘salvage’ pathway, which is a part of the aromatic amino acid hydroxylase system, but will 
not be discussed in this thesis (for review see Thony et al, 2000).
GTPCH1 catalyses the initial conversion of GTP to7,8-dihydroneopterin triphosphate and 
is considered the rate limiting step in BH4 synthesis. Its expression can be up-regulated by 
various cytokines including tumour necrosis factor-a (TNF-a), interferon-y (IFN-y), 
interleukin-ip (IL-1) and also bacterial endotoxin -  lipopolysaccharide (LPS). Increased
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GCH1 transcription upon stimulation with cytokines is also associated with increased 
enzyme activity and elevation of intracellular BH4 in endothelial cells (Wemer-Felmayer et 
al., 1989; Wemer-Felmayer et al., 1993; Hattori et al., 1993). In contrast PTPS and SR 
have been considered to be largely constitutive (Werner et al., 1990), though at least one 
group has demonstrated cytokine inducibility of PTPS (Linscheid et al., 1998). GTPCH1 
enzyme activity is regulated via post-translational modification, which has been shown to 
occur by phosphorylation, and is associated with an increase in enzyme activity and 
elevated BH4 production (Lapize et al., 1998). Phosphorylation can be mediated through 
protein kinase C, and amino acid sequence studies have revealed a possible target (Ser 167 
in rat and mouse protein sequence) for protein kinase C phosphorylation that is conserved 
between several species including man. In addition several sites for potential 
phosphorylation by casein kinase II have also been reported (Hatakeyama et al., 1991). 
Enzyme activity is also regulated by the GTPCH1 feedback regulatory protein (GFRP), 
which in the presence of BH4 and GTP forms an inhibitory complex with the GTPCH1 
enzyme (Figure 4.1). This inhibition is non-competitive, and can be reversed by L- 
phenylalanine (Harada et al., 1993; Yoneyama et al., 1997).
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Figure 4.1 Synthesis of BH4 and its regulation by GFRP
BH4 synthesis is regulated by feedback inhibition by the product via GTPCH1 feedback 
regulatory protein (GFRP). In the presence of BH4 and GTP, GFRP forms an inhibitory 
complex with GTPCH1. Inhibition can be reversed by L-phenylalanine.
GTPCH1 cDNA was first isolated from a rat library by Hatakeyama et al., 1991. In 1992, 
three different human GTPCH1 cDNA clones were isolated from a human liver cDNA 
library, each with identical 5’ and central structures but differing 3’ ends (Togari et al., 
1992). Subsequently the human GCH1 gene was mapped to chromosome 14q22.1-q22.2 
by fluorescence in situ hybridisation (Ichinose et al., 1994), which led to a comprehensive 
characterization of human and mouse GCH1 genes (Ichinose et al., 1995). Human GCH1 
is encoded by a single copy gene composed of 6 exons spanning a length of ~30kb, and 
alternate splicing at the sixth exon was discovered to generate the three cDNAs (type 1 - 
118 lbp, type 2 - 994bp and type 3 - 819bp) isolated by Togari et al. The presence of two
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of these cDNAs (Type 1 + 2) in a human liver cDNA library was confirmed by Gutlich et 
al., 1994, and expression of all three cDNA types in E.coli demonstrated that only the full- 
length type 1 cDNA has GTPCH1 enzyme activity (Gutlich et al., 1994). In contrast 2 
species of mRNA (3.6kb and 1.4kb) were identified in rat and mouse tissues corresponding 
to type 1 and type 2 cDNAs. The biological significance of multiple splice variants of 
GTPCH1 is unknown, but could be important in cell-specific regulation of BH4 synthesis. 
GTPCH1 mRNA has been isolated from a variety of tissues including liver, brain, kidney, 
spleen, lymphocytes and vascular smooth muscle cells endothelial cells reflecting its 
function in the synthesis of catecholamines and NO (Gutlich et al., 1992; Hattori et al., 
1993; Katusic et al., 1998).
The 5’ region of the human GCH1 gene, which incorporates the promoter is ~600bp in 
length upstream of the translation start site (Ichinose et al., 1995; Witter et al., 1996). No 
TATA sequence motif was observed in this region. Instead an AT-rich sequence and a 
CAAT box are present 21 bp upstream and 6 8 bp upstream of the transcription start site 
respectively, both of which are conserved between human and mouse GCH1 promoters 
(Witter et al., 1996; Ichinose et al., 1995). In addition putative consensus sequences for 
transcription factors CCAAT-box/enhancer binding protein (C/EBP), hepatic nuclear factor 
1 (HNF1), upstream stimulating factor (USF), activator protein 1 (AP-1), serum response 
factor (SRF), glucocorticoid response element (GRE), nuclear factor kB (NFkB) and 
several GC boxes (SP1 sites) have been identified in the promoter region (Witter et al., 
1996). Interestingly no consensus sequences for IFN-y signal tranduction such as the IFN-y
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activated site (GAS) or IFN-y response region (GRR) have been identified. This is 
particularly surprising since GTPCH 1 expression is upregulated by interferon-y.
To date 80 mutations have been reported in the human GCH1 gene (BH4 database, 
http://www.bh4.org accessed Jan 2003), but these are rare, and many are now known to be 
the cause of monogenic diseases such as dopa-responsive dystonia (DRD) and atypical 
hyperphenylalaninaemia (Bandmann et al., 2002; Niederwieser et al., 1984). The effect 
that these and indeed any undiscovered polymorphisms may have on BH4 production in the 
vasculature is unknown, but could have implications for NO synthesis. Common sequence 
variation within the GCH1 gene between individuals could result in subtle differences in 
the amount of BH4 available to the eNOS enzyme and act as a predisposing factor for CVD 
development.
The aim of this study was therefore to screen the GCH1 gene for novel common 
polymorphisms using a technique called single strand conformation polymorphism analysis 
(SSCP). This is a relatively quick and easy way to detect inter-individual differences in the 
DNA sequence in any given region of the genome. Disadvantages of this technique 
however are its limited sensitivity. The principle relies on the fact that single stranded 
DNA will take on a particular conformation dependent on its base sequence. Sequences of 
different conformation will migrate differently when electrophoresed on acrylamide gels, 
thereby allowing the detection of polymorphisms without the need for large-scale 
sequencing efforts.
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4.3 Subjects and Methods
4.3.1 Subjects
Anonymised DNA samples from 32 healthy unrelated individuals, were used to screen the 
GCH1 gene for polymorphisms. Written informed consent was obtained from each 
volunteer and medical status ascertained by questionnaire. Blood was collected into EDTA 
tubes and DNA extracted by Qiagen DNA purification kit method (Chapter 2.2.1.2).
4.3.2 Oligonucleotide design and amplification of genomic DNA
Oligonucleotides were designed to cover the promoter and exons of the GCH1 gene. All 
oligonucleotides were designed to be approximately 50% GC rich with minimum 
secondary structure formation. Each oligonucleotide pair was designed to have similar 
annealing temperatures, non-complementary sequence (which could result in ‘primer- 
dimer’ production) and produce a PCR product 200-400bp in length (optimum length for 
SSCP analysis). Promoter oligonucleotides were designed using the Genbank/EMBL 
database sequence (accession number NT_026437). Five pairs of oligonucleotides were 
designed to produce five PCR products, which overlapped one another to cover the region 
spanning +48 to -1080 relative to the transcription start site. This incorporates the 600bp 
sequence depicted to be the GCH1 promoter by Ichinose et al., 1995. Oligonucleotides 
used to amplify exons 2-6 have been reported previously (Bandmann et al., 1998). Exon 1 
was divided into two overlapping PCR products because of its relatively large size (506bp),
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and oligonucleotides designed from the Genbank/EMBL database. Tables 4.1 and 4.2 list 
all oligonucleotide sequences, positions relative to the transcription start site and PCR 
conditions.
Amplification was carried out by PCR as described in Chapter 2.2.2. All PCR products 
were electrophoresed on 1% agarose gels with lOObp ladder to ensure a single-band 
product of the correct size was achieved.
4.3.3 Screening for polymorphisms by SSCP analysis
Two SSCP methods were used to scan the GCH1 gene for polymorphisms. The promoter 
region was screened in collaboration with Dr. Noor Jeerooburkhan (UCL) using the 
radioactive method as described in Chapter 2.2.4.1. The non-radioactive PhastSystem was 
used to scan the six exons as described in Chapter 2.2.4.2.
4.3.4 DNA sequencing to define the nature of variants detected by SSCP
Genomic regions exhibiting different banding patterns on gel electrophoresis were chosen 
for sequence analysis. Samples were selected so that each different banding pattern 
produced by SSCP was represented at least twice and the region re-amplified from genomic 
DNA. The PCR product was used as a template and both forward and reverse sequencing 
reactions set up using the same oligonucleotides as for PCR. Sequencing was carried out as 
described in Chapter 2.2.5.
I l l
Position of 
oligonucleotides 
relative to 
transcription start 
site
MgCl2
(mM)
Annealing
Temp
(°C)
Sequence
Promoter 1
(-258 -> +48)
1.5 56 F -  5 ’ ttt teg ggt teg get cat tcc 
R -  5 ’ gtg ate taa gca ggt ege gta
Promoter 2
(-379 -> -163)
2 . 0 64 F -  5 ’ ttt cac agg geg agg gga ccg g 
R -  5 * etc cct geg ctt geg aac ccc
Promoter 3
(-552 -342)
1.5 60 F -  5’ gtg aca ctt gcc ccg aca geg 
R -  5* acc gga gcc ctt caa tgc age
Promoter 4
(.768 -> -421)
1.5 62 F- 5 ’ tat gtt ttc cag get ggt etc g 
R -  5’ gtt ggt tcc taa teg gtg get t
Promoter 5
(-1080 ->-707)
1.5 62 F -  5’ acc cag gag geg gag gat gaa g 
R -  5’ tcc tcc ege etc ggt etc cc
Table 4.1. Oligonucleotides designed to amplify the GCH1 promoter. A set of five 
overlapping oligonucleotides were designed to amplify the GCH1 promoter by PCR. The 
region amplified by each oligonucleotide pair is shown with the corresponding MgCb 
concentration and annealing temperature.
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Exon amplified MgCh Annealing Sequence
and position of (mM) Temp
oligonucleotides (°C)
Exon la
(-64 ->226) 2.0mM 64°C F - 5’ gtt tag ccg cag acc teg aag eg 3’
Exon lb R - 5’acg agt agg egg ctg cca ggt ta 3’
(178->431) 1.5mM 6 8 °C F - 5’agg agg ata acg age tgaa cct c 3’
Exon 2
(37441 ->37127) 1.5 mM 64° C
R - 5’gag gca act ccg gaa act tcc tg 3’
F - 5’acc tga gat ate age aat tgg cag c 3’
Exon 3
(42789 ->43048) 2.5 mM 64° C
R - 5’gta acg etc get tat gtt gac tgt c 3’ 
F - 5’tag att etc age aga tga ggg cag 3’
Exon 4
(55449 ->55739) 1.5 mM 60° C
R - 5’aga tgt ttt caa ggt aat aca ttg teg 3’ 
F - 5’gtc ctt ttt gtt tta tga gga agg c 3’
Exon 5
(56768 ->56943) 1.5 mM 64° C
R - 5’ggt gtg cac tct tat aat etc age 3’ 
F - 5’gtg tea gac tct caa act gag etc 3’
Exon 6
(58695 ->58462) 1.5 mM 6 8 ° C
R - 5’tea ctt eta gtg cac cat tat gac g 3’ 
F - 5’acc aaa cca gca get gtc tac tcc 3’ 
R - 5’aat get act ggc agt acg ate gg 3’
Table 4.2. Oligonucleotides designed to amplify GCH1 exons. Oligonucleotides were 
designed to cover exons 1-6 of the GCH1 gene. A set of 2 overlapping oligonucleotide 
pairs were designed to cover exon 1. Oligonucleotide sequences, annealing temperatures, 
MgCh, concentrations and the region amplified by each oligonucleotide pair are shown.
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4.3.5 Search of the National Center for Biotechnology Information (NCBI) SNP 
database for GCH1 polymorphisms
The NCBI SNP database (http://www.ncbi.nlm.nih.gov/SNP/) was also searched for all 
polymorphisms identified to date within the GCH1 gene as described in Chapter 2.2.7. The 
database was established in 1988 and is a resource of freely available molecular biology 
information compiled by genome sequencing consortiums worldwide.
4.3.6 Search of the Matlnspector promoter database for putative GCH1 
transcription factor binding sites
A search of the Matlnspector database (http://www.genomatix.de/free_login.html) with the 
GCH1 promoter sequence was undertaken to identify transcription factor binding sites as 
described in Chapter 2.2.8.
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4.4 Results
4.4.1 Polymorphisms identified in GCH1
Four novel polymorphisms were identified within the GCH1 gene (Figure 4.2). SSCP 
analysis revealed a difference in banding pattern for PCR products generated with the 
oligonucleotides promoter 4, promoter 5 and exon lb (Tables 4.1 and 4.2), suggesting the 
presence of genetic variation within these regions. This was confirmed by DNA 
sequencing, which revealed a total of four single base substitutions. Three of these variants 
were found to be located in the promoter (one within PCR product promoter 4 and two 
within PCR product promoter 5) at positions -796 (G-»A), -741 (T->C) and -577 (G->A) 
(Figures 4.3-4.5). The fourth variant (observed within PCR product exon lb) was 
identified as a C-»G substitution at position +559, which lies within intron 1 (Figure 4.6).
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-796G/A -741T/C -577G/A 559C/G
506bp llObp 56bp 32bp 85bp 2127bp
>15kb 5.6kb 9kb 1.2kb 1.4kb
PROMOTER tsP
Figure 4.2 GCH1 gene structure.
The human GCH1 gene is encoded by a single copy gene on chromosome 14. The promoter is highlighted in blue, 
and spans a distance of at least 600bp upstream of the tsp. Exons are numbered 1 -6 and the size of each exon and 
intron indicated (kb). The position of polymorphisms identified by SSCP analysis are indicated by I .
t C C C A T  ( 7 £ ) g  c a  t t t t c  t
Figure 4.3. DNA sequence (of the reverse strand) confirming a G->A substitution at 
position -796 in the GCH1 promoter. The top sequence shows a homozygote for the C 
(G on forward strand) allele, the middle sequence a homozygote for the T (A on forward 
strand) allele and the bottom sequence a heterozygote showing both the C and T alleles.
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T G A  G G C C  A G T  T  C «
T  G A G G C C  A ©  G A G T  T  C
Figure 4.4 DNA sequence (of the reverse strand) confirming a T—>C substitution at 
position -741 in the GCH1 promoter. The top sequence shows a homozygote for the A 
(T on forward strand) allele, the middle sequence a homozygote for the G allele (C on 
forward strand) and the bottom sequence a heterozygote showing both the A and G alleles.
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T A  G A C A  T A  ( cT ) g G A C C C
G A C A T  A C £) G A C C C A
Figure 4.5 DNA sequence electropherogram confirming a G—»A substitution at 
position -577 in the GCH1 promoter. The top sequence shows a homozygote for the G 
allele, the middle sequence a homozygote for the A allele and the bottom sequence a 
heterozygote showing both the G and A alleles.
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Figure 4.6 SSCP gel image (Phastsystent) 
and DNA sequence of GCH1 Exon lb  PCR.
Samples 2 and 4 have a different banding pattern 
(4 visible bands) on the SSCP gel, suggesting the 
presence of a polymorphism in this PCR 
fragment. The DNA sequence electropherogram 
confirms a C-»G substitution at position 559 in 
intron 1. The top sequence shows a homozygote 
for the C allele, the middle sequence a 
homozygote for the G allele and the bottom 
sequence a heterozygote showing both the C and 
G alleles.
4.4.2 Analysis of the GCH1 promoter and comparison of polymorphisms in the 
NCBI SNP database and those identified by SSCP.
The NCBI SNP database (http//www.ncbi.nlm.nih.gov/SNP/) revealed the presence of 5 
previously identified polymorphisms in the 3kb upstream of the GCH1 transcription start 
site (tsp). The nature of each SNP, identification number and position are shown in table 
4.3. The three promoter polymorphisms (-796, -741 and -577) identified by SSCP during 
this study were not represented on the NCBI SNP database. One polymorphism was found 
in the database 44bp downstream of the tsp, and lies in the sequence of the reverse 
oligonucleotide promoter 1 (Figure 4.7). The location of this polymorphism within an 
oligonucleotide makes it difficult to identify by SSCP. The +559C/G variant was 
represented in the NCBI database (Table 4.3), but no further information regarding 
heterozygosity was available at the time of writing this thesis.
Matlnspector analysis (http//www.genomatix.de) of the 1.2kb immediately upstream of the 
GCH1 transcription start site indicated that none of the polymorphisms identified by SSCP 
were situated in transcription factor binding sites or other known regulatory regions (Figure 
4.7). However the -741 T/C lies just downstream of a shear stress element (SSRE) encoded 
by the sequence GAGACC and lbp upstream of a nuclear factor 1 site (NF1). The - 
796G/A polymorphism is situated lObp from the core binding domain of a signal 
transducer and activator of transcription site (STAT3) and the -577 G/A lies 5bp upstream 
of a serum response factor site (SRF).
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NCBI SNP 
ID
Base change Position relative 
to tsp
rs2183080 C/G +559
rs3759660 C/T -1042
rs3759661 C/T -1044
rs3759664 C/T -2034
rs3759665 C/T -2059
rs3074168 CT/- -2811
Table 4.3 Human GCH1 promoter polymorphisms identified in the NCBI SNP 
database. The three promoter polymorphisms identified by SSCP during this study were 
not represented on the NCBI SNP database.
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CGGCATTATGAGATAATCCCTCAAGTGAGGAAAAAGGTCCATTTATTAATCTCAAAGAAA
AC AGT T AC AGC AG AT GT CAC T GGT T AAG AGT T C AGTT GGT GAAT AG CAT T T CAC AAT T T G
E2F
TACCAACATCTGGGGAAAGACGCTTTGCATGGAACTGTAAAACAATTGAGCACCAAATCT 
STAT3 -796 TATA v-Jun
G C A C A A C TG C G TTTC TA G A A A A TG C G A TG G G TTTTA TA G A G A TG A G G TC TTG C TA TG TTT
-741 NF1 4F------------------
TCCAGG CTG GTCTCG AAC TC TTG G C CTCAA G C G A TC CTCCCG CC TC G G TCTCCC CAA G C G
--------------------------------- ►----------------------------------------------A ------------------------------------------- 5R
CCGGGAGTACAGGCGTGAGCCACCGACGGAAATGGATTTTAAGTGAAAGTCCTATCTTCG
CREB
TTTGCAAATCAATTTTTCCAGGATCAAAGTTCTAGCAACCATAAATCCTATCCTTCTAGA  
-577 SRF
CA TAGG G ACCCACATAAG G GCCACTTGATG TGACACTTG CCCCG ACAGCGG TGCCACCTG
3F ------------------------------------------ ►
GCCCCTAGGTGGCAGGTGCGTTTTTAACTAAACCCAAGAGTCTGAAGTCACATTATTCTC
TTG C C TTG A A A G C TTA A G A G TTG G TTC C TA A TC G G TG G C TTA A C TC G G TC TC TC TC C A G G
A ----------------------------------------------------  4R
C A A G G C C A C C T G T T T G C T G y CTTTCACAGG G CG AG GG (j^CgGGAG C C C TTCA ATG C AG C 3R
GCCCTCTTGGCCTGAAGAGGGGGCGACTGGGCGCCCAGACCGCGTCTTTCTCACTGAGAT
C C CAG CTCC TG G ACG AC TG CCTCTTTTCG G G TTCG G C TCA TTCC G C AATAA G TG G A G G G G
SP1 IF ----------------------------------►
TCCC G C C TG A TC C TA G G G G C C G G C G C C C TTTTC C TTC C C TC C C TG C G C TTG C G A A C C C C T
A ------------------------------------------- 2R
CCGGGCGTCTCCGGAGCCGCGACCCCTGCTGGGGACCCCGGGGGCGGGAGGCCGAGGGGC
SP1 CCAAT box
GCGGCGAGGGCCGTGACGCGAGGCGGGGCCGGCCAATGGGAGCGCTCCGCGGCGCAGGCT
^CAGg a g c c g c c g g g c c a t a a A a g g a g g c g c g g c c g g g c t t t c c a g c c t g t g g c c g c t c c c g g
tsp
c t c g g a g t g t g a t c t a a g c a g g t t g c g t a c c t t c c t c a g g t g a c t c c g g c c a c a g c c c a t
A -------------------------------------------------  1R
TGTCCGCGGCCACCGGCGGAGTTTAGCCGCAGACCTCGAAGCGCCCCGGGGTCCTTCCCG
AACGGCAGCGGCTGCGGCGGGTCCATgGAGAAGGGCCCTGTGCGGGCACCGGCGGAGAAG
Figure 4.7. Nucleotide sequence of the human GCH1 promoter region. The
transcription start site is indicated by tsp and exon 1 is highlighted in blue. Oligonucleotide 
sequences are in bold and underlined by arrows. Transcription factor binding sites identified 
by Matlnspector software are highlighted in bold blue. Polymorphisms at positions -796, - 
741 and -577 are indicated in red type, and the SNP at position +44 identified from the 
NCBI SNP database is highlighted in pink type.
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4.5 Discussion
4.5.1 GCH1 promoter polymorphisms
Three new polymorphisms were identified in the promoter of GCH1 during this study. 
Two of these polymorphisms lie further upstream than the predicted ~600bp core promoter 
sequence reported by Ichinose et al., 1995 and Witter et al., 1996, but are situated just 
downstream of putative transcription factor binding sites. The -741 T/C polymorphism lies 
6 bp from a shear stress response element (SSRE), and the -796 G/A lies 3bp from a 
CCAAT box/enhancer binding protein element (C/EBP). Although these polymorphisms 
are outside the core sequence binding motifs for these transcription factors, it is possible the 
protein-DNA interaction extends to the upstream and downstream flanking sequences. It is 
therefore conceivable that variation within these regions could influence transcription factor 
binding or stability of the protein-DNA complex. CCAAT enhancer elements play a role in 
determining promoter efficiency, therefore disruption of this site could result in a weaker 
promoter and decreased gene expression. SSRE sites convey responsiveness to laminar 
shear stress (LSS), which is generated by blood flow over the endothelium. It is not 
surprising therefore that a number of endothelial genes contain SSRE consensus sequences 
and exhibit markedly elevated gene expression under experimentally induced shear stress 
(Gimbrone et al., 2000). Areas of high LSS are known to be less susceptible to 
atherosclerotic lesion formation (Comhill et al., 1976; Zarins et al., 1983), and it has been 
proposed that coordinated up-regulation of so-called atheroprotective genes such as eNOS 
via SSRE sites could account for this phenomenon (Topper et al., 1996). Further studies
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are required to deduce if GCH1 is also upregulated by LSS in endothelial cells, but logic 
suggests that if eNOS expression and activity is increased then an increase in BH4  
production may also be required to support NO production.
4.5.2 Polymorphisms within GCH1 exons
Only one polymorphism (559 C/G) was identified by SSCP analysis of the GCH1 coding 
regions. This variant was found to lie just downstream of exon 1 (made possible due to the 
fact that each oligonucleotide for PCR was designed within an intronic region, resulting in 
a small amount of intron being amplified as well as the exon itself). Disappointingly, as 
well as not residing within the coding sequence, this polymorphism did not lie within any 
obvious consensus sequence involved in splicing. In addition, a search of the NCBI SNP 
database indicated that no polymorphisms have as yet been identified in the GCH1 coding 
region, however the NCBI database only compares sequences from a small number of 
chromosomes. It is therefore possible that as more sequences are analysed, polymorphisms 
will be identified.
This study indicates that very little genetic variation is present within the GCH1 coding 
regions, which may be indicative of an essential role of GTPCH 1 for survival, which in 
turn has ensured the GCH1 gene has remained highly conserved throughout evolution 
(McLean et al., 1993). However, it is also possible that in this instance SSCP failed to 
reveal the presence of additional polymorphisms due to the limited (80-90%) sensitivity of 
detection of this technique. Advances in high-throughput sequencing technology have now
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made it possible to accurately sequence and compare genes from hundreds of individuals 
relatively quickly without the need for SSCP. These large-scale sequencing efforts have 
led to the generation of SNP databases, which can provide an easily accessible source of 
information about potentially functional polymorphisms.
A search of the NCBI SNP database revealed the +559G/A polymorphism identified by 
SSCP during this study has already been described. The NCBI SNP database also 
highlighted a single polymorphism in the 5* untranslated region that was not detected by 
SSCP. This polymorphism at position +44bp lies within the reverse oligonucleotide 
sequence used to amplify the promoter 1 fragment.
4.5.3 Future work
The 3’ untranslated sequence of the GCH1 gene was omitted from SSCP analysis, but it is 
now recognized that this region could be involved in the regulation of translation through 
the interaction of specific 3’UTR binding proteins (Mazumder et al., 2003). One 
polymorphism has recently been described in the GCH1 3’UTR (NCBI accession number 
NT_026437). SSCP analysis of the GCH1 3’UTR is therefore needed to complete a full 
scan of the gene. Promoter-reporter gene assays are required in order to elucidate the 
importance of the promoter variants with respect to regulation of gene expression, and 
band-shift experiments to determine if either the -796G/A or -741T/C polymorphisms 
influence the binding of transcription factors to consensus sequences in close proximity.
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However, the potential for the GCH1 promoter variants described to influence GTPCH1 
activity and endothelial function is further discussed in Chapter 5.
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CHAPTER 5
GCH1 POLYMORPHISMS AND THEIR FUNCTIONAL 
IMPACT ON PTERIN METABOLISM AND ENDOTHELIAL
FUNCTION
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5.1 Aim
To investigate the relationship between GCH1 promoter polymorphisms (-577G/A and - 
796G/A) pterin metabolism and endothelial function in healthy individuals.
5.2 Background
Endothelial dysfunction and reduced NO availability are thought to be important in the 
initiation, progression and complications of atherosclerosis. Decreased synthesis or 
increased inactivation of the vasodilator NO is thought to play a vital part in this process. 
The mechanisms by which biologically active NO levels are reduced are not fully 
understood, but one important process might be depletion of the essential NOS cofactor 
BH4, resulting in the preferential generation of 0 2' instead of NO by eNOS (Vasquez-Vivar 
et al., 1999; Wever et al., 1997; Xia et al., 1998). Generation of 0 2* can itself result in 
excessive oxidation of BH4  leading to its inactivation (Laursen et al., 2000). Endothelium 
dependent vasodilation is attenuated in smokers, hypertensives, hypercholesterolemics and 
diabetics, and administration of low dose BH4 to these individuals can improve endothelial 
function possibly by restoring N 0 /0 2* balance (Ueda et al., 2000; Stroes et al., 1997; Pieper 
et al., 1997). Improved endothelial function upon supplementation with BH4, suggests this 
essential cofactor could be limited in patients at risk of vascular disease.
Administration of anti-oxidants such as vitamin C and folic acid has also been shown to 
improve endothelial function in patients with coronary artery disease (CAD), hypertension,
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diabetes, hypercholesterolemia and smokers, and low plasma levels of ascorbic acid have 
been correlated with atherosclerosis (Levine et al., 1996; Solzbach et al., 1997; Ting et al., 
1996; Ting et al., 1997; Homig et al., 1998; Heitzer et al., 1996). The protective 
mechanism behind administration of such anti-oxidants however is now thought to be more 
complex than just the scavenging of ROS. Baker et al., 2001 reported increased eNOS 
activity and BH4  levels in cultured human umbilical vein endothelial cells (HUVEC) upon 
administration of vitamin C. However no such effect was observed upon treatment with the 
ROS scavenger Mn(III) tetrakis (4-benzoic acid) porphyrin chloride (MnTBAP), suggesting 
that the ability of vitamin C to restore endothelial function may be through increased 
intracellular BH4  levels rather than ROS scavenging alone. This theory is supported by a 
recent publication that demonstrated ONOO' (generated by the reaction of NO and O2 ') is a 
potent oxidizer of BH4 . The authors also showed that the reaction between ONOO" and 
BH4 results in the production of the intermediate BH3 radical, and that BH3 can be recycled 
back to BH4  by ascorbate reinstating NO synthesis from'eNOS (Kuzkaya et al., 2003).
The consequence of depleted BH4 is the generation of ROS such as 0 2' and H20 2 by eNOS 
itself which, in turn, might mediate oxidative inactivation of BH4. The cause of the initial 
depletion of BH4 in the presence of atherosclerotic risk factors is unclear. Many theories 
have been proposed including the up-regulation of ROS by systems such as NADPH 
oxidase (discussed in chapter 3) by oxLDL, ATII or high glucose and down-regulation of 
SOD (Fukai et al., 1998; Landmesser et al., 2000). Another possibility is that some 
individuals have reduced pterin pathway activity due to common polymorphisms in pterin 
synthesizing enzymes. The synthesis of BH4 begins with the conversion of GTP to
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dihydroneopterin triphosphate by GTPCH1. The majority of dihydroneopterin triphosphate 
is converted to 6 -pyruvoyl tetrahydropterin by 6 - pyruvoyl tetrahydropterin synthase 
(PTPS) and finally to BH4  by sepiapterin reductase (SR). In human cells the low activity of 
PTPS results in a proportion of dihydroneopterin triphosphate being converted to neopterin, 
an inert molecule excreted by the kidneys which serves as a marker of pterin pathway 
activity and which has been used to assess the activation state of the cellular immune 
system (Murr et al., 2002; Berdowska et al., 2001). The circulating pool of neopterin 
probably reflects that generated by neuronal cells, immune cells and endothelial cells, but 
the relative contributions of these cell types to the overall pool is not known.
Genetic variation within genes encoding the enzymes involved in the synthesis of BH4 
could result in differences in local cellular as well as circulating BH4 or neopterin levels 
thereby predisposing to endothelial dysfunction and vascular disease. GTPCH1 is the first 
and rate-limiting enzyme in the synthesis pathway of BH4 (Duch and Smith, 1991). A 
number of rare mutations within the gene encoding GTPCH1 (GCH1) are known to cause 
DRD and hyperphenylalanemia but, as yet, no mutations or polymorphisms influencing 
endothelial function or risk of CVD development have been described. The detection of 
BH4 requires HPLC-based techniques that are time consuming and consequently difficult to 
apply at the population level. Enzyme linked immunoassays (ELISA) for neopterin are 
commercially available in which multiple samples can be analysed in parallel in 96-well 
plate format.
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This study has investigated whether novel polymorphisms in the GCH1 gene are related to 
variation in plasma neopterin level in a subset of healthy subjects from the NPHSII cohort. 
We then investigated whether these polymorphisms were also associated with functional 
differences in endothelial function, in a cohort of young adults for whom non-invasive 
high-resolution ultrasound measurements of endothelial dependent flow mediated dilatation 
were available.
5.3 Subjects and Methods
Two subject groups were analysed for association between GCH1 polymorphisms, serum 
noepterin, and endothelial function during this study.
5.3.1 Subjects investigated for association between GCH1 genotype and neopterin
Northwick Park Heart Study II (NPHSII)
Subjects were selected from the NPHSII prospective cohort for analysis (section 2.2.12.1). 
Briefly this cohort comprises approximately 3000 men recruited from 9 primary care 
practices in the UK. All subjects selected for the study were healthy at the time of 
recruitment. The men were aged between 50 and 61 years and medical history was 
assessed by questionnaire. All subjects were reviewed annually. Smoking status, blood 
pressure (mmHg), BMI (kg/m2), serum cholesterol (mmol/L), trigycerides (mmol/L), 
fibrinogen (pmol/L), factor VII coagulant activity (FVIIc % standard) and HDL cholesterol
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(mmol/L) were measured at the time of recruitment and during follow-up visits over the 
following 9 years. Venous blood was taken at time of recruitment and the plasma separated 
and stored at -80°C. DNA was extracted by the salting-out method described in section
2.2.1.1 and also stored at -80°C. All IHD events have been recorded over the time of the 
study and the mean follow up is 5 years. A total of 2390 out of 3000 subjects were 
genotyped for GCH1 polymorphisms and plasma neopterin measured in a subset of 939 
individuals during this study.
5.3.2 Subjects investigated for association between GCH1 genotype and endothelial 
function
Cambridge Young Adults Study cohort
248 subjects aged 20 to 28 years for whom blood had been stored for genotyping were 
studied from the Cambridge Young Adults Study (section 2.2.12.1). The study group 
comprised a sample of individuals bom in Cambridge Maternity Hospital between 1969 
and 1975 as described previously (Leeson et al., 2002). They were invited to attend a clinic 
for cardiovascular risk profile evaluation by questionnaire followed by venepuncture, 
physical measurements and vascular studies. In each subject, a fasting venous blood 
sample was analysed for insulin, glucose, total cholesterol, HDL and triglycerides, and 
LDL. Personal and family medical history (including details of heart disease and risk 
factors) was gathered by questionnaire at interview. Current or past smoking was recorded. 
Blood pressure was measured as the average of the last two of three seated readings using 
an automated oscillometric device (Critikon Inc, USA). Weight was recorded (to +/- 0.1
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kg) using scales (Soenhle Ltd) and height (to +/- 0.1 mm) with a portable stadiometer. 
Every subject underwent measurement of endothelial dependent and independent vascular 
responses of the brachial artery, using high-resolution ultrasound imaging as described in 
section 2.2.13.2.
5.3.3 Measurement of plasma neopterin in the NPHSII cohort
Neopterin measurements were taken from a total of 939 individuals from the NPHSII 
cohort, using the ELItest® competitive enzyme immunoassay kit (B.R.A.H.M.S 
diagnostica GMBH) as described in section 2.2.10. All measurement were carried out in 
collaboration with Dr Noor Jeerooburkhan (University College London). 243 and 288 
neopterin samples were collected from the Chesterfield and North Mymms primary care 
practices respectively and a further 513 neopterin measurements collected from a random 
data set. The three data sets were pooled to give a total data set of 939 subjects. Plasma 
samples were collected and stored at -80°C until required. Neopterin has been shown to be 
stable in this state. The lower limit of detection for this assay was 2nmol/L, with an intra­
assay variation of 3.5% and an inter-assay variation of 6.5%.
5.3.4 Genotyping studies
PCR-RFLP analysis was used for genotyping studies as described in section 2.2.6. Two out 
of the four GCH1 polymorphisms identified by SSCP (-577G/A and -796G/A) were 
chosen for genotyping analysis. Genomic DNA was amplified by PCR as described in
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chapter 4 (section 4.3.2). The restriction enzyme BsmFl (which cuts in the presence of the 
G allele) was used for genotyping the -577G/A polymorphism to produce bands of 206 and 
142bp. The restriction enzyme BsrDl (which cuts in the presence of the A allele) was used 
for genotyping the -796G/A polymorphism to produce bands of 290 and 84bp. Digested 
products were electrophoresed on 2.5% agarose gels and visualised by ethidium bromide 
staining.
5.3.5 Statistical Analysis
Observed numbers of each genotype were compared with those expected under the 
assumption of Hardy-Weinberg equilibrium by %2 analysis. Allele frequencies were 
deduced from genotype frequencies. Pairwise linkage disequilibrium coefficients between 
polymorphisms were estimated by log linear analysis (Chakravarti et al., 1984). Data are 
presented as arithmetic mean (±SD) except for neopterin for which geometric mean 
(approximate SD) is presented due to the skewed nature of the distribution. Allelic 
associations were carried out by One-Way Analysis of Variance (ANOVA) and the 
significance of differences between genotype groups by Students t-test. Standard regression 
and interaction models were used to determine whether the association between endothelial 
function and genotype was influenced by classical risk factors. The primary hypothesis 
was that polymorphisms in the GCH1 gene would be associated with differences in 
neopterin and/or endothelial function. Sixty subjects were required to detect a 0.25 
standard deviation difference in log neopterin between rare allele carriers and non-carriers 
at 80% power, 2P=0.05. With a sample size of 248 individuals from the Cambridge Young
135
Adults cohort, the study had 80% power at 2P=0.05 to identify a 0.02 mm or 0.6% 
difference in FMD between groups. A secondary hypothesis, that GCH1 polymorphisms 
would be associated with cardiovascular events was also tested. With 188 events in the 
genotyped NPHSII cohort the study had an 80% power to detect an odds ratio of 1.4 among 
rare allele carriers at 2P=0.05.
5.4 Results
5.4.1 Genotype and allele frequency of GCH1 polymorphisms
Genotype and allele frequencies for the -577G/A and -796G/A GCH1 polymorphisms are 
shown in table 5.1. The -796G/A variant did not conform to the Hardy Weinberg rule in 
either the NPHSII cohort (x2=275.3, P=<0.0001) or the Cambridge Young Adults Study 
cohort (x2=20.8, P=<0.05). Repeat genotyping and DNA sequencing confirmed that this 
was not the result of mis-genotyping. As there were no related individuals within the 
NPHSII cohort this was also ruled out as an explanation for the difference in observed and 
expected genotypes. The -796G/A and -577G/A polymorphisms were in tight linkage 
disequilibrium in both cohorts (NPHSII A0.79, P=<0.0001; Cambridge Young Adults 
cohort A0.66, P=<0.0001).
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NPHSII cohort
Polymorphism
GG
Genotype
N (%) 
GA AA
Allele
%
G A
x2 P
-577G/A 1897 (79.0) 453 (19.0) 40(2.0) 8 8 . 0  1 2 . 0 3.96 0.05
-796G/A 1770 (74.0) 437 (18.0) 179 (8.0) 83.0 17.0 275.3 <0 . 0 0 0 1
Cambridge Young Adults cohort
Polymorphism Genotype Allele x2 P
N (%) %
GG GA AA G A
-577G/A 185(82.0) 37(16.0) 4(2.0) 90.0 1 0 . 0 1.7 0.19
-796G/A 171 (77.0) 38 (17.0) 13 (6 .0 ) 86.0 14.0 2 0 . 8 <0.05
Table 5.1 Genotype and allele frequencies of GCH1 polymorphisms in the NPHSII 
cohort (top panel) and the Cambridge Young Adults Study cohort (bottom panel).
The -796G/A polymorphism did not conform to the Hardy-Weinberg equilibrium in either 
cohort.
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5.4.2 Baseline demographics of NPHSII study participants
Baseline characteristics of the NPHSII cohort according to GCH1 genotype are shown in 
tables 5.2a and 5.2b. Orthodox cardiovascular risk factors such as blood pressure, pulse 
pressure, cholesterol, fibrinogen, BMI or age did not differ among groups of different 
genotype.
Genotype -577G/A
GG
Mean (SD) 
N=1789
GA+AA
Mean (SD) 
N=485
P
Age (Years) 56.1 (3.4) 56.0 (3.4) 0.77
Diastolic BP (mmHg) 84.6(11.4) 84.8(11.1) 0.64
Systolic BP (mmHg) 138.7 (19.2) 138.5 (19.4) 0.84
Pulse Pressure 54.1 (14.5) 53.6 (14.7) 0.53
Cholesterol (mmol/L) 5.72(1.02) 5.72 (0.98) 0.98
Fibrinogen (pmol/L) 0.08 (0 .0 2 ) 0.08 (0 .0 2 ) 0.33
BMI (kg/m2) 26.5 (3.5) 26.2 (3.3) 0 . 1 1
Table 5.2a Demographic details of subjects in the NPHSII cohort according to 
GCH1 -577G/A genotype. GA+AA individuals were grouped and analysed together. No 
significant difference was found in age, blood pressure, cholesterol, fibrinogen or BMI 
between genotypes.
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Genotype -796G/A
GG
Mean (SD) 
N=1666
GA+AA
Mean (SD) 
N=572
P
Age (Years) 56.0 (3.4) 56.2 (3.4) 0.44
Diastolic BP (mmHg) 84.4(11.3) 84.2(11.1) 0.67
Systolic BP (mmHg) 138.3(19.1) 137.5 (19.2) 0.38
Pulse Pressure 53.9 (14.4) 53.3 (14.3) 0.41
Cholesterol (mmol/L) 5.72 (1.01) 5.75 (1.00) 0.52
Fibrinogen (pmol/L) 0.08 (0 .0 2 ) 0.08 (0 .0 2 ) 0.29
BMI (kg/m2) 26.5 (3.5) 26.5 (3.4) 0 . 8 6
Table 5.2b Demographic details of subjects in the NPHSII cohort according to 
GCH1 -796G/A genotype. GA+AA individuals were grouped and analysed together. No 
significant difference was found in age, blood pressure, cholesterol, fibrinogen or BMI 
between genotypes.
5.4.3 Distribution and determinants of plasma neopterin
Among the 939 healthy men from the NPHSII cohort, the distribution of neopterin values 
were skewed with a geometric mean neopterin value of 6.0nmol/L (range: 2.16 nmol/L to
33.5 nmol/L), similar to that reported previously (Diamondstone et al., 1994). Univariate 
analysis revealed a significant positive correlation between plasma neopterin and fibrinogen 
(r=0 .1 1 , p=0.0006), and negative correlations with cholesterol (r= -0 .1 2 , p=0 .0 0 0 2 ) and 
apoAl (r= -0.16, p=0.0001) (Table 5.3). Plasma neopterin was not significantly different 
between smokers (n=228) and non-smokers (n=711) (mean neopterin 6.11±1.42nmol/L vs 
5.95±1.46nmol/L, p=0.16). No significant correlation was observed between levels of 
neopterin and systolic or diastolic pressure. Cardiovascular events were recorded in 41 
individuals out of the 939 with neopterin measurements. No evidence of an association
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between neopterin levels and cardiovascular outcome was observed, mean (SD) neopterin 
values for subjects in whom an event was recorded and those without an event was 6 . 1 0  
(1.00) nmol/L and 6.25 (1.56) nmol/L respectively (P=0.38).
Characteristic R P
Diastolic BP 0 . 0 1 0.75
Systolic BP* -0.04 0.23
Triglycerides -0.03 0.4
ApoAl* -0.16 <0 . 0 0 0 1
ApoB -0.007 0.84
Cholesterol* -0 . 1 2 0 . 0 0 0 2
Fibrinogen4' 0 . 1 1 0.0006
BMI -0.008 0.81
Age 0.05 0 . 1 0
Table 5.3. Correlation of neopterin with risk factors for cardiovascular disease 
in the NPHSII cohort by stepwise multiple regression. An inverse relationship 
was observed between neopterin and cholesterol and ApoAl*. A positive 
relationship was observed between neopterin and fibrinogen4'.
5.4.4 Relationship between GCH1 genotype and plasma neopterin in the NPHSII 
cohort
Full genotype and neopterin data were available for 696 individuals out of the 939 selected. 
Both the -577G/A and -796G/A polymorphisms showed significant association with 
neopterin levels both before and after adjustment for fibrinogen, cholesterol, apoAl and 
primary care practice (Table 5.4). The associations also persisted after correction for renal
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function (p=0.001 for both variants, table 5.4) with A-allele carriers having lower 
neopterin/creatinine ratio. In a stepwise multiple regression analysis fibrinogen (r=0.13, 
p=0.001), cholesterol (r=-0.09, p=0.02), ApoAl (r=-0.15, p=<0.0001) and genotype (r=- 
0.11, p=0.004) were independently associated with plasma neopterin, accounting for 6.9% 
of variation.
Genotype -577G/A
GG
Mean (SD) 
N=565
GA+AA 
Mean (SD) 
N=131
P P*
Neopterin 6.30(1.69) 5.87 (1.35) 0.006 0.004
Neopterin/ Creatinine 0.067 (0.019) 0.061 (0.014) 0.0008 0 . 0 0 1
Genotype -796G/A
GG
Mean (SD) 
N=565
GA+AA 
Mean (SD) 
N=131
P P*
Neopterin 6.29(1.61) 5.95 (1.52) 0 . 0 2 0 . 0 1
Neopterin/Creatinine 0.066 (0.018) 0.061 (0.016) 0.0006 0 . 0 0 1
Table 5.4. Neopterin and neopterin/creatinine according to GCH1 -577G/A (top 
panel) and -796G/A genotype (bottom panel). Individuals homozygous for the GCH1 -  
577 and -796 G allele (GG) had significantly higher neopterin and neopterin/creatinine 
compared to A allele carriers (GA+AA). Data has been adjusted for practice. *Also 
adjusted for fibrinogen, cholesterol and apoAl.
141
5.4.5 GCH1 polymorphism, and CVD risk
A secondary hypothesis explored in the NPHSII cohort was that GCH1 genotype 
influenced CHD risk. The total number of CHD events for the whole NPHSII cohort was 
188. No evidence was found of an association between genotype and risk of IHD overall 
(Table 5.5). However, a significant interaction was observed between -796 genotype and 
smoking (p=0.02). Individuals homozygous for the -796 A allele who smoked had a 
hazard ratio for CHD of 7.78 (95%CI: 2.12-29.14), compared to a hazard ratio for CHD of 
1.51 (95%CI: 1.11-2.06) for smokers overall. No evidence was found for an interaction 
between -577 genotype and smoking (p=0.92).
Polymorphism Genotype Hazard Ratio (95% Cl) P value
-577 G/A GG 1 . 0 0
GA/AA 0.76(0.46-1.24) P=0.27
-796 G/A GG 1 . 0 0
GA/AA 1.11(0.58-2.12) P=0.76
Table 5.5. GCH1 genotype and IHD risk in the NPHSII cohort. A allele carriers were 
grouped and analysed against GG homozygotes. No association was found between GCH1 
genotype and IHD risk.
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5.4.6 Baseline demographics of Cambridge Young Adults Study participants
The characteristics of the study sample according to GCH1 genotype are summarised in 
tables 5.6a and 5.6b. There were no significant differences between genotype groups in 
levels of cholesterol, LDL, HDL, blood pressure, BMI, age, height, weight or smoking 
status within the whole group, males or females.
As previously reported (Leeson et al., 2002), there were no associations between 
cardiovascular risk factors and resting vessel size or brachial artery blood flow in this 
cohort. There was no difference in mean FMD or GTND between sexes. Smokers had 
lower mean FMD than non-smokers (0.090 ± 0.080 mm v 0.109 ± 0.081 mm respectively, 
p<0.05), with no difference in GTND (0.677 ± 0.225 mm v 0.674 ±0.184 mm, p=0.90).
Genotype -577G/A
GG
Mean (SD) 
N=175
GA+AA
Mean (SD) 
N=38
P
Age (range, years) 23.0 (20-27) 23.0 (20-27) ns
SBP (mmHg) 128.0 (14.0) 128.0 (14.0) ns
DBP (mmHg) 71.0 (9.0) 71.0 (8.0) ns
Cholesterol (mmol/L) 4.54 (0.94) 4.69(1.11) ns
LDL (mmol/L) 2.81 (0.83) 2.89 (0.96) ns
HDL (mmol/L) 1.19(0.3) 1.18(0.33) ns
BMI (kg/m2) 2.4 (0.4) 2.5 (0.4) ns
Table 5.6a. Demographic characteristics of the Cambridge Young Adults Study 
cohort according to GCH1 -577G/A genotype. No significant difference was observed in 
age, blood pressure, cholesterol or BMI between genotypes (ns=not significant, P>0.05).
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Genotype -796G/A
GG
Mean (SD) 
N=161
GA+AA
Mean (SD) 
N=47
P
Age (range, years) 23.0 (20-27) 23.0 (20-27) ns
SBP (mmHg) 128.0 (14.0) 129.0(14.0) ns
DBP (mmHg) 71.0 (8.0) 71.0 (7.0) ns
Cholesterol (mmol/L) 4.52 (0.91) 4.67 (0.97) ns
LDL (mmol/L) 2.78 (0.80) 2.92 (0.87) ns
HDL (mmol/L) 1.20 (0.29) 1.17(0.36) ns
BMI (kg/m2) 2.4 (0.3) 2.4 (0.4) ns
Table 5.6b. Demographic characteristics of the Cambridge Young Adults Study 
cohort according to GCH1 -796G/A genotype. No significant difference was observed in 
age, blood pressure, cholesterol or BMI between genotypes (ns=not significant, P>0.05).
5.4.7 Relationship between GCH1 genotype and endothelial function.
The association between genotype and FMD is shown in table 5.7. Only subjects from 
whom scans of adequate quality for endothelial function together with successful 
genotyping data were chosen for analysis, leaving full details of genotype and vascular 
function available for 213 individuals for the -577G/A variant and 208 individuals for the -  
796G/A variant. FMD was lower in A-allele carriers for the -796G/A variant (p=0.03) and 
a similar but non-significant trend was observed between groups for the -577G/A variant 
(p=0.27). There were no differences in GTND between genotype groups.
144
Genotype -577G/A
GG
Mean (SD) 
N=175
GA+AA
Mean (SD) 
N=38
P
Resting vessel size (mm) 3.30(0.61) 3.27 (0.52) 0.76
FMD (mm) 0.115(0.09) 0.095 (0.06) 0.18
FMD (%) 3.55 (2.64) 3.05 (2.18) 0.27
GTND (mm) 0 . 6 8 8  (0 .2 0 ) 0.674 (0.15) 0.54
GTND(%) 21.75 (7.79) 21.22 (6.72) 0.69
Genotype -796G/A
GG
Mean (SD) 
N=161
GA+AA 
Mean (SD) 
N=47
P
Resting vessel size (mm) 3.31 (0.62) 3.27 (0.48) 0.64
FMD (mm) 0.118(0.09) 0.087 (0.06) 0 .0 2 *
FMD (%) 3.62 (2.64) 2.78 (1.92) 0.03*
GTND (mm) 0.692 (0.20) 0.663 (0.14) 0.26
GTND(%) 21.88 (7.98) 20.77 (5.80) 0.37
Table 5.7. Endothelial function according to GCH1 -577G/A (top panel) and -  
796G/A (bottom panel) genotype in the Cambridge Young Adults Study cohort. A
significant difference in FMD was observed between GG homozygotes and A allele carriers of the -  
796G/A polymorphism. A allele carriers had lower FMD than GG individuals (% FMD, *P=0.03). 
A similar but non-significant trend was observed for the -577G/A polymorphism (P=0.27)
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5.5 Discussion
This study has identified two common novel variants in the GCH1 gene and examined their 
phenotypic consequences in two large population-based studies of healthy individuals. 
Carriage of an A-allele for the -796G>A and -577G>A variants for the GCH1 gene was 
associated with lower levels of plasma neopterin in the NPHSII cohort. Carriage of an A- 
allele for the -796G>A variant was associated with reduced endothelial-dependent 
vasodilation in the Cambridge Young Adults cohort, with a similar, though non-significant 
trend in endothelial function noted for the -577G>A variant.
We hypothesised that common genetic variation of the GCH1 gene could influence 
expression or activity of the GTPCH-1 enzyme in the general population and that this in 
turn could affect BH4  availability. This study has demonstrated an association between two 
variants within the GCH1 promoter and levels of plasma neopterin, a surrogate marker of 
BH4  synthesis. These variants might themselves influence GCH1 mRNA expression, or 
might be in linkage disequilibrium with regulatory variants elsewhere in the gene. The -  
796 G>A polymorphism lies 3bp from a CCAAT box/enhancer binding protein element 
(C/EBP) and could alter transcription factor binding and therefore gene expression. 
However, further in vitro analysis is needed to clarify the molecular mechanism of the 
observed associations.
GCH1 variants associated with changes in neopterin concentration were also associated 
with corresponding changes in endothelium-dependent vasodilation of the brachial artery, a
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systemic in vivo bioassay of endothelial NO availability. This association was independent 
of any effect of classical cardiovascular risk factors on vascular responses. Impaired flow 
mediated dilatation has been shown to relate to the presence of cardiovascular risk factors 
and disease in the general population (Celermajer et al., 1992), to be predictive of future 
vascular events (Gokce et al., 2003), and to be largely mediated by endothelium-derived 
NO (Palmer et al., 1987). Impaired endothelium-dependent dilatation and NO availability 
may be due to reduced NO synthesis, increased inactivation by rapid chemical reaction with 
reactive oxygen species including O2 ', or both. The restoration of endothelial function by 
local intra-arterial BH4 infusion demonstrated in previous studies might therefore reflect 
augmentation of NO synthesis or an antioxidant effect of this molecule (Fukuda et al., 
2002; Maier et al., 2000; Heitzer et al., 2000). Some studies suggest that functional BH4 
deficiency in cardiovascular disease is itself the result of increased oxidative inactivation of 
BH4 (Heller et al., 2001). Our data suggest that changes in pterin synthesis, regulated by 
GCH1 expression might also play a role.
Despite associations between GCH1 polymorphisms, neopterin concentration and 
endothelial function, the NPHSII study of 2390 males did not provide evidence that GCH1 
genotype altered future risk of CHD events. However, the NPHSII study is only powered 
to detect a genotype relative risk of >1.4 with 80% power at 2p=0.05 and thus relative risks 
of 1.2-1.3, such have now been demonstrated in combined data sets for variants in other 
candidate genes such as ACE or MTHFR, could not be excluded (Keavney et al., 2000; 
Wald et al., 2002). There was statistical evidence that the -796 genotype, but not the -577 
genotype, interacted with smoking to increase coronary disease risk. A significant
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association was only demonstrated between the -796 genotype and flow mediated 
dilatation. However, differences in neopterin were seen with both genotypes and there was 
a trend to an association between flow mediated dilatation and the -577 genotype. Due to 
the small numbers involved these data must be interpreted with caution.
In summary we have identified novel variants in the GCH1 gene. Those situated within the 
promoter region are associated with plasma neopterin levels in a large prospective cohort of 
healthy men, which suggests neopterin and therefore BH4 synthesis is influenced by GCH1 
genotype. Furthermore, in a cohort of young adults the -796 G>A variant is associated 
with significant differences in NO-dependent endothelial function, which is known to be a 
key early pathophysiological stage in the development of atherosclerosis. Variants relevant 
to BH4 synthesis appear to have an independent impact on endothelial function in healthy 
individuals from early in life.
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CHAPTER 6
IDENTIFICATION OF POLYMORPHISMS IN THE HUMAN 
DIMETHYLARGININE DIMETHYLAMINOHYDROLASE
GENE (DDAH2)
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6.1 Aim
To scan the human dimethylarginine dimethylaminohydrolase gene (DDAH2) for novel 
genetic variants, with the intention of investigating the role of any polymorphisms in the 
regulation of ADMA metabolism, in the modulation of endothelial function and the 
susceptibility to CVD.
6.2 Background
Asymmetric dimethylarginine (ADMA) is a naturally occurring methylated arginine that 
inhibits the synthesis of nitric oxide (NO) from L-arginine. It impairs endothelium- 
dependent vasodilation, is found in elevated concentrations in plasma from patients with 
risk factors for vascular disease and its levels predict future vascular events (Vallance et al., 
1992; Boger et al., 1998; Pettersson et al., 1998; Usui et al., 1998). Although ADMA 
levels vary between individuals little is known about the mechanism of such variation.
ADMA and symmetric dimethylarginine (SDMA) are generated by methylation of proteins 
by protein arginine methyltransferases (PRMTs) (Clarke, 1993). Unlike ADMA, SDMA 
has no inhibitory activity on the NOS enzyme. Whilst both ADMA and SDMA are 
excreted by the kidneys, and so accumulate when the kidneys fail, ADMA is also actively 
metabolised by the dimethylarginine dimethylaminohydrolase enzymes -DDAH1 and 
DDAH2 (Ogawa et al., 1987; Ogawa et al., 1989; Leiper et al., 1999).
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The DDAH1 enzyme was first identified in rat kidney by Ogawa and colleagues in 1989. 
Ten years later Leiper et al reported the cloning and deduced amino acid sequence of 
human DDAH1 and the discovery of a novel DDAH isoform termed DDAH2. The 
DDAH2 isoform was shown to share approximately 62% homology with the DDAH1 
amino acid sequence, and the DDAH2 cDNA and protein sequences exhibit 98% homology 
between human and mouse species. Northern blot experiments revealed distinct tissue 
distributions for DDAH1 and DDAH2, which showed some similarities with the tissue 
distribution of NOS isoforms. DDAH1 is highly expressed in brain, kidney, pancreas and 
liver, tissues in which the neuronal isoform of NOS is predominant. In contrast DDAH2 is 
highly expressed in the heart, kidney and placenta correlating with expression of eNOS 
(Leiper et al., 1999). A more in depth analysis of the tissue distributions of DDAH1 and 
DDAH2 also revealed that DDAH2 is highly expressed in foetal tissue and may have a role 
to play in cellular differentiation and cell cycle control (Tran et al., 2000). Thus tissue 
specific regulation of ADMA concentrations by distinct DDAH isoforms could be an 
important process regulating NO bioavailability. The expression of DDAH2 in highly 
vascularised tissues has also led to interest in this enzyme as a potential candidate for the 
predisposition to CVD.
Ribas et al, 1999, were the first to report the chromosomal localisation of a human gene 
thought to be homologous to rat DDAH. This gene (which they termed G6 A) is located 
within the class three region of the major histocompatibility complex (MHC class III) on 
chromosome 6p21.3. The identity of this gene was confirmed as being DDAH2 by Tran et 
al., 2 0 0 0  who also verified its location by radiation hybrid mapping and fluorescent in-situ
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hybridisation (FISH). This region of human chromosome six contains a number of genes 
that are thought to be involved in autoimmune diseases such as insulin dependent diabetes 
mellitus, ankylosing spondylitis and coeliac disease (Bertrams, 1984; Brown et al., 1998; 
McManus et al., 1996). Localisation of DDAH2 to the MHC class III region and the 
observation that DDAH2 is expressed in many types of immune cell, suggests that 
regulation of ADMA may also be important for iNOS activity which is known to contribute 
to many autoimmune pathophysiologies (Weinberg et al., 1994).
The DDAH2 gene comprises 8  exons that span a distance of 3kb. The 5’ untranslated 
region of the mRNA is encoded by exons 1, 2 and part of exon 3. Three transcription 
initiation sites have been identified at the beginning of exons 1, 2 and 3, and alternate 
splicing results in transcripts originating from all three as identified by EST database 
searches (Ribas et al., 1999; Tran et al., 2000). In comparison the DDAH1 gene has 6  
exons spread over a distance of more than 65kb. The translation start site of DDAH1 lies 
within exon 1, but no splice variants have been identified. The highly conserved 
exon/intron boundaries between DDAH1 and DDAH2 have led to the theory that these two 
genes arose through block duplication (Tran et al., 2000).
Publication of the crystal structure of a bacterial DDAH by Murray-Rust et al., 2001, 
revealed the nature of the enzyme active site and opened the way for research into the 
regulation of DDAH activity. They reported a catalytic triad (Cys-His-Glu), which is 
conserved in all known DDAH enzymes including human DDAH1 and DDAH2. Further 
work by Leiper et al., 2002 demonstrated that S-nitrosylation of the active site cysteine
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(Cys) residue reversibly inhibits enzyme activity, and these authors proposed that in-vivo S- 
nitosylation in the presence of high concentrations of NO for example seen after induction 
of iNOS, could lead to elevated ADMA levels. The authors also suggested that the 
elevated ADMA would lead to inhibition of all three NOS isoforms, explaining the 
observation that very high levels of NO from iNOS can suppress endothelium-dependent 
vasodilation due to NO release from eNOS (Kessler et al., 1997). Nitrosylation of DDAH 
could also account for the observations of Ito et al., 1999, who showed DDAH activity but 
not expression is reduced in ECV304 cells treated with oxLDL or cytokines and also in 
rabbits fed a high cholesterol diet. Initial up-regulation of iNOS by oxLDL and cytokines 
is now a plausible explanation for these findings.
Regulation of DDAH at the level of enzyme expression is also attracting interest as a 
mechanism of regulating circulating ADMA. To date the only publication demonstrating 
direct regulation of DDAH expression has highlighted all-trans retinoic acid (at-KA) as a 
transcription factor capable of increasing DDAH2 expression. Treatment of sEndl cells (a 
murine cell line) with atf-RA not only increased DDAH2 expression, but also decreased 
ADMA and increased NO production without increasing NOS expression (Achan et al., 
2 0 0 2 ). ,4f-RA is a powerful morphogen and has important effects on the developing 
cardiovascular system (Lansink et al., 1998), and these findings re-enforce the theory that 
DDAH2 may be involved in cell cycle control in the cardiovascular system.
Up to the writing of this thesis, no mutations or polymorphisms had been identified in 
either DDAH1 or DDAH2 by other groups. However, DDAH2 is a potential candidate gene
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for vascular disease because of its likely importance in regulating ADMA levels, and 
through this NO availability and vascular function. The aim of this study was to screen the 
DDAH2 gene for common polymorphisms or mutations by SSCP analysis.
6.3 Subjects and Methods
6.3.1 Subjects
Anonymised DNA samples from 32 healthy unrelated individuals, was used to screen the 
DDAH2 gene for polymorphisms. Blood was collected into EDTA tubes and DNA 
extracted by the Qiagen DNA purification kit method (section 2.2.1.2).
6.3.2 Oligonucleotide design and amplification of genomic DNA
Oligonucleotides were designed to cover the promoter and exons of the DDAH2 gene. All 
oligonucleotides were designed to be approximately 50% GC rich with minimum 
secondary structure formation. Each oligonucleotide pair was designed to have similar 
annealing temperatures, non-complementaiy sequence (which could result in ‘primer- 
dimer’ production) and produce a PCR product 200-400bp in length (the optimum for 
SSCP analysis). Oligonucleotides were designed using the Genbank/EMBL database 
sequence (accession number AJ012Q08). Table 6.1 lists all oligonucleotide sequences, 
positions relative to the translation start site, and PCR conditions. Three pairs of
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oligonucleotides were designed to produce three PCR products, which overlapped one 
another to cover the promoter region spanning -1078 to -1881 relative to the translation 
start site. Because of the small size of exon 4, intron 4 and exon 5 (lOObp, 122bp and 73bp 
respectively), oligonucleotides were designed to amplify both exons in one PCR reaction.
Amplification was carried out by PCR as described in section 2.2.2. All PCR products 
were electrophoresed on 1% agarose gels with lOObp ladder to ensure a single-band 
product of the correct size was achieved.
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Position of MgCl2 Annealing Sequence
oligonucleotides (mM) Temp (°C)
relative to
translation start site
Promoter 1
-1536—> -1881
Promoter 2
-1315—> -1617
Promoter 3
-1078—> -1389
Exon 1 
-869->-1221
Exon 2 
-403-* -652
Exon 3 
-121—> +297
Exon 4 +5
389-» 751
Exon 6
818-> 1273
Exon 7
1398—> 1795
Exon 8
1769-»2164
1.5
1.5
1.5
1.5
1.5
1.5
1.5 
2.0
1.5 
2.0
64
64
64
68
62
62
68
68
64
67
F - 5’ggt eta aca tgt tgg tcc ctci’
R - 5 ’etc ttc cac cac acc ate ccgi ’
F - 5 ’tgc tac cca atg gac aca ctci ’ 
R - 5’age age ccc acc aca aac a tti'
F - 5 'agg ggt ggg tea gtg ate ttgi ’ 
R - 5 ’egg etc egg ggc att gtc taai ’
F - 5 'cga aga age ccc gcc ccg tcci' 
R - 5 'ggc ccc ccc acg caa gac tcai ’
F - 5 'ctt egg gac teg gtc tgg ttt3 ’
R - 5 'tta acc etc age tgc teg ctai'
F - 5 'aac gcc ctt gtc tgc atg tcti ’
R - 5 'tct gcc ttt ccc cat acc acai ’
F - 5 'cct gca ccc cct ccc tcc ctai'
R - 5 'get ccg tgc cct ctt etc ctai'
F - 5 'ata ccc cat cac ccc tcc egei' 
R - 5 'ttt caa ccc cct acc ttc ccci'
F - 5 'tta gtg gtg gtt gag cag gca3’ 
R- 5 'aca tgg agt ggg gag agg ggai'
F - 5 'tct cac tcc cct etc ccc acti'
R - 5 'cct ate cct ttg ccc ctg taai'
Table 6.1. Oligonucleotides used for PCR amplification of the human DDAH2 gene.
A set of three overlapping oligonucleotide pairs were designed to amplify the promoter 
region from position -1078 to -1881 relative to the translation start site. The region 
amplified by each oligonucleotide pair is shown with corresponding MgCl2 concentration 
and annealing temperatures for PCR.
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6.3.3 Screening for polymorphisms by SSCP analysis
The non-radioactive PhastSystem SSCP technique was used to scan the DDAH2 gene as 
described in section 2 .2 .4.2 .
6.3.4 DNA sequencing to define the nature of variants detected by SSCP
Genomic regions exhibiting different banding patterns on SSCP gel electrophoresis were 
chosen for sequence analysis. Samples were selected so that each different banding pattern 
produced by SSCP was represented at least twice and the region re-amplified from genomic 
DNA. The PCR product was used as a template and both forward and reverse sequencing 
reactions set up using the same oligonucleotides as for PCR. Sequencing was carried out as 
described in section 2.2.5.
6.3.5 Search of the National Center for Biotechnology Information (NCBI) SNP 
database for DDAH2 polymorphisms
The NCBI SNP database (http://www.ncbi.nlm.nih.gov/SNP/) was searched for all 
polymorphisms identified to date within the DDAH2 gene as described in chapter 2.2.7. 
The database was established in 1988 and is a resource of freely available molecular 
biology information compiled by genome sequencing consortiums worldwide.
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6.3.6 Search of the Matlnspector promoter database for putative DDAH2 
transcription factor binding sites
A search of the Matlnspector database (http://www.genomatix.de/free_login.html) with the 
DDAH2 promoter sequence was undertaken to identify transcription factor binding sites as 
described in chapter 2 .2 .8 .
6.3.7 Identification of restriction enzyme sequences and genotyping of DDAH2 
polymorphisms
Restriction enzyme sites created or abolished by the presence of a polymorphism were 
identified using Webcutter software (http://www.firstmarket.com/cutter/cut2.html). Two 
cohorts of healthy subjects were used for initial genotyping analysis to ascertain genotype 
and allele frequencies of polymorphisms identified by SSCP. Individuals from the NPHSII 
cohort (North Mymms and Chesterfield clinics, n=498) described in section 2.2.12.1, were 
genotyped for the -449G/C, -1151 A/C and -1020C/G polymorphisms, and 128 individuals 
from the German population screen (section 2.2.12.1) were genotyped for the -1151 A/C, - 
1020C/G and -871 6G/7G polymorphisms.
Genotyping of the -1151 A/C, -1020C/G and -449G/C polymorphisms was carried out by 
PCR-RFLP analysis as described in chapter 2.2.6.1, using restriction enzymes BstUl, 
Mwol and BstUl respectively (table 6.2). The -871 6G/7G bi-allelic length variation 
polymorphism was genotyped by Genescan analysis as described in section 2.2.6.2, using
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the fluorescent labelled forward reading oligonucleotide -  5’ 6-FAM-
TCTCCACCAACTCTGTCCTC3’ and reverse oligonucleotide
5TAGCTCCGCGCCCAAATACCC3’ to amplify a 191bp fragment containing the 6G 
variant or a 192bp fragment containing the 7G.
DDAH2
Polymorphism*
Restriction
enzyme
Recognition
sequence
Digest 
products 
(size bp)
-1151 C/A BstUl 5’ CG>LCG 3’ 238+73
-1020C/G Mwol 5’ GCNNNNNlNNGC 3’ 144+109
-449C/G BstUl 5’ CGlCG 3’ 204+46
Table 6.2 DDAH2 polymorphisms -  restriction enzymes and digestion products.
Characters in bold type indicate polymorphic bases recognized and cut by the restriction 
enzyme. -I =cutting site. * numbering with respect to the translation start site.
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6.4 Results
6.4.1 Polymorphisms in DDAH2
Six polymorphisms were identified within the DDAH2 gene (Figure 6.1). The position of 
each polymorphism is numbered relative to the translation start site (ATG). SSCP analysis 
revealed a difference in banding pattern for PCR products generated with the 
oligonucleotides promoter 2, promoter 3, exon 1, exon 2 and exon 4+5 (tables 6.1), 
suggesting the presence of genetic variation within these regions. Figures 6.2a-6.2d show 
the SSCP gel images and the variation in banding pattern between individuals for the 
promoter 3, exon 1, exon 2 and exon 4+5 PCR products. Genetic variation in these regions 
was confirmed by DNA sequencing, which revealed a total of five single base substitutions 
at positions -1415G-+A, -1151C->A, -1020C->G, -449C->G and +618C->T and a 6G/7G 
bi-allelic length variation at position -871 (Figures 6.3a-6.3f). Two of the polymorphisms 
reside upstream of exon 1 (-1415G/A and -1151C/A), one within exon 1 (-1020C/G), one 
within intron 1 (-871 6G/7G), one within intron 2 (-449C/G) and one within intron 4 
(618C/T).
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Prom oter
Figure 6.1 DDAH2 gene structure and polymorphisms identified by SSCP.
Polymorphisms identified by SSCP during this study are indicated by vertical arrows I.  The position of each variant is numbered 
relative to the translation start site located in exon 3 (ATG). Exons 1-8 are numbered and filled in red. Five polymorphisms were 
identified upstream of the translation start site, one of these residing in the non-coding exon 1(-1020C/G). Only one polymorphism 
was found downstream of the translation start site within intron 4 (618C/T).
AFigure 6.2a. SSCP gel of DDAH2 promoter 3 
PCR. An extra band can be seen in samples 2, 3, 6 
and 7 (indicated by an arrow). DNA sequencing 
identified this polymorphism as a C-»A 
substitution at position -1151 (figure 6.3b).
1 2 3-4 5 6 7 8
9  *r i  1® •  mm Mgl
^ ■ — I.,—.Hiif r
Figure 6.2b. SSCP gel of DDAH2 exon 1 PCR. An
extra band is observed in lanes 2, 4 and 5 (indicated by 
an arrow). DNA sequencing identified this 
polymorphism as a C-»G substitution at position -  
1020 (figure 6.3c). DNA sequencing also revealed an 
insertion/deletion (6g/7g) polymorphism at position -  
87Ufieure 6.3d).
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cFigure 6.2c. SSCP gel of DDAH2 Exon 2 PCR
Lanes 3 and 6 have two bands that have migrated to 
different positions compared to three bands 
observed in all other lanes. DNA sequencing 
identified this polymorphism as a C—>G 
substitution at position -449 (figure 6.3e).
D
1 2 3 4 5 6 7 8
Figure 6.2d. SSCP gel of DDAH2 Exon 4+5 
PCR. Extra bands in samples 3 and 6 indicate the 
presence of sequence variation in these PCR 
products. DNA sequencing identified this 
polymorphism as a C->T substitution at position 
618 (figure 6.3f).
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G G G G S T  T T
Homozygous GG
Heterozygous GA
Figure 6.3a. DNA sequence confirming a G—»A substitution at position -1415 in 
DDAH2 promoter 2 PCR. Each peak is generated by the fluorescence emitted by the dye- 
terminator nucleotides. Each termination nucleotide is labeled with a different fluorescent 
dye, which emits light of different wavelengths (A=green. G=black, C=blue, T=red). The 
upper sequence shows a homozygote for the G allele, the lower sequence a heterozygote for 
both G and A alleles.
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T R R  T G G G C G( f l  Q 6 C T T R  M C R H G G
Homozygous AA
d j ) ;T R R  T G G G C (kfl J j G C T T R G C R G G G
H eterozygous A C
T R R  T G G G C ( ? ) G  G C T T R H C R G G G
H om ozygous CC
Figure 6.3b. DNA sequence confirming a C—>A substitution a position -1151 in the DDAH2 
promoter 3 PCR. The upper sequence shows a homozygote for the A allele, the middle sequence a 
heterozygote for both A and C alleles, and the lower sequence a homozygote for the C allele. The 
numbers represent the position of each nucleotide in the PCR product. This sequence variation 
confirms the presence of a polymorphism as was indicated by SSCP (Figure 6.2a).
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Heterozygous CG
Homozygous CC
Figure 6.3c. DNA sequence confirming a C-»G substitution at position -1020 in 
DDAH2 exonl. The upper sequence shows a heterozygote for both the C and G alleles, the 
lower sequence a homozygote for the C allele. No sequence electropherogram was 
available to illustrate a GG homozygote. This sequence variation confirms the presence of 
a polymorphism as was indicated by SSCP (Figure 6.2b).
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Homozygote 6G
Homozygote 7G
T g g g g g g N C C C
Heterozygote 6G/7G
Figure 6.3d. DNA sequence electropherogram confirming the presence of an extra G 
at position -871 in the DDAH2 promoter. The upper sequence illustrates a homozygote 
carrying 6G nucleotides at position -871, the middle sequence shows a homozygote 
carrying 7G nucleotides, and the lower panel identifies a heterozygote who has both 6G and 
7G alleles.
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Homozygous GG
Heterozygous CG
Homozygous CC
Figure 6.3e. DNA sequence electropherogram confiming the presence 
of a C-»G polymorphism within the DDAH2 exon2 PCR. The upper 
sequence shows a homozygote GG, the middle sequence a heterozygote G/C 
and the lower sequence a homozygote CC. This sequence variation 
confirms the presence of a polymorphism as was indicated by SSCP (Figure 
6.2c).
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Homozygous CC
Heterozygous CT
Figure 6.3f. DNA sequence eletropherogram confirming the presence 
of a C—»T polymorphism within the exon 4+5 PCR product. The upper 
sequence shows illustrates a homozygote for the C allele and the lower 
sequence a heterozygote for both T and C alleles. No sequence 
electropherogram was available for a TT homozygote. This sequence 
variation confirms the presence of a polymorphism as was indicated by 
SSCP (Figure 6.2d).
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6.4.2 Analysis of the DDAH2 promoter and comparison of polymorphisms in the 
National Center for Biotechnology Information (NCBI) SNP database with 
those identified by SSCP.
At the time of writing the NCBI SNP database contained information on 6 polymorphisms 
in the DDAH2 gene. The nature of each SNP, identification number and position are 
shown in table 6.3. All polymorphisms in the SNP database lie upstream of the translation 
start site and, in line with the current study no polymorphisms were identified in the coding 
exons or in the 3’ region of the gene. The -1415 C/T, -1151 C/A and the -449G/C 
polymorphisms identified by SSCP during this study were represented in the NCBI SNP 
database. The average allele frequencies reported for these variants are; -1415 G=90%, 
A=8%, -1151 A=64%, C=36%. Allele frequency was unavailable for the -449 variant.
NCBI SNP 
ID
Base change Position relative 
to tsp
rs2272592 G/A -1415
rs805304 C/A -1151
rs453560 G/C -738
rs3763297 G/C -728
rs707916 T/C -620
rs805305 G/C -449
Table 6.3. Human DDAH2 promoter polymorphisms identified in the NCBI SNP 
database. The -1415 C/T, -1151 A/C and the -449C/G polymorphisms were also 
identified by SSCP during this study. No polymorphisms have been identified in the 
coding exons.
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Matlnspector analysis of the 1.6kb immediately upstream of the DDAH2 translation start 
site revealed two of the polymorphisms identified by SSCP were situated in potential 
transcription factor binding sites (Figure 6.4). The -1020C/G polymorphism lies with a 
putative E2F transcription factor binding site (TTTCGCGC), and the -871 6G/7G bi-allelic 
length variation lies in a region encoding a nerve growth factor induced protein C/ early 
growth response (NGFIC/Egr-3) binding sequence GCGTGGGGGG and a MYC- 
associated zinc finger protein related transcription factor site (MAZF).
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agaattcgct tccacctgtc cagatgatga ggagatcgag ctcgcctatg 
agcaagtggc aaaggccctc aaataagccc ctcctgggac tccctcaacc 
ccctccattt tctccacaaa ggccctggtg gtttccacat tgctacccaa
P ro 2  R --------------------------------
tggacacact ccaaaatggc cagtgggcag ggaatcctgg agcacttgtt 
 ►
ccgggatggt gtggtggaag aggggatgag ggaaagaaat ggggggcctg
ggtcagattt ttattgtggg gtgggatgag taggacaaca tatttcagta
-1415
ataaaataca gaataaaaat caagtgtttt tacgcaatgg gggtttaaag
tgtgggcgac atggaatgag gggtgggtca gtgatcttga gctcagggca
P ro 3  F  ►
gaagccagga attaagaagg gaaatgtttg tggtggggct gctatgtttc
<4 — -----------------------------------  P ro 2  R
gtgccggtcc gccggtccgc cgttgcgctg ttctgaggtc tacgaagcgt
ttgcagcccc gtcgccaggg ccggccagat ctgggtgggc ctgggcagcg 
SP1ctcgctgggc ggtgccgatt tctggcaagg ggggcgcagt ctggatgtaa 
-1151
tgggcgCggc ttagcagggc ggaatgggcg tggcccgaag aagccccgcc
IF  ------------------------------------------------
ccc^tcccgct tagacaatgc cccggagccg ^ ccagaccgtc gcgcccctgc
-1020 E2F
cccatcgtag tatatgagct cgcctacaca aggaccccCg ctaaaagcca
NFkB
gagctcccag tccccgaggc ttgaagacgg ggactccctt ctccaccaac
PPAR/RXR SP1
t c t g t c c t c g  gggggtgggg ccccagccga gatcacagcg cgacaggagt
-871 N G FIC +M A ZF
gggggtggcc gctggaggtg agtcttGCGT gggggggccc tgaaccgtgt
<--------------------------------------------------------  1R
gggggccgga gtttgggggt gccgggccca tgcctgcacc agacagagag 
SRF
tatggggagc c g g t a t t t g g  gcgcggagct aggcggggtg gactttggga 
catagacggg gaaccgggtg ctggagccgg gagtagtgcc agcgccccgg 
Figure 6.4 continued —»
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aaccacgccc cctgttaccc cgcccctcgc atttcgtttt agacctctcc
cagtccttcg ggactcggtc tggtttatac taggtcgtgc taggggcagc
2F
gtgaccagcc agggcggaga gaggatgctt aactccttag gctcgaactc
ctcccttcct acccacctct ctcccttctc gttcgggtat tcaggacttc
cattccccag cccctgcctc tccagctttc tccttctgtc ccataacccc
-449
tgcgggtcCc gggctggact tccagtccct gcggtagcga 
<----
gcagctgagg
SP1gttaaggggg cggggctgct gcatttttgg ggagtgagcg catcctagtg
----------
gctgccaaga ggggcgcccg acagggacct cacaagcccc caagcagggg
caacaggtgt tttggagatt agagacccta gccttgttcc tcaggctcct
cttaaagaat ctgacccctg agggtgctgg gtagagtgag gtcgacagga
gcggaaggtc 4- s p 4  tggagtgggt ggggcggagt gggagggacg cctagagatg
gcaggaggaa gacctgggcg ctcttaacca NGFICcccccaacgc ccttgtctgc
atgtcttttt ctctgtctcc tccttttctg tttcttctcc cagacaggtg
aagaaacaag aaaactaaga aatccgagcg gttggagggg gagtctgtgt
ggatgggatg
+1
gggacgccgg gggaggggct gggccgctgc tcccatgccc
Figure 6.4 DNA sequence of the DDAH2 5’ untranslated region. Exon 
sequences are indicated in blue. Oligonucleotide sequences are underlined by 
arrows. The position of transcription factor binding sites identified by Matlnspector 
are shown in green and polymorphisms are shown in red type and numbered by 
position relative to the translation start site. The -1020C/G polymorphism lies in an 
E2F transcription factor binding site and the -871 6G/7G polymorphism lies within 
a NGFIC/MAZF binding sequence.
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6.4.3 Genotype and allele frequencies of DDAH2 polymorphisms
Gel images representing common homozygotes, heterozygotes and rare homozygotes for 
the single nucleotide polymorphisms -1151 A/C, -1020C/G and -449G/C polymorphisms 
are shown in figure 6.5. Figure 6.6 shows the electropherogram trace produced by 
Genescan analysis of the -871 6G/7G insertion/deletion polymorphism. The peaks 
correspond to PCR products 191bp (6G/6G), 191+192bp (6G/7G) and 192bp (7G/7G).
The genotype and allele frequencies of each polymorphism are shown in table 6.4. Rare 
allele frequency for the -1151 A/C, -1020C/G and -449G/C, polymorphisms in the NPHSII 
cohort were 0.31, 0.12 and 0.34 respectively. Rare allele frequencies for the -1151 A/C, - 
1020C/G and -871 6G/7G polymorphisms in the German population screen were 0.31, 0.16 
and 0.01 respectively. All polymorphisms were in Hardy-Weinberg equilibrium except for 
the -1020C/G polymorphism in the German population screen (%2 =8.6, P=0.003). Table 
6.5 shows the linkage disequilibrium coefficients for each polymorphism. The -1151 A/C, - 
1020C/G and -449G/C polymorphisms were in very tight linkage disequilibrium in the 
NPHSII cohort (P=<0.0001). In the German population screen the -1151 A/C and -  
1020C/G were in tight linkage disequilibrium (*A=-0.3, P=0.0008).
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1 2 3 4 5 6 7 8
r 1 JjI I
H QH
^  -
| 1
356bp
283bp
73bp
BstUl restriction digest of 
th e -1151 A/C 
polymorphism.
Lane 1 -  lOObp ladder. 
Lanes 2+5 -  CC individuals 
(283bp and 73bp).
Lane 9 -  heterozygote A/C  
(356bp+283bp+73bp). 
Lanes 3,4,6 ,7,8 -  AA  
individuals (356bp).
1 2 8 9
253bp
144bp
109bp
M wol restriction digest of 
the -1020C/G  
polymorphism.
Lane 1 -  1 OObp ladder. 
Lanes 2-5+8-9 CC 
individuals (253bp).
Lane 6 -  GG individual 
(144bp+109bp).
Lane 7 -  Heterozygote C/G 
(253bp + 144bp +109bp)
1 2 3 4 5 6 7 8 9
BstUl restriction digest of the 
-449C/G polymorphism.
Lane 1 -  lOObp ladder 
Lanes 2, 5, 6+9 CC
hom ozygotes (250bp)
P Lane 3 -  C/G heterozygote 
204bp individuals
(250bp+204bp+46bp)
Lanes 4+8 -  GG homozygous 
individuals (204bp)
Figure 6.5 Restriction digest gel images. The top panel shows the digest products 
after restriction of the -1151 A/C polymorphisms with the enzyme BstUl. The middle 
panel shows the digest products after restriction of the -1020C/G polymorphism with 
M wol and the bottom panel shows the digest products after restriction of the -449G/C 
polymorphism with BstUl. All three genotypes for each polymorphism are represented
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191 bp
190bp
191 bp
6G/7G
7G/7G
190bp
6G/6G
Figure 6.6 Genescan trace produced upon genotyping the DDAH2 -871 6G/7G bi- 
allelic length variation. The region encompassing the polymorphism was amplified by 
PCR using a fluorescent labelled forward oligonucleotide and electrophoresed on an ABI 
377 DNA sequencer. Data from 3 individuals is shown. The top trace shows two peaks 
(190bp+191bp) corresponding to a heterozygous 6G/7G individual. The middle trace 
shows 1 peak (191 bp) corresponding to a homozygous 7G/7G individual and the bottom 
trace shows 1 peak (190bp) corresponding to a homozygous 6G/6G individual. Peaks were 
automatically sized by Genotyper software.
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NPHSII cohort
Polymorphism Genotype
N
Allele
%
x2 P
-1151A/C AA=216 AC=184 CC=44 A=69.0 C=31.0 0.3 0.6
-1020C/G CC=342 CG=94 GG=7 C=88.0 G=12.0 0.0 0.89
-449G/C GG=186 GC=184 CC=54 G=66.0 C=34.0 0.6 0.42
German Population Screen
Polymorphism Genotype
N
Allele
%
x2 P
-1151A/C AA=64 AC=45 CC=16 A=69.0 C=31.0 3.0 0.08
-1020C/G CC=94 CG=26 GG=8 C=84.0 G=16.0 8.6 0.003*
-871 6G/7G 6G6G=123 6G7G=3 7G7G=0 G=99.0 C=1.0 0.0 0.89
Table 6.4. Genotype and allele frequencies of DDAH2 polymorphisms in the 
NPHSII cohort (top panel) and the German Population Screen cohort (bottom panel).
All polymorphisms conformed to the Hardy-Weinberg equilibrium except the -1020C/G 
polymorphism in the German Population Screen (% =8.6, *P=0.003).
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-1020C/G
A (P)
-1151A/C
A (P)
-449G/C -0.24 (O.OOOl)'1' -0.45 (<0.0001)'F
-871 6G/7G -0.05 (0.58) 0.17 (0.06)
-1020C/G -0.30 (0.0008) 
-0.54 (O.OOOl)4'
Table 6.5. Pairwise linkage disequilibrium coefficients (A) for DDAH2 
polymorphisms. The -1020C/G and -1151 A/C polymorphisms were in tight linkage 
disequilibrium in both the German population screen (*A=-0.30, P=0.0008) and NPHSII 
cohort (^A=-0.54, P=<0.0001). The -449G/C polymorphism was in tight linkage with both 
the -1020C/G and the -1151 A/C polymorphisms in the NPHSII cohort (^=<0.0001). The 
-871 6G/7G polymorphism was not in linkage disequilibrium with either the -1020C/G or 
-1151 A/C polymorphisms in the German population screen.
6.5 Discussion
6.5.1 DDAH2 promoter polymorphisms
Five polymorphisms were identified upstream of the DDAH2 translation start site during 
this study in the putative promoter region. The DDAH2 translation start site is located 
within exon 3, and therefore the promoter incorporates the non-coding exons 1 and 2. 
Alternate splicing between exons 1, 2 and 3 generates three transcripts, which have been 
identified in the EST database. The -1020C/G polymorphism is situated within exon 1. 
Although this exon is non-coding in terms of protein synthesis, it may act as a promoter for
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transcription starting at exons 2 and 3. Alternatively, as the -1020C/G polymorphism 
changes a nucleotide that will reside in the 5’ untranslated region (5’UTR) of the mRNA, it 
could effect gene expression through mRNA stability and translation efficiency. 
Matlnspector analysis revealed the presence of putative transcription factor binding sites 
within this region, and the position of the -1020G/C variant falls within an E2F consensus 
sequence. E2F transcription factor sequences are a common feature within the promoter 
regions of genes involved in control of the cell cycle. Interaction of the E2F protein with 
the retinoblastoma (RB) family of proteins (pRb/105, 107, and pRb/pl30) determines 
transcription of E2F regulated genes. VSMCs from atherosclerotic plaques have a higher 
ratio of the active form of RB compared to the inactive form and show lower level of E2F 
regulated gene transcription and cell proliferation compared to normal VSMCs. This fits 
with the observation that plaque VSMCs exhibit slow proliferation, senescence and 
undergo apoptosis in culture (Gordon et al., 1990; Bennett et al., 1995). E2F regulation of 
DDAH2 transcription during VSMC proliferation could be involved in the process of 
atherosclerotic plaque formation and restenosis (Black et al., 1999; Bennett et al., 1998). 
Further work is needed to determine if this polymorphism is functional via interaction with 
E2F.
The four remaining upstream polymorphisms do not lie within exon sequences. The -  
1415G/A and -1151C/A are situated farthest upstream and are not known to reside within 
any important regulatory regions. The -871 6G/7G bi-allelic length variant and the -  
449C/G are located in introns 1 and 2 respectively. Neither polymorphism disrupts an 
exon/intron boundary sequence, but the -871 6G/7G lies within a nerve growth factor
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induced protein C/early growth response (NGFIC/Egr-3) consensus site which overlaps 
with a MYC-associated zinc finger protein related transcription factor site (MAZF). 
Genotyping of 128 healthy German subjects revealed a 7G allele frequency of just 1%. 
Previous investigators have shown that length variations in runs of bases such as Gs may 
alter the rate of gene transcription. Such genes include the stromelysin and plasminogen 
activator inhibitor (PAI) genes among others (Terashima et al., 1999; Gardemann et al., 
1999). Stromelysin (MMP3) is a member of the matrix metalloproteinase enzyme family, 
which regulates the accumulation of extracellular matrix (Sellers and Murphy, 1981) and 
has been implicated in connective tissue remodeling during atherogenesis (Ye et al., 1996). 
A common polymorphism at position -1171 in the MMP3 promoter, which results in one 
allele containing a run of 5A nucleotides and the other allele 6A nucleotides, has been 
shown to alter gene transcription in a promoter/reporter assay (Ye et al., 1996). A common 
polymorphism in the PAI1 gene promoter, which results in ether 4 or 5G nucleotides has 
also been shown to influence gene expression. The 5G allele demonstrated reduced 
promoter activity, and an additional protein binding site not present in the 4G allele 
(Dawson et al., 1993). It was subsequently shown that the 4G allele binds only to an 
activator, whereas the 5G allele binds an activator and an inhibitor protein. The 4G allele 
has been associated with higher levels of PAI1 and increased risk of vascular disease 
(Dawson et al., 1993; Rossaak et al., 2000).
The position of the -871 6G/7G polymorphism within a NGFIC/MAZF transcription factor 
site may have implications for DDAH2 expression. Nerve growth factor (NGF) mediates a 
whole host of responses including cell differentiation, cell survival and gene expression.
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Recently, studies have shown that NGF activates PRMT1 activity in PC 12 cells, 
consequently leading to the asymmetric methylation of arginine residues in target proteins, 
which upon metabolism release free ADMA (Cimato et al., 2002). NGF has also been 
shown to induce GCH1 and NOS expression leading to elevated BH4 and NO respectively 
(Anastasiadis et al., 1996; Hirayama et al., 1995; Peunova et al., 1995; Kalisch et al., 2002). 
Evidence of a role for NGF in the development of atherosclerosis has been put forward by a 
number of investigators who have observed reduced NGF expression in atherosclerotic 
coronary arteries and reduced levels of plasma NGF in individuals with congestive heart 
failure compared to healthy controls (Chaldakov et al., 2001; Kaye et al., 2000). Taken 
together these observations suggest that NGF might provide co-ordinate regulation of NO 
synthesis in target cells by concerted modulation of multiple relevant target genes in the 
NO pathway. Disruption of the NGFIC binding site in the DDAH2 gene promoter by the -  
871 6G/7G polymorphism could alter DDAH2 expression and the breakdown of ADMA in 
the body, but further research will be needed to test this hypothesis. The transcription 
factor MAZF has been identified as an important regulator of TATA-less promoters (Parks 
et al., 1996). In addition to binding its consensus DNA sequence, MAZF also interacts 
with SP1 to modulate gene transcription (Parks et al., 1996). Genes identified as being 
regulated by MAZF include eNOS, serotonin la  receptor, c-myc and CD4 (Karantzoulis- 
Fegaras et al., 1999; Parks et al., 1996; Bossone et al., 1992; Duncan et al., 1995). The 
observation that eNOS expression is regulated by MAZF raises the possibility that this 
transcription factor is also involved in the control of genes that regulate cell differentiation, 
survival and in particular NO availability.
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6.5.2 Polymorphisms within DDAH2 coding exons
Only one polymorphism was identified downstream of the translation start site. This 
variant encodes a C->T substitution at position +618 within intron 4. No obvious 
consensus sequences for splicing are situated in this region. The absence of any 
polymorphisms in the coding exons, either suggests this region has remained highly 
conserved throughout evolution or that SSCP failed to detect all variants present in the 
samples analysed.
A search of the NCBI SNP database revealed six polymorphisms in the DDAH2 5’ 
untranslated region, three of which (-1415 G/A, -1151 A/C and the -449C/G) were 
identified by SSCP during this study. Of the remaining three (rs453560, rs3763297 and 
rs707916) none are located in consensus sequences for any transcription factor binding sites 
or other important regulatory sequences. The NCBI SNP database did not contain any 
polymorphisms downstream of the translation start site, indicating that this region is highly 
conserved.
In summary, six polymorphisms were identified by SSCP in the DDAH2 gene. Three of 
these variants have been described on the NCBI SNP database. Two polymorphisms 
upstream of the translation start site reside with transcription factor binding sites and may 
influence DDAH2 promoter activity. A luciferase promoter/reporter gene assay has been 
used to investigate the effect of the -1151 A/C and -871 6G/7G polymorphisms on DDAH2 
expression, and the results are described in chapter 7.
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CHAPTER 7
INFLUENCE OF DDAH2 POLYMORPHISMS ON 
PROMOTER FUNCTION
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7.1 Alms
To assess the influence of DDAH2 polymorphisms on DDAH2 gene expression in vitro 
using a luciferase reporter assay.
7.2 Background
Common genetic variation within the promoters of many genes has been demonstrated 
to alter gene expression. A polymorphism that resides in the consensus sequence for a 
transcription factor may modulate the affinity of that factor for its binding site, thereby 
either enhancing or repressing gene transcription. The identification of several 
polymorphisms within the DDAH2 gene promoter (Chapter 6 ) raises the hypothesis that 
DDAH2 expression maybe influenced by common genetic variation at these sites. If so, 
variation in DDAH2 expression between individuals could have consequences for local 
or systemic concentrations of ADMA and rates of NO synthesis. Therefore, in theory, 
individuals with a lower DDAH2 expression would be expected to have elevated levels 
of ADMA, which would compete with L-arginine for the active site of the NOS 
enzyme, leading to decreased NO synthesis and, potentially, an increased risk of 
cardiovascular disease.
The analysis of gene expression by commercially available genetic reporter systems is 
now a widely used technique. In essence, a promoter of interest is cloned into a vector 
containing a gene whose protein product can be readily assayed, the construct is 
transfected into a target cell, and protein expression or activity quantified. Expression 
or activity of the reporter protein serves as an indirect semi-quantitative index of
184
promoter function. Basal reporter activity, as well as activity following exposure of 
cells to chemical or physical signals can be assayed. Several different vector systems 
are available to clone and study virtually any eukaryotic gene promoter. Examples 
include plasmids, which can accommodate relatively small pieces of DNA sequence 
(typically up to ~ 8 kb), cosmids (hybrids between a phage DNA molecule and a bacterial 
plasmid), which can hold more than 40kb of sequence and yeast expression vectors such 
as yeast artificial chromosomes (YAC), which are capable of accommodating much 
larger DNA sequences. Commercial vectors contain a range of genetic elements to 
facilitate cloning and expression. For example, polylinkers which contain many 
restriction enzyme sites into which DNA can be inserted, an origin of replication, 
enhancer and promoter sequences. The critical component of a reporter vector is the 
presence of genes such as luciferase or chloramphenicol acetyltransferase (CAT) whose 
expression can be readily quantified by standard techniques. Reporter gene vectors also 
contain selectable genes such as antibiotic resistance genes. During this study, the 
plasmid vector pGL3basic (manufactured by Promega) was used to clone the DDAH2 
promoter. This vector comprises 4818bp of circular DNA and harbours a polylinker 
upstream of the firefly (Photinus pyralis) luciferase reporter gene, and the ampicillin 
resistance gene for easy selection (Figure 7.1).
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Figure 7.1 Diagrammatic representation of the vector pGL3basic. The circular 
vector comprises 4818bp of DNA and incorporates the luciferase gene (luc+), ampicillin 
resistance gene (Ampr) and a polylinker site into which a promoter sequence can be 
inserted. Adapted from Promega-Protocols and Applications Guide, 1996.
The luciferase reporter assay involves inserting the DNA of interest (in this case the 
DDAH2 promoter) into a vector (pGL3basic), upstream of the firefly luciferase reporter 
gene. The reporter construct is then transfected into a relevant target cell maintained in 
cell culture. The construct will then be replicated along with the host cell genome, and 
the luciferase enzyme expressed in proportion to the activity o f the promoter of interest. 
Upon addition o f the luciferase substrate (beetle luciferin) the product oxyluciferin is 
generated together with AMP, PPi, CO2 and a flash of light (in proportion to the amount 
o f luciferase expressed), which can be quantified in a luminometer (Figure 7.2).
To assess the influence of polymorphisms on DDAH2 promoter activity, constructs 
representing all four possible permutations of the -871 6G/7G and -1151 A/C variants
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(6G/A, 6G/C, 7G/A, 7G/C) were made and expressed in HUVEC. These variants were 
chosen because the -871 6G/7G polymorphism lies in a transcription factor binding site 
for NGFIC/MAZF and preliminary genotyping analysis o f the -1151 A/C variant 
suggested a possible association with ADMA/SDMA ratio. Primary HUVEC were 
chosen because DDAH2 is highly expressed in this cell type (Tran et al., 2000) and 
therefore all the necessary components for transcription o f the DDAH2 gene are 
available. HUVEC were simultaneously co-transfected with the pRL-SV40 vector 
(Promoga, Dual-Luciferase Reporter Assay System), which contains the Renilla 
(Renilla reniformis) luciferase gene under control of the SV40 promoter. Co­
transfection of HUVEC with the Renilla luciferase allows correction for variability in 
transfection efficiency. Due to the different evolutionary origins of the firefly and 
Renilla luciferases, they have dissimilar enzyme structures and substrate requirement, 
making it possible to discriminate between the bioluminescence reactions (Figure 7.2).
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Figure 7.2. Bioluminescent reactions of the firefly and Renilla luciferases. The firefly 
and renilla luciferase enzymes have different evolutionary origins and therefore different 
enzyme structures and substrate requirements. Firefly luciferase catalyses the oxidation of 
beetle luciferin and renilla luciferase the oxidation of coelenterazine to produce light and C02. 
Adapted from Promega Technical Manual No. 040.
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A restriction fragment spanning nucleotides -1755 to -216 and incorporating the 
DDAH2 promoter has already been shown to direct gene expression in an ECV304 cell 
line (Achan et al., 2002). Several at-RA acid transcription factor-binding sequences 
(PPAR/RXR) are present within the DDAH2 promoter, and treatment of transfected 
ECV304 cells with at-RA. was shown to enhance DDAH2 promoter activity by 47% 
during this study. During the same study treatment of murine endothelioma cells 
(sEnd.l) with at-RA was shown to increase N 02‘ production without increasing eNOS 
expression. The authors concluded that increased generation of NO by at-RA treatment 
might be mediated through changes in DDAH2 expression and modulation of ADMA 
concentrations and eNOS activity.
The DDAH2 gene has three transcription initiation sites at exons 1, 2 and 3. Alternate 
splicing between the 3* ends of exons 1 and 2 and an internal site within exon 3 results 
in 3 possible DDAH2 transcripts (Tran et al., 2000). The aim of this study therefore, 
was to identify which splice variants of the DDAH2 gene are expressed in HUVEC and 
therefore which sequences might be acting as a promoter in these cells. This study also 
investigated whether the -871 6G/7G (which lies within a NGFIC and a MAZF 
consensus sequence) and -1151 A/C polymorphisms affect DDAH2 promoter activity in 
primary HUVEC. As a positive control, promoter activity in the presence of <atf-RA was 
also assessed.
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7.3 Materials and Methods
7.3.1 Identification of DDAH2 transcripts in HUVEC
mRNA was isolated form HUVEC and cDNA generated by Dr. Juan Pablo Casas 
Romero (University College London). mRNA was isolated using the Microfast Track 
kit (Invitrogen). mRNA was reverse transcribed by RT-PCR in a 20pl reaction volume 
containing 2pl of mRNA, 150ng of random primers (hexamers), 0.5mM each of dATP, 
dCTP, dGTP and dTTP, 5x first strand buffer (250mM Tris-HCl [pH8.3], 375mM KC1, 
15mM MgCl2), 0.1M dithiothreitol (DTT), 9pl of DEPC H20  and 200units of 
superscript!! RNAse H‘ (Life Technologies). The reactions were incubated at 42°C for 
55 minutes followed by 72°C for 10 minutes.
PCR to amplify exons 1, 2 and 3 was carried out as described in Chapter 2.2.2 using the 
following oligonucleotides; Exon 1 forward (-1097 to -1076)
5 ’TTAGACAATGCCCCGGAGCCGC3 Exon 1 reverse (-929 to -908) 
5’ATCCTGTCGCGCTGTGATCTC3’ (product 190bp), Exon 2 forward (-588 to -568) 
5’ GAGAGGATGCTTAACTCCTTA3 Exon 2 reverse (-544 to -524)
5 ’GAACGAGAAGGGAGAGAGGTG3 ’ (product 66bp), Exon 3 forward (-148 to - 
127) 5 * AGACCTGGGCGCTCTTAACCAC3 ’ and Exon 3 reverse (59-80)
5 ’TCCCCCGACGCGAGGCTCTCTG3 ’ (product 230bp). The annealing temperature 
for each PCR reaction was 60°C. PCR amplification of the glyceraldehyde-3 phosphate 
dehydrogenase (GAPDH) housekeeping gene was used as a positive control (forward 
oligo 5 ’ AAGGTGAAGGTCGGAGTCAACG3 reverse oligo
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5’GGCAGAGATGATGACCCTTTTGGC3’). PCR products were electrophoresed on 
1% agarose gels and visualised by ethidium bromide staining.
7.3.2 Cloning of human DDAH2 promoter/reporter constructs containing allelic 
variants
Promoter/reporter constructs containing allelic variants identified by SSCP at position -  
871(6G/7G) and -1151(A/C) were generated as shown in figure 7.3. A 1.6kb fragment 
containing the DDAH2 promoter was cloned into the vector - pGL3basic by Miss Lucy 
Tran, University College London (Achan et al., 2002). The region containing the -871 
6G/7G and -1151 A/C variants was sequenced to identify the genotype of the primary 
construct. This construct was used as a template for generating allelic variants by site- 
directed mutagenesis, so that all four possible permutations were represented: - 6G/A, 
7G/A, 6G/C and 7G/C. All variants were verified by DNA sequencing.
7.3.2.1 Site-directed mutagenesis
DNA sequencing revealed the DDAH2 promoter cloned into the vector pGL3basic, 
contained the 6G variant at position -871 and an A allele at position -1151. Both 
forward and reverse allele-specific oligonucleotides for site-directed mutagenesis were 
designed to cover the regions incorporating the -871 7G allele and -1151 C allele 
(Table 7.1). Two PCR reactions for each variant were carried out using the allele- 
specific oligonucleotides and the forward and reverse reading vector oligonucleotides 
RV3 and GL2 (Table 7.1). PCR reactions were carried out in 50pl volumes containing 
lp l of pGL3basic vector containing the DDAH2 promoter, 5 pi lOx buffer, dNTPs,
190
50pmol of each oligonucleotide, 1.5mM MgCb and 2 units of Taq Expand (Roche 
Expand High Fidelity PCR kit). Cycling conditions were 95 °C for 5mins followed by 
10 cycles of 95°C for 30sec, 60°C for 30sec and 72°C for 2mins and a final extension at 
72°C for lOmins. PCR products were electrophoresed on a 1% agarose gel to check 
products were the expected size and gel extracted using the QIAquick gel extraction kit 
(Qiagen).
The two PCR products were annealed to give the full DDAH2 promoter containing the 
desired allelic variant by 5 cycles of PCR in which oligonucleotides were omitted from 
the reaction. After 5 cycles 50pmol of the forward and reverse vector oligonucleotides 
-  RV3 and GL2 were added and the reaction continued for a further 20 cycles. PCR 
products were electrophoresed on a 1% agarose gel to check the expected band size 
(1.6kb), and sequenced to confirm the desired allele had been incorporated.
Oligonucleotide Sequence
DDAH2 -871 7G F 5’ ttg cgt ggg ggg gcc ctg aac 3’
R 5’ gtt cag ggc ccc ccc acg caa 5’
DDAH2 -1151 C F 5’ taa tgg gcg egg ctt age agg 3’
R 5’ cct get aag ccg ege cca tta 3’
pGL3 basic vector RV3 F 5’ eta gca aaa tag get gtc cc 3’
pGL3 basic vector GL2 R 5’ ctt tat gtt ttt ggc gtc ttc c 3*
Table 7.1 Allele-specific and vector oligonucleotides used for site directed 
mutagenesis to generate DDAH2 promoter constructs. Mismatched bases are 
highlighted in bold.
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7.3.2.2 TOPO TA cloning of allele-specific PCR products
Allele-specific PCR products were initially TA cloned using the TOPO TA cloning kit. 
(Invitrogen). 2pi of PCR product was TA cfoned into TOPO vector by incubating at 
room temperature for 5 minutes. 2pi of the cloning reaction was then added to a vial of 
One Shot chemically competent E.coli cells and incubated on ice for 30 minutes. Cells 
were then heat-shocked for 30 seconds at 42°C to facilitate uptake of DNA. 250pl of 
SOC medium (containing 2% tryptone, 0.5% yeast extract, NaCl2, KC12, MgCl2, MgS04, 
and glucose) was added to the reaction and the cells incubated at 37°C for 1 hour. 
lOOpl of cells was then spread onto agar plates containing the p-galactosidase substrate- 
X-gal (5-bromo-4-chloro-indolyl-p-D-galactosidase) and incubated overnight at 37°C. 
Insertion of the PCR product into the TOPO cloning vector disrupts the p-galactosidase 
(lacZ) gene' and renders the cell unable to metabolise X-gal resulting in white colonies 
on agar/xgal plates. Non-transformed cells produce blue colonies on agar/X-gal plates. 
White colonies were picked and grown overnight in 3ml of LB media containing 
O.lmg/ml Ampicillin. The plasmid DNA was isolated using the Qiagen DNA miniprep 
kit.
7.3.2.3 Cloning allele-specific constructs into pGL3basic vector
The TOPO vector containing the DDAH2 promoter allele-specific PCR was digested 
with Hindlll to excise the DDAH2 promoter sequence and electrophoresed on a 1% 
agarose gel. The 1.6kb product was then gel purified using the QIAquick gel extraction 
kit (Qiagen). The purified 1.6kb product was ligated into Hindlll digested pGL3basic 
vector in a 10pl reaction containing lpl Hindlll digested pGL3basic vector, 2pi of the
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1.6kb product, 2pi T4 DNA ligase buffer (Gibco) and lp l T4 DNA ligase (Gibco). The 
reaction was incubated at 4°C overnight.
7.3.2.4 Transformation ofDH5a competent cells
Subcloning efficiency DH5a competent cells were purchase form Invitrogen, UK. IO jliI 
of ligation reaction was added to lOOpl of cells and incubated on ice for 30 minutes. 
The cells were then heat-shocked at 37°C for 45 seconds and placed immediately on ice 
for 2 minutes. 950pl of SOC media was added to the cells and incubated while shaking 
at 37°C for 1 hour. The cells were pelleted by centrifugation and 900pl of spent media 
removed. The cells were re-suspended in the remaining media and lOOpl spread onto 
agar/X-gal plates. Plates were incubated overnight at 37°C. White colonies were 
picked, grown in 3ml of LB media and the plasmid isolated using the Qiagen DNA 
miniprep kit. To identify colonies containing the DDAH2 promoter and the orientation 
of the insert, samples were digested with restriction enzymes Hindlll and Narl 
respectively.
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Figure 7.3. A diagramatic representation of the steps involved in cloning 
DDAH2 promoter/reporter constructs containing allelic variants. Step 1. 
Incorporation of the desired allele (represented in green) into the DDAH2 promoter 
sequence (shown in grey) by two rounds of PCR (site-directed mutagenesis). Step 2. 
Cloning the allele-specific PCR product into the TOPO vector, transformation of E.coli 
and harvesting the recombinant plasmid. Step 3. Ligation of the new DDAH2 promoter 
into pGL3basic vector for luciferase assay.
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7.3.3 Luciferase reporter gene assay
7.3.3.1 Cell culture and transfection
HUVEC were purchased form Promocell (Germany) and cultured prior to transfection 
as described in Chapter 2. Transfection of HUVEC with the promoter/reporter 
constructs and renilla expression vector (to control for transfection efficiency) was 
carried out in 12 well culture plates as described in Chapter 2. Briefly, transfection of 
HUVEC was mediated by incubating the cells with lipofectin reagent (Invitrogen) in 
serum free media (Optimem 1) for four hours, after which the transfection reagent was 
removed and replace with endothelial cell growth media (EGM). For each experiment 
transfections were performed in triplicate for each construct and luciferase activity was 
normalised to renilla activity. A total of 7 independent experiments were conducted for 
each construct. To test the effect of atf-RA on promoter activity, HUVEC were treated 
for 24 hours with lOpmol/L atRA 24 hours after transfection.
7.3.3.2 Cell lysis and luciferase assay
Cell lysis and luciferase measurements were performed using the dual light luciferase 
reporter assay kit (Promega, Madison, USA) as described in Chapter 2.2.11.2.
7.3.3.3 Statistical analysis
Transformations were performed in triplicate and the average reading taken after 
correction for transfection efficiency. Promoter activity between constructs was
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analysed by One-way ANOVA and Students t-test where appropriate. Results are 
presented as relative activity measured by the amount of light generated by activation of 
luciferase, which is proportional to promoter activity.
7.4 Results
7.4.1 Identification of DDAH2 transcripts in HUVEC
PCR bands corresponding to exons 2 and 3 were amplified from HUVEC cDNA 
(Figure 7.4). No PCR band was observed corresponding to exon 1. This data 
indicates that transcription of the DDAH2 gene in HUVEC begins at exon 2 and the 
sequence residing upstream of exon 2 could potentially function as a promoter. This 
region incorporates four of the polymorphisms identified by SSCP (Chapter 6) 
including the -871 6G/7G and the -1151 A/C polymorphisms.
1 8 Lane l = 100bp ladder 
Lane 2=G A PD H  +ve control 
Lane 3=G A PD H  -ve control 
Lane 4=E xon 1 PCR  
Lane 5=Exon 1 -ve control 
Lane 6=E xon 2 PCR (66bp) 
Lane 7=Exon 2 -ve control 
Lane 8=Exon 3 PCR (230bp) 
Lane 9=E xon 3 -ve control
Figure 7.4 DDAH2 transcripts identified in HUVEC. PCR bands corresponding to 
exons 2 and 3 were amplified from HUVEC cDNA by PCR, indicating that transcription starts 
at exon 2. No band was amplified corresponding to exon 1 (top panel). The bottom panel 
illustrates alternate slicing between the 3’ ends of exons 1 and 2 and an internal site in exon 3 of 
the DDAH2 gene. Three transcription start sites are indicated by arrows.
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7.4.2 Effect of DDAH2 polymorphisms on promoter activity
Reporter gene constructs representing the four possible permutations for the -1151 A/C 
and -871 6G/7G polymorphisms were transfected into HUVEC and assayed for 
luciferase activity. A significant difference in promoter activity was observed between 
the four DDAH2 constructs with the highest activity being seen with the 7G/C construct 
and the lowest activity with the 6G/A construct (*P=0.01 one-way ANOVA, Figure 
7.5). Both constructs containing the 7G variant had greater activity than their 6G 
counterparts (*P=0.001, figure 7.6). The 7G allele enhanced promoter activity to a 
greater degree in the presence of a -1151C allele (mean difference between 6G/A and 
7G/A was 0.63, and between 6G/C and 7G/C was 1.42, P=0.33). Treatment with af-RA 
increased promoter activity in all constructs by at least 48% (Figure 7.7). The largest 
increase was seen for the 6G/C variant (179%). Increased activity of the 7G/C construct 
in response to af-RA indicates that the higher basal expression demonstrated by this 
construct can be increased still further by transcriptional regulators.
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Figure 7.5 Effect of different promoter variants on DDAH2 expression.
Mean luciferase activity generated by the 4 DDAH2 constructs representing the -  
1151 A/C and -871 6G/7G polymorphisms transfected into HUVEC cells. The 
construct representing 7G at position -871 and C at position -1151 of the DDAH2 
promoter demonstrated the greatest promoter activity (*P=0.01 for 7G/C compared to 
6G/A by One-Way ANOVA). n=7
Genotype
Figure 7.6 Promoter activity of 6G constructs compared to 7G constructs. Mean 
luciferase activity was combined for the two 6G constructs and compared with 
luciferase activity for the combined 7G constructs transfected into HUVEC. Mean 
luciferase activity for the 7G constructs was significantly greater than the 6G constructs 
(*P=0.001 by Students t-test).
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Figure 7.7 Effect of af-RA treatment on DDAH2 promoter activity. To test if at- 
RA  had any effect on DDAH2 promoter activity and to ascertain if this was influenced 
by promoter genotype, HUVEC were treated 24 hours post transfection with lOpmol/L 
fl/-RA for 24 hours. atf-RA increased DDAH2 promoter activity of all constructs by at 
least 48% (P=>0.05 for each construct).
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7.5 Discussion
SSCP analysis of the DDAH2 promoter identified several polymorphisms of potential 
interest (Chapter 6). RT-PCR of mRNA isolated from HUVEC revealed that exons 2 
and 3, but not exon 1 were expressed in this cell type and therefore the sequence 
upstream of exon 2 could act as a promoter. Two polymorphisms situated upstream of 
exon 2 were chosen for further investigation for potential effect on promoter activity 
using a luciferase promoter/reporter assay in HUVEC. The -871 6G/7G variant was 
chosen because of its location within a putative NGFIC/MAZF transcription factor 
binding sequence and because it is located in the core promoter sequence identified by 
site specific deletion analysis (Jones et al., 2003). The -1151 A/C variant was chosen 
because the results of preliminary genotyping analysis indicated this variant might be 
associated with plasma ADMA/SDMA concentration (see Chapter 8). To determine if 
either of these variants influenced promoter activity, promoter/reporter constructs 
representing all four possible permutations of the -1151 A/C and -871 6G/7G 
polymorphisms in the DDAH2 promoter (linked to the luciferase reporter gene) were 
made and expressed in HUVEC.
Based on the promoter/reporter gene assay, at least one of these polymorphisms was 
identified as being of potential interest as a functional variant. A genotype specific 
difference was observed in promoter activity between the four constructs, with the 
construct containing 7G at position -871 showing highest promoter activity. Indeed, in 
HUVEC, constructs carrying the 7G variant showed a 2-fold increase in activity 
compared to constructs with the 6G variant at this position. Although the 7G variant 
appeared to increase promoter activity, in all constructs, the size of the effect was
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contingent on the allele at the -1151 locus. The 7G allele enhanced promoter activity to 
a greater degree in the presence of a C allele at position -1151. This observation 
suggests that -1151 genotype might modulate the effect of the -871 genotype. 
Furthermore, the 6G/7G polymorphism lies in a region defined as a basal promoter 
element on the basis that the region from -927 to -216 (relative to the translation start 
site) supports transcription at the same level as the full length promoter in ECV304 
cells. It is possible that binding of the transcription factor NGFIC or MAZF may be 
either up or down regulated due to the presence of an extra G allele at position -871, 
resulting in variation of DDAH2 expression. NGF has been shown to influence the 
expression or activity of several genes involved in the regulation NO synthesis such as 
PRMT, GCH1 and eNOS (Cimato et al., 2002; Anastasiadis et al., 1996; Hirayama et al., 
1995; Peunova et al., 1995; Kalisch et al., 2002). NGF exerts its effects by binding two 
distinct receptors on the cell surface, the high affinity trkANGFR receptor and the low 
affinity p75NTR receptor. It is thought that the trkANGFR receptor mediates cell 
proliferation and differentiation while the p75NTR receptor is thought to mediate 
apoptosis in some cell types (Barker, 1998; Lopez-Sanchez et al., 2002). Binding of 
NGF to the trkANGFR receptor causes activation of the receptor tyrosine kinase and 
downstream signalling cascades, resulting in mobilisation of transcription factors such 
as NGFIC/Egr-3. Recent research has shown that HUVEC express both the trkANGFR 
and p75NTR receptors, and also significant levels of NGF protein and mRNA under 
standard culture conditions that are up-regulated during serum starvation (Cantarella et 
al., 2002). NGF promotes HUVEC proliferation and exerts a potent angiogenic effect 
in-vivo possibly through regulation of NO synthesis (Cantarella et al., 2002). The 
transcription factor MAZF has been shown to interact with the human eNOS promoter 
and exhibits a negative effect on eNOS promoter activity in Drosophila Schneider cells
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(Karantzoulis-Fegaras et al., 1999). Further studies to investigate the possible role of 
these transcription factors on DDAH2 expression are now required.
yff-RA was capable of inducing the DDAH2 promoter activity of all four constructs in 
HUVEC including the 7G variants, indicating that although the 7G increased basal 
expression, these constructs retained the ability to increase activity in response to at- 
RA. Upregulation of expression in response to at-RA in HUVEC is in agreement with 
the findings in the ECV304 cell line reported by Achan et al., 2002, and served as a 
useful positive control for the integrity of the assay system. ^ -R A  is known to be an 
important mediator in the development of the cardiovascular system and may exert its 
effects by upregulating genes involved in maintaining sufficient NO production. 
Although it is likely that this regulation is likely to operate through transcription factor 
binding distinct from the -1151A/C and -871 6G/7G sites studied here, the observation 
that the magnitude of the at-RA  response differed by -1151 and -871 genotype suggests 
that these sites may modulate transcription regulated primarily through the PPAR/RXR 
sites, in particular the PPAR/RXR site at position -927.
In summary, the presence of an extra G allele at position -871 within the DDAH2 
promoter is associated with increased basal DDAH2 expression and might be expected 
to confer protection against the harmful effects of elevated ADMA generation. Further 
analysis to determine if  the increased DDAH2 promoter activity of the 7G variant at 
position -871 is relevant to in vivo concentrations of ADMA is needed. Genotyping 
cohorts of individuals and comparing their circulating ADMA and SDMA levels is one 
possible way to achieve this, and the results of such investigation are presented in 
Chapter 8.
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CHAPTER 8
DDAH2 POLYMORPHISMS AND CIRCULATING 
METHYLARGININE CONCENTRATION
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8.1 Aims
To investigate the association between DDAH2 polymorphisms and plasma 
concentrations of ADMA, SDMA and the ADMA/SDMA ratio.
8.2 Background
Synthesis of NO can be inhibited by the endogenous methylarginine ADMA. Vallance 
et al., 1992, were the first to describe elevated plasma ADMA concentrations in patients 
with renal failure, and proposed that impaired renal excretory function would result in 
accumulation of ADMA which, in sufficient concentrations, would inhibit the synthesis 
of NO and lead to endothelial dysfunction. They proposed that this might account for 
the increased susceptibility to CVD among such patients (Vallance et al., 1992). Recent 
studies have shown that ADMA concentration in patients with renal failure is predictive 
of future CVD (Zoccali et al., 2001), and that dialysis, which significantly reduces 
serum ADMA levels, is associated with improved endothelial function (Cross et al., 
2001). One potential explanation for higher ADMA concentrations in renal failure is 
reduced excretion of ADMA by the kidneys. However, in contrast to SDMA, which is 
exclusively eliminated by renal excretion, ADMA is also metabolised by the enzymes 
DDAH1 and DDAH2. Indeed, increases in SDMA concentration in renal failure are 
greater than the increase in ADMA concentration suggesting that metabolism of ADMA 
persists. However, since DDAH2 is expressed in the kidney (Tran et al., 2000), it is 
conceivable that the elevated ADMA concentration seen in patients with renal failure 
reflects both decreased elimination and reduced metabolism. It is possible that inter­
individual differences in the expression or activity of the DDAH enzymes (DDAH1 and
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DDAH2) could influence ADMA levels not only in renal failure but also in patients 
with disorders such as diabetes, preeclampsia, hypertension and hypercholesterolemia 
where ADMA levels are high but renal function is normal (Stuhlinger et al., 2002; 
Pettersson et al., 1998; Boger et al., 1997; Surdacki et al., 1999; Boger et al., 1998b). 
Both ADMA and SDMA are generated upon metabolism of methylated proteins, and 
both are excreted via the kidneys. However, ADMA but not SDMA is additionally 
metabolised by the DDAH enzymes and therefore the ADMA/SDMA ratio may be used 
as an index of DDAH activity.
The DDAH2 isoform is highly expressed in endothelium and is thought to play an 
important role in regulating ADMA levels and endothelium-derived NO synthesis in the 
vasculature. Thus variation in DDAH2 expression or activity maybe an important 
mechanism underlying variation in ADMA concentrations, either locally within 
endothelial cells or systemically. The aim of the studies in the present chapter was to 
determine whether the novel common polymorphisms in the DDAH2 gene identified as 
part of this thesis (Chapter 6), and which were associated with differences in promoter 
activity relate to differences in ADMA concentration or ADMA/SDMA ratio in healthy 
subjects and in individuals with renal failure.
205
8.3 Subjects and Methods
8.3.1 Subjects investigated for association between DDAH2 polymorphisms and 
ADMA, SDMA and ADMA/SDMA ratio.
Three subject groups with differing and complementary phenotypic measurements were 
analysed for association between DDAH2 polymorphisms and plasma ADMA and 
SDMA concentration and ADMA/SDMA ratio as well as other relevant cardiovascular 
disease phenotypes or risk factors. Table 8.1 summarises the cohorts and their 
phenotypic characteristics. Full demographic characteristics of each study cohort are 
outlined in Chapter 2.
Healthy subjects (German population screen)
Blood was collected from a cohort of 128 healthy individuals from a German population 
screen (Chapter 2.2.12.1) and genotyped for the -1020C/G, -1151 A/C and the -871 
6G/7G DDAH2 polymorphisms. ADMA and SDMA measurements were made using 
HPLC by Professor Rainer Boger (Department of Clinical Pharmacology, University of 
Hamburg). Measurements of age, height, weight, blood pressure, heart rate, 
triglycerides and cholesterol were recorded and entered into an Excel database.
Renal failure patients (London Renal Failure cohort)
A cohort of individuals comprising 126 patients with renal failure (London Renal 
Failure cohort) of varying ethnicity (recruited from the Middlesex Hospital, London by 
Dr. Jenny Cross) were also genotyped for the -1020C/G, -1151 A/C and the -871 6G/7G 
DDAH2 polymorphisms (Chapter 2.2.12.2). Endothelial function was assessed in vivo
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by FMD measurement of the conduit artery in a subset of these patients, and ADMA 
and SDMA measurements were made by HPLC.
Renal failure patients (CREED)
DNA from 277 renal failure patients was kindly donated by Dr Carmine Zoccali (D3IM- 
CNR, Italy) for association studies between DDAH2 genotype and plasma ADMA and 
SDMA concentrations and ADMA/SDMA ratio (Chapter 2.2.12.2). Subjects were 
originally recruited for the CREED (Cardiovascular Risk Extended Evaluation in 
Dialysis) study, in which a total of 278 dialysis patients were followed up over a four 
year period and in whom baseline ADMA concentrations have been found to be 
predictive of later CVD (Malatino et al., 1999).
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Phenotypes Genotypes
Cohort Description of 
Cohort
Conventional CV 
risk factors
ADMA/SDMA Polymorphism
■1020 -1151 -871
C/G C/A 6G/7G
HEALTHY
Healthy subjects 
(German)
128 healthy subjects + + + 4- +
DISEASE
Renal failure 
(London)
Renal failure 
(CREED)
126 renal failure patients +
277 renal failure patients +
+
+
+ + +
+ +
Table 8.1 Summary of cohorts genotyped for association between DDAH2 polymorphisms and various risk factors for 
CVD. Risk factors and polymorphisms analysed for each cohort are indicated by +.
8.3.2 Genotyping DDAH2 polymorphisms
Three out of the six DDAH2 polymorphisms identified by SSCP in chapter 6 were 
chosen for genotyping studies. The -1020C/G and -1151 A/C were genotyped by PCR- 
RFLP analysis (Chapter 6.3.7). The -871 6G/7G bi-allelic length variation 
polymorphism was genotyped by Genescan analysis (Chapter 6.3.7).
8.3.3 Measurement of plasma ADMA and SDMA by HPLC analysis
Plasma concentrations of ADMA and SDMA were measured by HPLC. ADMA and 
SDMA concentrations in the London renal failure subjects were measured in our 
laboratory by Miss Rachel Jackson using the method described by Vallance et al., 1992. 
Briefly, venous blood samples were centrifuged at 3000rpm for 15 minutes at 4°C to 
separate plasma. 1ml of plasma was loaded onto a 2ml Bondelut SCX column 
(Anachem) previously washed with ddH20 and HPLC grade methanol. 
Methylarginines were serially eluted in 25% ammonia/methanol and the 50% 
ammonia/methanol eluate evaporated at 100°C. The dried extract was resuspended in 
2ml ddH20 and applied to a washed Bondelut CBA column. Methylarginines were 
again eluted using 10% ammonia/methanol and the eluate dried at 100°C and then 
resuspended in lOOpl ddH20. Each sample was spiked with a known quantity of L- 
NMMA, which acted as an internal standard and allowed calculation of extraction 
efficiency. The extracted samples were applied to a C l8 HPLC column (BDH). 40jil 
of the lOOpl sample was injected into the column and the absorbance read at 200nm.
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8.3.4 Statistical Analysis
Observed numbers of each genotype were compared with those expected under the 
assumption of Hardy-Weinberg equilibrium by x2analysis. Allele frequencies were 
deduced from genotype frequencies. Values are represented as median (inter-quartile 
range) for skewed distributions and mean (standard deviation) for normally distributed 
data. Allelic associations were assessed using parametric (One-Way Analysis of 
Variance or Students t test) and non-parametric (Kruskal-Wallis test or Mann-Whitney 
test) where appropriate.
210
8.4 Results
8.4.1 Genotype and allele frequencies of DDAH2 polymorphisms in study
cohorts.
The allele frequencies for the -1020C/G, -1151 A/C and the -871 6G/7G polymorphisms 
for each cohort are shown in table 8.2. Genotype frequencies did not differ from those 
expected under Hardy-Weinberg equilibrium except for the -1020C/G polymorphism in 
the German population screen (*P=0.003, table 8.2) and the -1151A/C polymorphism 
in the renal failure cohort (*P=0.04, table 8.2). The -1151 A/C polymorphism was in 
Hardy-Weinberg equilibrium in the London renal failure cohort only after adjustment 
for race.
-1020C/G
C(%) G (%) 
x! (P)
-1151A/C
A (%) C(%) 
X2 (P)
-871 6G/7G
6G (%) 7G (%)
x2 (P)
German Population 
screen
84.0 16.0 
8.6 (0.003)*
69.0 31.0
3.0 (0.08)
99.0 1.00 
0.0 (0.89)
Renal Failure 
(London)
96.0 4.00 
3.5 (0.06)
51.0 49.0 
4.1 (0.04)*
95.0 5.00 
0.4 (0.5)
Renal Failure 
(CREED)
69.0 31.0 
0.0 (0.9)
95.0 5.00 
0.7 (0.4)
Table 8.2. Allele frequencies, %2 and P values of each DDAH2 polymorphism.
All polymorphisms were in Hardy Weinberg equilibrium except the -1020C/G in the 
German population screen (*P=0.003) and -1151 A/C in the London renal failure cohort 
(*P=0.04). The London Renal Failure cohort was in Hardy Weinberg equilibrium after 
adjusting for race. The -1020C/G polymorphism was omitted from genotyping analysis 
in the CREED cohort due to limited availability of genomic DNA.
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8.4.2. Relationship between DDAH2 genotype, ADMA and SDMA concentration 
and ADMA/SDMA ratio in the German population screen.
Demographic characteristics o f the cohort are shown according to -1020C/G, -1151 A/C 
and -871 6G/7G genotype in tables 8.3a-c. A significant difference in systolic and 
diastolic blood pressure was observed between homozygous 6G individuals and 7G 
allele carriers for the -871 6G/7G polymorphism (*P=0.01 and *P=0.005 respectively, 
table 8.3c). Blood pressure was 14% lower in the 7G allele carriers compared to 6G/6G 
individuals.
Genotype -1020C/G
CC
Mean (SD)
N=93
CG
Mean (SD)
N=26
GG
Mean (SD)
N=8
P
Systolic BP (mmHg) 128.4 (12.44) 125.6(11.55) 121.9 (8.43) 0.24
Diastolic BP (mmHg) 78.45 (6.92) 76.40 (7.0) 75.63 (8.21) 0.30
Cholesterol (mmol/1) 4.60 (0.82) 4.37(1.22) 4.38 (0.71) 0.44
LDL (mmol/1) 2.77 (0.72) 2.72(1.19) 2.53 (0.65) 0.72
HDL (mmol/1) 1.12(0.33) 1.04 (0.25) 1.29 (0.73) 0.23
Triglycerides (mmol/1) 1.59(1.04) 1.29 (0.69) 1.30 (0.89) 0.32
Age (Years) 36.25 (10.51) 35.21 (11.55) 40.83 (8.47) 0.51
Weight (Kg) 76.22 (14.02) 77.64(13.08) 80.13 (20.45) 0.72
Table 8.3a Demographic characteristics of the German Population Screen cohort 
according to -1020C/G genotype. No significant association was found between 
genotype and any of the conventional cardiovascular risk factors measured (by One-Way 
ANOVA).
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Genotype -1151 A/C
AA
Mean (SD)
N=64
AC
Mean (SD)
N=45
CC
Mean (SD)
N=16
P
Systolic BP (mmHg) 128.8(11.19) 125.9 (13.44) 127.5 (13.12) 0.50
Diastolic BP (mmHg) 78.31 (6.71) 77.20 (7.42) 77.86 (8.02) 0.74
Cholesterol (mmol/1) 4.47 (0.87) 4.58 (0.99) 4.81 (0.78) 0.38
LDL (mmol/1) 2.71 (0.80) 2.74 (0.93) 3.01 (0.67) 0.44
HDL (mmol/1) 1.10(0.37) 1.12(0.29) 1.04 (0.40) 0.77
Triglycerides (mmol/1) 1.43 (0.83) 1.60(1.18) 1.73 (0.89) 0.46
Age (Years) 37.67 (10.82) 34.42 (9.95) 38.31 (11.83) 0.25
Weight (Kg) 78.10(14.93) 74.88 (14.05) 77.36(13.08) 0.53
Table 8.3b Demographic characteristics of the German Population Screen cohort 
according to -1151 A/C genotype. No significant association was found between 
genotype and any of the conventional cardiovascular risk factors measured (by One- 
Way ANOVA).
Genotype-871 6G/7G
6G/6G 
Mean (SD)
N=123
6G/7G 
Mean (SD)
N=3
P
Systolic BP (mmHg) 127.9(11.88) 110.0(10.00) 0.01*
Diastolic BP (mmHg) 78.09 (6.77) 66.67(11.55) 0.005*
Cholesterol (mmol/1) 4.55 (0.91) 4.20 (0.82) 0.51
LDL (mmol/1) 2.75 (0.83) 2.53 (0.81) 0.65
HDL (mmol/1) 1.11 (0.36) 1.10(0.36) 0.96
Triglycerides (mmol/1) 1.53 (0.99) 1.23 (0.55) 0.61
Age (Years) 36.29 (10.36) 31.67(11.02) 0.45
Weight (Kg) 77.03 (14.41) 66.67(6.11) 0.22
Table 8.3c Demographic characteristics of the German Population Screen cohort 
according to -871 6G/7G genotype. No 7G/7G homozygotes were observed in this 
cohort. A significant association was found between genotype and blood pressure (* 
Students t-test).
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ADMA and SDMA measures were successful in 126 and 127 individuals respectively 
out of 128 subjects recruited. Both ADMA and SDMA exhibited skewed (to the right) 
distributions with median (IQR) values of 0.85pmol/l (0.63-1.21) and 0.55pmol/l (0.38- 
0.79) respectively. The median ADMA/SDMA ratio for the whole cohort was 1.44 
(1.05-2.56)
DNA from 128 healthy individuals was genotyped for the DDAH2 -1020C/G, - 
1151 A/C and -871 6G/7G polymorphisms and analysed for association between 
genotype and plasma ADMA, SDMA and ADMA/SDMA ratio (Figures 8.1a-c.). No 
association was detected between -1020 genotype and either ADMA, SDMA or 
ADMA/SDMA ratio (P>0.05, figure 8.1a). A trend towards a lower ADMA/SDMA 
ratio was observed for -115ICC homozygous individuals (P=0.04, figure 8.1b). This 
approached statistical significance when A allele carriers were grouped and analysed 
against CC homozygotes (1.62 [1.05-2.67] versus 1.16 [1.05-1.36], P=0.05 Mann- 
Whitney test). No significant association was detected between -871 6G/7G genotype 
and ADMA, SDMA or ADMA/SDMA ratio (P>0.05, figure 8.1c). The three 
individuals carrying the -871 7G allele had a lower median ADMA/SDMA ratio (1.08 
[1.00-1.11]) compared to 6G homozygotes (1.48 [1.05-2.57]).
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AGenotype -1020C/G
CC
Median (IQR) 
N=93
CG
Median (IQR) 
N=25
GG
Median (IQR) 
N=8
P
ADMA (pmol/1) 0.83 (0.63-1.25) 0.90 (0.65-1.15) 0.78 (0.62-1.02) 0.62*
SDMA (pmol/1) 0.55 (0.38-0.79) 0.54 (0.35-0.77) 0.64 (0.37-0.77) 0.86*
ADMA/SDMA 1.40(1.08-2.37) 1.68 (0.97-2.71) 1.02 (0.90-2.49) 0.41*
B
1 0 .0-1
o 7 . 5 -  
*
Q(t>
Q<
5 . 0 -
2 . 5 -
0.0
•  • •  
• • • •
P
cc
o°
o
o§o°
oo°
° 0 0 o 0 0 0
C G
Genotype
P=0.41
G G
Figure 8.1a. ADMA and SDMA concentrations and ADMA/SDMA ratio 
according to -1020C/G genotype in the German Population Screen. A. Table 
showing the median (IQR) ADMA, SDMA and ADMA/SDMA ratio. No significant 
difference was observed for ADMA, SDMA or ADMA/SDMA ratio between genotypes 
(*Kruskal-Wallis test). B. Scatter plot of ADMA/SDMA ratio according to genotype. 
The median value is marked with a horizontal bar.
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AGenotype -1151 A/C
AA
Median (IQR) 
N=62
AC
Median (IQR) 
N=44
CC
Median (IQR) 
N=16
P
ADMA (pmol/1) 0.83 (0.62-1.15) 0.92 (0.67-1.26) 0.77 (0.59-1.06) 0.40*
SDMA (pmol/1) 0.55 (0.38-0.81) 0.49 (0.32-0.70) 0.66 (0.48-0.81) 0.14*
ADMASDMA 1.43 (0.99-2.50) 1.91 (1.17-3.02) 1.16(1.05-1.36) 0.04*
B
10 .0-1
o
7 .5 -
•  •
5.0 -
•  •
Q
<  2 .5 -
0.0
AA AC CC
Genotype
Figure 8.1b. ADMA and SDMA concentration, and ADMA/SDMA ratio 
according to -1151 A/C genotype in the German Population Screen. A. Table 
showing the median (IQR) ADMA and SDMA concentration and ADMA/SDMA ratio. 
A significant difference was observed for ADMASDMA ratio between genotypes 
*Kruskal-Wallis test. B. Scatter plot of ADMA/SDMA according to genotype. The 
median value is indicated by a horizontal bar.
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AGenotype -871 6G/7G
6G/6G
Median (IQR) 
N=119
6G/7G 
Median (IQR)
N=3
P
ADMA (p.mol/1) 0.90 (0.64-1.23) 0.59 (0.54-0.83) 0.15*
SDMA (prnol/1) 0.55 (0.37-0.79) 0.53 (0.50-0.83) 0.79*
ADMA/SDMA 1.48(1.05-2.57) 1.08(1.00-1.11) 0.16*
B
10—|
0
1  k_
<
2
Q
CO
5
2
• • P=0.16
• •
• •
o<
6g/6g 7g carriers
Genotype
Figure 8.1c. ADMA and SDMA concentration, and ADMA/SDMA ratio 
according to -871 6G/7G genotype in the German Population Screen. A. Table 
showing the median (IQR) ADMA and SDMA concentration and ADMA/SDMA ratio. 
The SDMA concentration in this cohort exhibited a normal distribution. No 7G/7G 
homozygotes were observed in this cohort. No significant difference was observed in 
ADMA, SDMA or ADMA/SDMA ratio between genotypes (* Mann-Whitney test, 
^Students t-test). B. Scatter plot showing ADMA/SDMA ratio for 6G/6G individuals 
versus 7G carriers. The median value is indicated by a horizontal bar.
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8.4.3. Relationship between DDAH2 genotype, ADMA and SDMA concentration
and ADMA/SDMA ratio in the London Renal Failure Cohort.
Demographic characteristics according to DDAH2 genotype are shown in table 8.4a-c. 
Systolic and diastolic blood pressure measurements were available for 96 individuals 
and age was known for 116 individuals. No association was detected between DDAH2 
genotype and either blood pressure or age.
Genotype -1020C/G
CC+CG 
Mean (SD) 
N
CG
Mean (SD) 
N
P
Systolic BP (mmHg) 144.2 (32.07) 
88
152.5 (34.60) 
8
0.49
Diastolic BP (mmHg) 80.15(17.09)
87
80.00(20.16)
8
0.98
Age (years) 53.68 (17.38) 
107
49.78(17.98)
9
0.52
Table 8.4a. Demographic characteristics of the London Renal Failure Cohort 
according to -1020C/G genotype. No association was detected between genotype and 
either systolic BP, diastolic BP or age (P>0.05, Students t-test).
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Genotype -1151 A/C
AA
Mean (SD) 
N
AC
Mean (SD) 
N
CC
Mean (SD) 
N
P
Systolic BP (mmHg) 136.1 (31.73) 
23
146.8 (29.44) 
41
148.7 (35.55) 
32
0.32
Diastolic BP (mmHg) 77.22 (17.45) 
23
77.29 (12.94) 
41
86.06 (20.76) 
31
0.06
Age (years) 50.24(20.16)
34
57.43 (16.05) 
47
51.00 (15.49)
35
0.12
Table 8.4b. Demographic characteristics of the London Renal Failure Cohort 
according to -1151 A/C genotype. No association was detected between genotype and 
either systolic BP, diastolic BP or age (P>0.05, One-Way ANOVA).
Genotype-871 6G/7G
6G/6G 
Mean (SD) 
N
6G/7G 
Mean (SD) 
N
P
Systolic BP (mmHg) 143.0 (32.09) 
82
157.8 (32.00) 
13
0.12
Diastolic BP (mmHg) 79.46(17.21)
82
84.38(17.51)
13
0.34
Age (years) 53.29 (17.67) 
103
52.08 (14.33) 
12
0.82
Table 8.4c. Demographic characteristics of the London Renal Failure Cohort 
according to -871 6G/7G genotype. No association was detected between genotype 
and either systolic BP, diastolic BP or age (P>0.05, Students t-test).
ADMA and SDMA measures were successful in all 126 subjects. Both ADMA and 
SDMA exhibited skewed (to the right) distributions with a median (IQR) of 1.28pmol/l 
(0.89-1.9) and 3.46pmol/l (2.35-4.41) respectively. The median ADMA/SDMA ratio 
for the whole cohort was 0.40 (0.25-0.62).
126 renal failure patients were genotyped for the DDAH2 -1020C/G and -1151 A/C 
polymorphisms, and 125 for the -871 6G/7G polymorphism and analysed for 
association with plasma ADMA, SDMA and ADMA/SDMA ratio (Figure 8.2a-c). No 
association was detected between DDAH2 genotype and ADMA, SDMA or 
ADMA/SDMA ratio in this cohort.
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AGenotype -1020C/G
CC
Median (IQR) 
N=117
CG+GG 
Median (IQR) 
N=9
P
ADMA (pmol/1) 1.26 (0.92-1.87) 1.48 (0.78-2.16) 0.82*
SDMA (pmol/1) 3.50(2.34-4.42) 3.16(2.46-3.70) 0.54*
ADMA/SDMA 0.40 (0.24-0.62) 0.45 (0.27-0.68) 0.67*
B
3-i P=0.67
* -  2 - •  •
1 -
• • •  • «
o 
o o■Oo-
00
o
CC CG+GG
Genotype
Figure 8.2a. ADMA and SDMA concentration, and ADMA/SDMA ratio 
according to -1020C/G genotype in the London Renal Failure cohort. A. Table 
showing the median (IQR) for ADMA and SDMA concentration and ADMA/SDMA 
ratio. Data for CG and GG individuals was combined due to the small number o f GG 
(n=l) individuals identified. No significant difference was observed for ADMA, 
SDMA or ADMA/SDMA ratio between genotypes (* Mann-Whitney test). B. Scatter 
plot o f ADMA/SDMA ratio according to genotype. The median value is marked with a 
horizontal bar.
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Genotype -1151 A/C
AA
Median (IQR) 
N=39
AC
Median (IQR) 
N=51
CC
Median (IQR) 
N=36
P
ADMA (pmol/1) 1.30 (0.87- 1.87) 1.35 (0.85- 2.06) 1.22(1.00-1.76) 0.97*
SDMA (pmol/1) 3.47 (2.49- 4.42) 3.25 (2.47- 4.29) 3.54 (2.01-5.63) 0.93*
ADMA/SDMA 0.43 (0.29- 0.57) 0.43 (0.25- 0.70) 0.38 (0.23- 0.67) 0.79*
B
3
0
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Figure 8.2b. ADMA and SDMA concentration, and ADMA/SDMA ratio 
according to -1151 A/C genotype in the London Renal Failure cohort. A. Table 
showing the median (IQR) for ADMA and SDMA concentration and ADMA/SDMA 
ratio. No significant difference was observed for ADMA, SDMA or ADMA/SDMA 
ratio between genotypes (*Kruskal-Wallis test). B. Scatter plot o f ADMA/SDMA ratio 
according to genotype. The median value is marked with a horizontal bar.
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AGenotype-871 6G/7G
6G/6G 
Median (IQR) 
N=112
6G/7G 
Median (IQR) 
N=13
P
ADMA (pmol/1) 1.30(0.91-1.87) 1.18 (0.86-1.62) 0.37*
SDMA (pmol/1) 3.46 (2.41-4.41) 3.26(1.80-5.50) 0.94*
ADMA/SDMA 0.42 (0.27-0.60) 0.24 (0.21-0.65) 0.26*
B
3 - i
OOq O
6 G / 6 G  6 G / 7 G
GENOTYPE
Figure 8.2c. ADMA and SDMA concentration, and ADMA/SDMA ratio 
according to -871 6G/7G genotype in the London Renal Failure cohort. A. Table 
showing the median (IQR) for ADMA and SDMA concentration and ADMA/SDMA 
ratio. No significant difference was observed for ADMA, SDMA or ADMA/SDMA 
ratio between genotypes (* Mann-Whitney test). B. Scatter plot o f ADMA/SDMA 
according to genotype. The median value is marked with a horizontal bar. Only 13 
individuals carrying the 7G allele were identified during this study. No 7G homozygotes 
were identified.
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8.4.4 Relationship between DDAH2 genotype and ADMA, SDMA and
ADMA/SDMA ratio in the CREED cohort.
Demographic characteristics according to DDAH2 genotype are shown in tables 8.5a-b. 
No significant correlation was observed between -1151 A/C genotype and risk factors 
for CVD (Table 8.5a). A significant association was observed between -871 6G/7G 
genotype and levels of triglycerides (*P=0.02, table 8.5b). Carriers of the 7G allele for 
this variant had higher circulating levels of triglycerides (mean=2.48 mmol/1) compared 
with 6G homozygous individuals (mean=1.98 mmol/1). 7G allele carriers also had 
lower HDL cholesterol levels, but this did not reach significance (P=0.05, table 8.5b). 
No 7G homozygous individuals were identified in this cohort.
Genotype -1151 A/C
AA
Mean (SD) 
N=125
AC
Mean (SD) 
N=112
CC
Mean (SD) 
N=26
P
Systolic BP (mmHg) 133.1 (21.87) 130.9(24.18) 133.5 (21.11) P=0.72
Diastolic BP (mmHg) 74.97(12.10) 73.80 (12.90) 73.96(10.27) P=0.76
Cholesterol (mmol/1) 5.43 (1.56) 5.44(1.44) 4.87(1.21) P=0.19
LDL (mmol/1) 3.43 (1.29) 3.46(1.28) 2.87(1.1) P=0.09
HDL (mmol/1) 1.05 (0.27) 1.09 (0.32) 1.00 (0.31) P=0.30
Triglycerides (mmol/1) 2.06(1.06) 1.94(1.03) 2.19(0.94) P=0.46
Age (years) 62.01 (15.68) 5 9 . 5 4  (14.45) 63.81 (15.01) P=0.29
BMI (kg/m2) 25.18(4.64) 24.50 (4.14) 25.25 (4.57) P=0.46
Fibrinogen (pmol/l) 13.31 (6.02) 13.34 (6.07) 15.42 (7.33) P=0.27
Table 8.5a Demographic characteristics of the CREED cohort according to -1151 A/C 
genotype. No significant association was found between genotype and any of the conventional 
cardiovascular risk factors measured (P>0.05, One-Way ANOVA).
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Genotype-871 6G/7G
6G/6G 
Mean (SD) 
N=230
6G/7G 
Mean (SD) 
N=25
P
Systolic BP (mmHg) 132.6 (23.13) 127.7 (21.52) P=0.31
Diastolic BP (mmHg) 74.26 (12.61) 75.20(10.10) P=0.72
Cholesterol (mmol/1) 5.37(1.52) 5.40(1.25) P=0.89
LDL (mmol/1) 3.40(1.30) 3.33(1.12) P=0.80
HDL (mmol/1) 1.07(0.29) 0.95 (0.29) P=0.05
Triglycerides (mmol/1) 1.98(1.03) 2.48(1.12) P=0.02*
Age (years) 61.35 (15.09) 62.84 (16.71) P=0.64
BMI (kg/m2) 24.76 (4.39) 25.65 (4.06) P=0.34
Fibrinogen (pmol/1) 13.55 (6.24) 12.94 (6.51) P=0.65
Table 8.5b. Demographic characteristics of the CREED cohort according to -871 
6G/7G genotype. No 7G/7G homozygotes were observed in this cohort. A significant 
association was found between genotype and triglyceride levels (*Students t-test).
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ADMA and SDMA measurements were available for 259 individuals out of 277 
recruited. Both ADMA and SDMA exhibited skewed (to the right) distributions with 
median (IQR) values of 3.02pmol/l (1.72-4.26) and 2.94pmol/l (2.30-4.41) respectively. 
The median (IQR) ADMA/SDMA for the whole cohort was 0.96 (0.36-1.82).
259 renal failure patients from the CREED study were genotyped for association 
between the -1151 A/C and -871 6G/7G DDAH2 polymorphisms and plasma ADMA, 
SDMA and ADMA/SDMA ratio (Figures 8.3a-c). The -1020C/G polymorphism was 
omitted from the genotyping study because of limited availability of DNA. No 
association was detected between -1151 A/C genotype and either ADMA, SDMA or 
ADMA/SDMA ratio (Figure 8.3a). This was also true after grouping A allele carriers 
and analysing against CC homozygotes (ADMA 3.00pmol/l [1.71-4.16] versus 
3.50|iimol/l [1.64-5.24], SDMA 2.91pmol/l [2.24-4.45] versus 3.58pmol/l [2.55-4.28], 
ADMA/SDMA ratio 0.96 [0.36-1.79] versus 1.06 [0.31-2.12] P>0.05, Mann-Whitney 
test). No association was detected between -871 6G/7G genotype and ADMA, SDMA 
or ADMA/SDMA ratio (Figure 8.3b).
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AGenotype -1151 A/C
AA
Median (IQR) 
N=122
AC
Median (IQR) 
N = ll l
CC
Median (IQR) 
N=26
P
ADMA (pmol/1) 2.95 (1.77-4.31) 3.00(1.67-4.15) 3.50(1.64-5.24) 0.67*
SDMA (pmol/1) 2.99 (2.21-4.55) 2.81 (2.28-4.27) 3.58 (2.55-4.28) 0.62*
ADMA/SDMA 0.94 (0.40-1.82) 1.01 (0.34-1.78) 1.06 (0.31-2.12) 0.94*
B
AA AC CC
Genotype
Figure 8.3a. ADMA and SDMA concentration, and ADMA/SDMA ratio 
according to -1151 A/C genotype in the CREED cohort. A. Table showing the 
median (IQR) for ADMA and SDMA concentration and ADMA/SDMA ratio. No 
significant difference was observed for ADMA, SDMA or ADMA/SDMA between 
genotypes (*Kruskal-Wallis test). B. Scatter plot of ADMA/SDMA according to 
genotype. The median value is marked with a horizontal bar.
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AGenotype-871 6G/7G
6G/6G 
Median (IQR) 
N=227
6G/7G 
Median (IQR) 
N=24
P
ADMA (pmol/1) 2.89(1.71-4.13) 2.79(1.51-4.77) 0.76*
SDMA (pmol/1) 2.86 (2.26-4.18) 3.60 (2.50-6.15) 0.11*
ADMA/SDMA 0.940 (0.36-1.89) 0.89 (0.29-1.65) 0.50*
B
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Figure 8.3b. ADMA and SDMA concentrations, and ADMA/SDMA ratio 
according to -871 6G/7G genotype in the CREED cohort. A. Table showing the 
median (IQR) for ADMA and SDMA concentration and ADMA/SDMA ratio. No 
significant difference was observed for ADMA, SDMA or ADMA/SDMA ratio 
between genotypes (*Mann-Whitney test). B. Scatter plot of ADMA/SDMA according 
to genotype. The median value is marked with a horizontal bar. No 7G homozygous 
individuals were identified in this study.
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8.5 Discussion
During this study the association between three polymorphisms in the DDAH2 promoter 
(identified by SSCP in Chapter 6 ) and plasma ADMA and SDMA concentrations and 
the ADMA/SDMA ratio as well as other relevant risk factors for the development of 
CVD has been explored. Three different cohorts were investigated including a group of 
healthy individuals and two groups of renal failure patients in whom susceptibility to 
CVD is greatly enhanced.
ADMA is an endogenous inhibitor of nitric oxide synthase (Vallance et al., 1992). It is 
synthesised during protein turnover (Najbauer et al., 1993) and is eliminated from the 
body via renal excretion (Kakimoto et al., 1970) and through metabolism by DDAH 
enzymes (Ogawa et al., 1987). In healthy individuals plasma levels of ADMA and 
SDMA are found in a ratio of approximately 1:1. However, in patients with renal 
failure, elevations in the circulating concentration of SDMA are higher than those of 
ADMA with the consequence that the ADMA/SDMA ratio falls to approximately 0.3 
(MacAllister et al., 1996). The plasma levels of ADMA and SDMA reported during 
this study are comparable to those reported previously (Fleck et al., 2001; Kielstein et 
al., 2002; MacAllister et al., 1996; Wahbi et al., 2001). ADMA and SDMA 
concentrations were higher in both the renal failure cohorts compared to the healthy 
cohort, consistent with the renal impairment in these subjects. Consistent with previous 
findings, the ADMA concentration was lower than the SDMA concentration in the 
London Renal Failure cohort, which is explained by the fact that ADMA but not SDMA 
is a metabolised by DDAH enzymes (Ogawa et al., 1987). The observed similarity in 
ADMA and SDMA levels in the CREED cohort (ADMA/SDMA ratio = 1) may suggest
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down-regulation of DDAH enzymes in these subjects, however no association was 
found between DDAH2 polymorphisms and either the ADMA, SDMA or the 
ADMA/SDMA ratio during this study.
On the basis of the promoter/reporter assay results obtained in Chapter 7 (which 
identified the -871 7G allele as having a greater promoter activity), it might be expected 
that carriage of the -871 7G allele would be associated with lower ADMA 
concentrations and/or ADMA/SDMA ratio. This was seen in the German sample of 
healthy individuals, with 7G allele carriers exhibiting a lower ADMA/SDMA ratio and 
interestingly significantly lower systolic and diastolic blood pressure. These data must 
be interpreted with caution, however, as they are based on only three 7G carriers. No 
association was observed between DDAH2 genotype and either circulating ADMA or 
SDMA concentration or the ADMA/SDMA ratio in either of the renal failure subjects 
during this study. There are several potential explanations for this including the 
relatively small size of the cohorts studied. The observation that the frequency of the 
7G allele for the -871 6G/7G polymorphism is very low (and no 7G/7G individuals 
were detected) limits further the statistical power to detect any association in cohorts of 
the size studied. Also, in patients with renal failure the decreased excretory function 
may outweigh any small genetic differences in metabolism and make genotype 
dependent changes in ADMA concentration difficult to detect. Alternatively, local 
changes in ADMA concentration may occur without changing the systemic ADMA 
concentration.
In summary, DDAH2 genotype was not associated with ADMA or SDMA 
concentration or ADMA/SDMA ratio in healthy subjects or renal failure patients during
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this study. Also DDAH2 genotype was not associated with conventional cardiovascular 
risk factors in the renal failure cohorts. Further work to compare DDAH2 genotype and 
expression in patient groups where ADMA concentration is elevated would be useful in 
determining the role of DDAH2 in diseases such as hypertension and 
hypercholesterolaemia.
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CHAPTER 9
DDAH2 POLYMORPHISMS, ENDOTHELIAL FUNCTION 
AND PLASMA NITROGEN OXIDES (NOx)
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9.1 Aims
To investigate the association between DDAH2 polymorphisms and plasma 
concentration of nitrate/nitrite (NOx) and endothelial function.
9.2 Background
The risk of developing CVD is significantly enhanced in many disease states. For 
example, diabetic patients are 3-8 times more likely to develop premature 
cardiovascular disease compared to healthy individuals (Bierman et al., 1992), and 
patients with renal failure have a 1 0 - 2 0  fold increased risk of developing cardiovascular 
disease compared to the general population (Wheeler et al., 1996). In addition, elevated 
cholesterol levels and increased blood pressure are also recognised as risk factors for the 
development of CVD (Danesh et al., 2000). Preeclampsia, which is characterised by 
hypertension and proteinuria during pregnancy has also been shown to be an 
independent risk factor for cardiovascular disease later in life. In a retrospective study 
of 129,290 births, women with a history of preeclampsia were shown to have a 1.5-2.0 
fold increased risk of IHD (Smith et al., 2003). Also, in a case control study (in which 
1199 women diagnosed with preeclampsia were compared to 1197 without 
preeclampsia/eclampsia and 1197 with gestational hypertension) women with 
preeclamsia/eclampsia had a 1.4-4.0 fold increased risk of hypertension and a 4 fold risk 
of stroke (Wilson et al., 2003).
The mechanism underlying increased risk of vascular disease in these patients is 
incompletely understood. However, individuals who have risk factors for CVD or
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established CVD also exhibit endothelial dysfunction, which predates and predicts CVD 
onset (Gaeta et al., 2000). Endothelial dysfunction is thought to be due in part to 
deficient NO synthesis or action (Vallance and Chan et al., 2001). Elevated circulating 
levels of the NOS inhibitor ADMA have been demonstrated in all of the disorders 
mentioned above (Vallance et al., 1992; Pettersson et al., 1998; Usui et al., 1998; 
Swurdaki et al., 1999; Stuhlinger et al., 2002), and correlate with endothelial 
dysfunction providing a possible mechanism for limited NO availability. It is not 
surprising therefore that a large amount of interest has been generated in evaluating the 
role of ADMA in endothelial dysfunction in patients at risk of CVD.
In vivo NO has a half-life of approximately 30 seconds (Ignarro et al., 1987) and is 
readily oxidised to NO2 ’ making it difficult to measure NO directly in biological 
samples. NO2’ can undergo further oxidation by oxyhaemoglobin (0 2 Hb) forming NO3 ' 
. NO2 ' andN 0 3 ' are stable in biological samples stored at -20°C (Moshage et al., 1995), 
existing in approximate proportions of 1:20. It has therefore been suggested that plasma 
levels of NO2 * and NO3 ' (NOx) can be used as an indirect measure of NO production. 
N 02* can be measured by quantifying the coloured diazonium product formed after the 
reaction between NO2 ’, sulfonilamide and N-(l-naphthyl)ethylenediamine (also known 
as the Greiss reaction) and the concentration of NO3 ’ can be ascertained by first 
converting NO3 ' to NO2’ using the enzyme nitrate reductase. However, since NO3 ' is 
also a dietary constituent (present mainly in vegetables such as lettuce, celery, 
cauliflower, spinach and broccoli) (White, 1975), such measurement is potentially 
complicated by NO3 ' intake. Nevertheless, plasma concentrations of NOx have been 
reported to be a reliable marker of NO synthesis via the L-arginine-NOS pathway in 
fasted humans (Rhodes et al., 1995), although, since there are three enzymatic sources
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of NO (iNOS, nNOS and eNOS) this technique cannot distinguish isoform specific NO 
formation. Several studies have reported lower plasma NOx levels in human and 
animal subjects with risk factors for CVD such as hypertension, renal failure, diabetes 
and LDL cholesterol (Node et al., 1997; Schmidt and Baylis, 2000; Kurioka et al., 2000; 
Tanaka et al., 1997). Plasma concentrations of NOx have also been reported to be lower 
in smokers compared to non-smokers and show a positive correlation with the 
percentage change in FMD (Jeerooburkhan et al., 2001; Hori et al., 2001).
Despite the evidence to support the theory that lower circulating NO levels are 
associated with risk factors for CVD, the cause of lower NO levels in individuals at risk 
of CVD is still unclear. Conflicting evidence has been put forward with regards to the 
influence of an individuals genetic ‘makeup* on ability to synthesise NO. Two studies 
have reported an association between a 27bp repeat polymorphism within intron 4 of the 
eNOS gene and plasma concentration of NO (Wang et al., 1997; Tsukada et al., 1998). 
However, no such association was observed between several eNOS polymorphisms and 
NO in the large NPHSII study (Jeerooburkhan et al., 2001). These conflicting results 
may be the consequence of the difficulty in controlling for dietary NOx intake and/or 
the relative insensitivity of the assays. The most reliable measure of NO in vivo has 
proved to be an indirect bioassay of its action, namely endothelium-dependent 
vasodilation. Several genes involved in the regulation of NO synthesis have been 
investigated in this tissue for association with endothelial dysfunction. For example, 
polymorphisms in the GCH1 gene were found to be associated with plasma neopterin 
levels (a marker of BH4  synthesis) and FMD in healthy individuals, supporting the 
theory that genetic regulation of the GCH1 gene can influence circulating BH4 which in 
turn would be expected to affect NO synthesis resulting in endothelial dysfunction
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(Chapter 5). The p22phox 242TT genotype was also associated with significantly 
greater FMD in healthy subjects, possibly due to reduced NADPH oxidase activity and 
therefore production of less (V  which could potentially react with NO (Chapter 3). In 
addition, variants in the eNOS, MTHFR, ACE and glutamate-cysteine ligase catalytic 
subunit (GCLC) genes, to name a few, have also been associated with differences in 
endothelial function (Sawidou et al., 2001; Leeson et al., 2002; Pullin et al., 2002; 
Mulder et al., 2003; Koide et al., 2003).
The aim of this study therefore was to investigate the hypothesis that DDAH2 
polymorphisms influence endothelial function and biochemical indices of NO synthesis. 
Although DDAH2 polymorphisms were not associated with plasma concentrations of 
ADMA (Chapter 8 ), given the in vitro data obtained by promoter/reporter analysis 
(Chapter 7), it was considered possible that DDAH2 polymorphisms might influence 
local endothelial cell ADMA and therefore endothelial function and NO availability, in 
the absence of detectable changes in circulating ADMA concentration.
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9.3 Subjects and Methods
Four subject groups with differing and complementary phenotypic measurements were 
analysed for association between DDAH2 genotype and either plasma NOx or 
endothelial function, as well as other relevant cardiovascular disease phenotypes or risk 
factors. Unfortunately, due to time constraints not all the polymorphisms identified by 
SSCP (Chapter 6) could be genotyped in every cohort. Where possible priority was 
given to the -1151 A/C and -871 6G/7G polymorphisms in view of the results obtained 
in chapter 7. Table 9.1 summarises the cohorts and their phenotypic characteristics. 
Full demographic characteristics of each study cohort are outlined in Chapter 2.
9.3.1 Subjects investigated for association between DDAH2 polymorphisms, 
plasma NOx and blood pressure.
Healthy subjects (NPHSII cohort)
Briefly, subjects from the prospective NPHSII cohort (Chapter 2.2.12.1) were analysed 
for association between DDAH2 polymorphisms, plasma NOx and blood pressure. This 
cohort comprises healthy men aged 50-61 years. Individuals from the Chesterfield 
(n=260) and North Mymms (n=290) clinics for whom plasma samples were available 
were selected. The -449G/C, -1020C/G and -1151 A/C polymorphisms were genotyped 
in these subjects as these were the first variants identified by SSCP.
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9.3.2 Subjects investigated for association between DDAH2 polymorphisms and 
endothelial function
Healthy subjects (Cambridge Young Adults Study cohort)
Blood was collected from 264 healthy subjects from the Cambridge Young Adults 
Study recruited by Dr. Paul Leeson and Professor J. Deanfield (Chapter 2.2.12.1). DNA 
was extracted using the Qiagen DNA purification kit method described in Chapter
2.2.1.2 and genotyped for the -1151 A/C and the -871 6G/7G polymorphisms. 
Measures of endothelium dependent and independent (mediated by GTN) vascular 
responses were performed using high-resolution ultrasound imaging (Leeson et al., 
2002). In each subject a fasting venous blood sample was analysed for total cholesterol, 
HDL, LDL and triglycerides. Blood pressure and weight were also recorded.
Healthy subjects (Pregnancy cohort)
A cohort of women with normal singleton pregnancies was investigated for association 
between DDAH2 genotype and endothelial function (Chapter 2.2.12.4). Common 
genetic variation in the eNOS gene had previously been associated with endothelial 
function in this cohort (Sawidou et al., 2001). Briefly, 139 unrelated Caucasian women 
with normal singleton pregnancies were recruited from the Harris Birthright Centre 
antenatal clinic by Dr. M Sawidou (Sawidou et al., 2001). All were healthy and had 
no history of cardiovascular disease. Age, smoking status, blood pressure (average of 
three seated readings), FMD, gestational age, parity and heart rate were recorded 
(Sawidou et al., 2001). DNA was extracted from whole blood using the Qiagen DNA 
purification kit method (Chapter 2.2.1.2) and genotyped for the -1020C/G, -1151 A/C 
and the -871 6G/7G polymorphisms.
238
Disease subjects (EBCT cohort)
DNA from the EBCT cohort of 385 individuals, comprising 188 type I diabetic patients 
and 197 control subjects recruited by Dr. H Colhoun (Chapter 2.2.12.3) was analysed 
for association between the -1020C/G and -1151 A/C DDAH2 polymorphisms and 
endothelial function (assessed by venous occlusion plethysmography) as well as for 
other relevant cardiovascular disease phenotypes or risk factors (Chapter 2.2.12.3). The 
EBCT cohort was recruited with the primaiy aim of examining the effect of type I 
diabetes on coronary artery calcification (CAC) assessed by electron beam 
computerised tomography (EBCT), a surrogate marker of coronary artery 
atherosclerosis (Colhoun et al., 2000). Type I diabetic subjects with age of onset <25 
years were recruited from five London hospitals. Control subjects were drawn from 
two London general practices and were included regardless of heart disease.
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Cohort Description of 
Cohort
Blood pressure Endothelial
function
NOx Polymorphism 
-449 -1020 -1151 -871 
C/G C/G C/A 6G/7G
HEALTHY
Middle Age: 
NPHSII
(Northwick Park 
Heart Study II)
Subjects selected 
from the Chesterfield 
(n=260) + N.Mymms 
(n=290) clinics
+ + + + +
Young:
Cambridge Young 
Adults Study
264 healthy subjects +
*
+ + +
Pregnancy Cohort 
DISEASE
139 Caucasian women 
with normal pregnancies
+ *+ + + +
EBCT (Diabetics+ 
Controls)
188 type 1 diabetics+ 
197 controls
+ +* + + +
Table 9.1 Summary of cohorts genotyped for association between DDAH2 polymorphisms and various risk factors for 
CVD. Risk factors and polymorphisms analysed for each cohort are indicated by +. * Measured by FMD ^ Measured by venous 
occlusion plethysmography.
9.3.3 Genotyping DDAH2 polymorphisms
Subjects were genotyped for the -449G/C, -1151 A/C and -1020C/G polymorphisms by 
PCR-RFLP analysis as described in Chapter 6.3.7. The -871 6G/7G polymorphism was 
genotyped by Genescan analysis as described in Chapter 6.3.7.
9.3.4 Measurement of plasma nitrite and nitrate (NOx)
Plasma NOx concentrations were measured in collaboration with Dr. Noor 
Jeerooburkhan (UCL) by the Griess reaction, in individuals from the Chesterfield 
(n=260) and North Mymms (n=290) clinics of the NPHSII cohort as described in 
Chapter 2.2.9. Briefly, plasma samples were filtered using Ultrafree microcentrifuge 
filter units (Biomax-5, Millipore) to remove proteins such as Hb, which could interfere 
with the reaction. NO3 ' was reduced to N 02‘ by the addition of nitrate reductase in the 
presence of NADPH, glucose-6 -phosphate and glucose-6 -phosphate dehydrogenase. 
Upon addition of sulphanilic acid the N 02' formed a diazonium salt, which when 
coupled with NED produced a purple chromophore. The absorbance measured at 
540nm is proportional to the amount of N 02* in the plasma sample. The lower limit of 
detection for this assay was 0.5pM, with an inter-assay variation of 4% and intra-assay 
variation of 3.4%.
9.3.5 Statistical Analysis
Observed numbers of each genotype were compared with those expected under the 
assumption of Hardy-Weinberg equilibrium by x2analysis. Allele frequencies were
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deduced from genotype frequencies. Plasma NOx concentrations and cardiovascular 
risk factors are represented as mean (SD) or mean (SEM) and allelic associations were 
examined by parametric or non-parametric tests where appropriate. Endothelial function 
measured by FMD was expressed as the mean (SD) % change in diameter. Endothelial 
function measured by venous occlusion plethysmography was represented as mean 
(SEM) % change in flow in response to intra-brachial infusion of acetylcholine (ACh) at 
doses 25, 50 and 100 nmol/min each dose for 3 minutes, bradykinin (BK) at doses 10, 
30 and lOOpmol/min each dose for 3 minutes, glyceryl trinitrate (GTN) at doses 4, 8  and 
16 nmol/min each dose for 5 minutes, Nc-monomethyl-Larginine (LNMMA) at doses 1, 
2 and 4jimol/min each dose for 5 minutes and noradrenaline (NA) at doses 60, 120 and 
240pmol/min each dose for 5 minute as described previously by Chan et al., 2003. The 
mean blood flow for each drug dose was assessed in each genotype group. From this, 
the difference in response between genotypes is expressed as the percentage difference 
in absolute flow in the presence of the drug, adjusted for baseline flow and averaged 
across three drug doses using the repeated-measures analysis of covariance model 
(XTREG procedure in STATA 6 ) with the data log transformed as appropriate 
(Statistical analysis was carried out by Miss Shona Livingstone, UCL).
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9.4 Results
9.4.1 Genotype and allele frequencies of DDAH2 polymorphisms in each study
cohort.
The allele frequencies for the -449G/C, -1020C/G, -1151 A/C and -871 6G/7G 
polymorphisms for each cohort are shown in table 9.2. Genotype frequencies did not 
differ from those expected under Hardy-Weinberg equilibrium except for the -871 
6G/7G polymorphism in the Cambridge Young Adults cohort (%2 =183.3, P=<0.05, table 
9.2). Repeat genotyping and DNA sequencing ruled out mis-typing as the cause of 
deviation from the Hardy-Weinberg equilibrium in this cohort.
Polymorphism
-449G/C
G(%) C(%)
x2 (P)
-1020C/G
C(%) G(%)
x2 (P)
-1151A/C
A(%) C(%)
x2 (P)
-871 6G/7G
6G(%) 7G(%)
x2 (P)
NPHSII
66.0 34.0 
0.6 (0.42)
88.0 12.0 
0.0 (0.89)
69.0 31.0 
0.3 (0.60) «
Cambridge 
Young Adults -
86.0 14.0 
0.4 (0.52)
71.0 29.0
3.0 (0.08)
90.0 10.0 
183.3 (<0.05)*
Pregnancy -
87.0 13.0 
0.3 (0.60)
67.0 33.0 
0.8 (0.37)
99.0 1.00 
0.0 (0.86)
EBCT -
92.0 8.00 
3.7 (0.06)
56.0 44.0 
2.5 (0.12) -
Table 9.2. Tests for Hardy-Weinberg equilibrium in four cohorts in which NOx or 
endothelial function was assessed. All polymorphisms were in Hardy-Weinberg 
equilibrium except the -871 6G/7G in the Cambridge Young Adults Study cohort 
(*P<0.05).
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9.4.2 Relationship between DDAH2 genotype and plasma NOx in the NPHSII
cohort.
Patients from two clinics o f the prospective NPHSII study cohort were analysed for 
association between DDAH2 genotype and plasma nitrite and nitrate (NOx) 
concentrations. Plasma NOx measurements were successful in 235 individuals out of 
260 from the Chesterfield cohort and 287 individuals out of 290 from the North 
Mymms cohort. Plasma NOx exhibited a skewed (to the right) distribution with median 
(IQR) of 9.21pmol/l (7.26-12.66) for the Chesterfield and 11.22pmol (9.10-14.65) for 
the North Mymms clinics respectively.
Subjects were genotyped for the -449G/C, -1020C/G and -1151 A/C DDAH2 
polymorphisms and analysed for association between genotype and plasma NOx 
(Tables 9.3a-c). Due to the small number of rare homozygotes (GG) for the -1020C/G 
polymorphism, heterozygotes and rare homozygotes were grouped and analysed 
together. A significant association was observed between -1020C/G genotype and 
plasma NOx in the Chesterfield clinic only (*P=0.01, table 9.3b). Individuals carrying 
the G allele had higher average plasma NOx than CC homozygotes. No association was 
observed between DDAH2 genotype and plasma NOx after combining the Chesterfield 
and North Mymms clinics (TP=0.59, table 9.3d).
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9.4.2.1 DDAH2 genotype and blood pressure in the NPHSII cohort
No statistically significant association was observed between genotype and blood 
pressure in either the North Mymms or Chesterfield subjects (Tables 9.3a-c, P>0.05) or 
when both clinics were combined (Table 9.3d, P>0.05).
Genotype ~^ 449G/C
GG
Mean (SD)
GC
Mean (SD)
CC
Mean (SD)
P
Chesterfield N=69 N=73 N=19
NOx (pmol/1)
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Cholesterol (mmol/1)
10.08 (4.82) 
141.3 (15.23) 
87.51 (11.40) 
5.78(1.06)
10.47 (6.02) 
139.3 (15.78) 
86.68 (10.52) 
5.82(1.14)
9.98 (4.27) 
143.2 (20.05) 
89.93 (11.51) 
5.74(1.14)
0.95*
0.57
0.52
0.96
North Mymms N=117 N=ll l N=35
NOx (pmol/1)
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Cholesterol (mmol/1)
12.23 (4.97) 
138.7 (20.74) 
85.82(11.09) 
5.88(1.91)
13.10(9.59) 
135.5 (19.78) 
84.90 (10.44) 
5.70 (0.92)
12.63 (4.90) 
133.3 (20.02) 
81.36(11.90) 
5.90 (0.85)
0.38*
0.28
0.12
0.27
Table 9.3a. Plasma NOx, systolic blood pressure (SBP), diastolic blood pressure 
(DBP) and cholesterol according to -449 G/C genotype for the Chesterfield (top) 
and North Mymms (bottom) NPHSII clinics. Genotyping was successful in 161 
subjects out of 235 with NOx measurements in the Chesterfield clinic and 263 subjects 
out of 287 in the North Mymms clinic. No statistical significant association was 
observed between genotype and NOx (*by Kruskal-Wallis test), blood pressure or 
cholesterol (by One-way ANOVA).
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Genotype -1020C/G
CC 
Mean (SD)
CG+GG 
Mean (SD)
P
Chesterfield N=128 N=40
NOx (pmol/1) 9.69 (5.33) 11.51 (4.8) 0.01*
Systolic BP (mmHg) 139.5 (16.88) 143.5(14.10) 0.18
Diastolic BP (mmHg) 86.55 (11.28) 88.82 (9.81) 0.26
Cholesterol (mmol/1) 5.76(1.15) 5.82 (0.87) 0.77
North Mymms N=214 N=62
NOx (pmol/1) 12.94 (7.56) 11.74 (5.5) 0.21*
Systolic BP (mmHg) 137.1 (20.87) 133.9 (18.30) 0.27
Diastolic BP (mmHg) 84.68(11.56) 85.18(9.91) 0.76
Cholesterol (mmol/1) 5.82 (0.88) 5.70 (0.93) 0.36
Table 9.3b. Plasma NOx, systolic blood pressure (SBP), diastolic blood pressure 
(DBP) and cholesterol according to -1020 C/G genotype for the Chesterfield (top) 
and North Mymms (bottom) NPHSII clinics. Genotyping was successful in 168 
subjects out of 235 with NOx measurements in the Chesterfield clinic and 276 subjects 
out of 287 in the North Mymms clinic. CG and GG individuals were analysed together 
because of the small number of GG homozygotes identified (n=3 Chesterfield, n=4 
North Mymms). No statistically significant association was observed between genotype 
and blood pressure or cholesterol in the Chesterfield or North Mymms clinics (P>0.05, 
Students t test). A significant association was observed between genotype and plasma 
NOx in the Chesterfield cohort only (*by Mann-Whitney test).
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Genotype -1151 A/C
AA
Mean (SD)
AC
Mean (SD)
CC
Mean (SD)
P
Chesterfield N=82 N=72 N=14
NOx (pmol/1)
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Cholesterol (mmol/1)
10.00 (4.78) 
140.4(15.66) 
86.94(11.27) 
5.81 (1.07)
10.26 (6.06) 
140.3 (16.78) 
86.38 (10.41) 
5.77(1.13)
9.65 (3.47) 
140.9 (19.38) 
90.41 (11.93) 
5.81 (1.29)
0.98*
0.99
0.45
0.97
North Mymms N=134 N=112 N=30
NOx (pmol/1)
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Cholesterol (mmol/1)
12.35 (5.02) 
138.3 (21.80) 
85.69(12.23) 
5.84 (0.87)
13.25 (9.65) 
135.3 (19.46) 
84.52 (9.71) 
5.76 (0.97)
11.76(4.11) 
134.9(18.54) 
83.50(11.52) 
5.72 (0.74)
0.71*
0.47
0.54
0.68
Table 9.3c. Plasma NOx, systolic blood pressure (SBP), diastolic blood pressure 
(DBP) and cholesterol according to -1151 A/C genotype for the Chesterfield (top) 
and North Mymms (bottom) NPHSII clinics. Genotyping was successful in 140 
subjects out of 235 with NOx measurements in the Chesterfield clinic and 276 subjects 
out of 287 in the North Mymms clinic. No statistically significant association was 
observed between genotype and NOx (*by Kruskal-Wallis test), blood pressure or 
cholesterol (by One-way ANOVA).
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Genotype —449G/C
GG
Mean (SD)
GC
Mean (SD)
CC
Mean (SD)
P
Combined clinics N=186 N=184 N=54
NOx (pmol/1) 11.52 (5.01) 12.10(8.50) 11.68(4.82) 0.48*
Systolic BP (mmHg) 139.7(18.88) 137.0 (18.34) 136.8 (20.41) 0.33
Diastolic BP (mmHg) 86.45(11.20) 85.61 (10.48) 84.37 (12.37) 0.45
Cholesterol (mmol/1) 5.85 (0.97) 5.75 (1.01)
Genotype -1020C/G
5.84 (0.95) 0.61
CC
Mean (SD)
CG+GG 
Mean (SD)
P
Combined clinics N=342 N=102
NOx (jimol/1) 11.79 (7.02) 11.66 (5.25) 0.59*
Systolic BP (mmHg) 138.0(19.48) 137.6(17.35) 0.86
Diastolic BP (mmHg) 86.38(11.47) 86.60 (9.98) 0.33
Cholesterol (mmol/1) 5.79 (0.99) 5.75 (0.90) 
Genotype-1151 AC
0.65
AA
Mean (SD)
AC
Mean (SD)
CC 
Mean (SD)
P
Combined clinics N=216 N=184 N=44
NOx (pmol/l) 11.54 (5.05) 12.12(8.57) 11.07(4.00) 0.76*
Systolic BP (mmHg) 139.1 (19.68) 137.3 (18.57) 136.8(18.80) 0.58
Diastolic BP (mmHg) 86.16(11.86) 85.25 (10.00) 85.70(11.97) 0.71
Cholesterol (mmol/1) 5.83 (0.95) 5.76(1.03) 5.75 (0.94) 0.75
Table 9.3d. Plasma NOx, systolic blood pressure (SBP), diastolic blood pressure 
(DBP) and cholesterol according to -449G/C (top), -1020C/G (middle) and -1151 
A/C (bottom) genotype for the combined Chesterfield and North Mymms NPHSII 
clinics. No statistically significant association was observed between genotype and 
NOx, blood pressure or cholesterol by One-way ANOVA or Student t-test unless 
otherwise stated. *Kruskal-Wallis test, ^Mann-Whitney test.
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9.4.3 Relationship between DDAH2 genotype and endothelial function in the 
Cambridge Young Adults Study
9.4.3.1 Baseline demographic details the Cambridge Young Adults Study
Characteristics of the study cohort according to DDAH2 genotype are shown in tables 
9.4a-c. No statistically significant association was observed between genotype and 
blood pressure, total cholesterol, HDL or LDL (P>0.05).
9.4.3.2 DDAH2 genotype and endothelial function
Subjects from the Cambridge Young Adults Study cohort comprising 264 healthy 
individuals were analysed for association between genotype and endothelial function. 
A total of 258 out of 264 individuals recruited were genotyped for the DDAH2 -  
1020C/G and -1151 A/C polymorphisms, and 261 individuals genotyped for the -871 
6G/7G polymorphism and analysed for association with endothelium-dependent and 
independent (GTN mediated) FMD of the brachial artery. No association was observed 
between DDAH2 genotype and either endothelium-dependent FMD or endothelium- 
independent (GTN mediated) dilation (Table 9.4a-c, P>0.05). Furthermore, no 
association was observed between genotype and endothelial function after 
heterozygotes and rare homozygotes were grouped together for both the -1151 A/C and 
-871 6G/7G polymorphisms (P>0.05, Students t test).
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Genotype -1020C/G
CC
Mean (SD)
N=188
CG+GG
Mean (SD)
N=70
P
Age-years 23.44(1.87) 23.7(1.90) 0.33
Systolic BP-mmHg 125.4 (14.44) 125.7(13.18) 0.86
Diastolic BP-mmHg 70.39 (10.09) 70.55 (8.88) 0.91
Cholesterol-mmol/1 4.62(1.06) 4.55 (0.87) 0.65
LDL cholesterol-mmol/1 2.88 (0.96) 2.78 (0.75) 0.43
HDL cholesterol -mmol/1 1.19(0.29) 1.21 (0.31) 0.77
FMD-% change 3.41 (2.69) 3.41 (3.37) 0.99
GTN -% change 21.20 (7.86) 22.35 (7.53) 0.31
Table 9.4a Endothelium-dependent and independent FMD and other CVD risk 
factors according to -1020C/G genotype in the Cambridge Young Adults Study 
cohort. Due to the small number of GG individuals (N=4) CG+GG individuals were 
grouped together. No significant difference was observed between genotype and either 
blood pressure, cholesterol or endothelium-dependent or independent dilation (by 
Students t test).
Genotype -1151 A/C
AA AC CC
Mean (SD) Mean (SD) Mean (SD) P
N=136 N=95 N=27
Age-years 23.67(1.95) 23.30(1.86) 23.29(1.49) 0.29
Systolic BP-mmHg 125.5 (15.29) 126.7 (15.00) 125.1(14.83) 0.80
Diastolic BP-mmHg 69.85 (8.66) 70.50 (10.38) 72.50(12.56) 0.43
Cholesterol- mmol/1 4.62 (0.93) 4.47 (0.98) 4.88 (1.44) 0.15
LDL cholesterol-mmol/1 2.88 (0.85) 2.73 (0.88) 3.06(1.24) 0.20
HDL cholesterol-mmol/1 1.18 (0.29) 1.22 (0.29) 1.22 (0.35) 0.56
FMD-% change 3.56 (3.19) 3.22 (2.59) 2.94 (2.30) 0.49
GTN-% change 22.40 (7.64) 20.99 (8.02) 18.62 (6.56) 0.05
Table 9.4b Endothelium-dependent and independent FMD and other CVD risk 
factors according to -1151 A/C genotype in the Cambridge Young Adults Study 
cohort. No significant difference was observed between genotype and either blood 
pressure, cholesterol or endothelium-dependent or independent dilation (by One-Way 
ANOVA).
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Genotype -871 6G/7G
6G/6G 6G/7G 7G/7G
Mean (SD) Mean (SD) Mean (SD) P
N=230 N=8 N=23
Age-years 23.43 (1.84) 24.75 (2.12) 23.68 (2.08) 0.13
Systolic BP-mmHg 125.7 (15.08) 130.5 (15.91) 123.0(13.37) 0.48
Diastolic BP-mmHg 70.33 (9.57) 74.50 (14.74) 68.00 (9.12) 0.27
Cholesterol-mmol/1 4.59(1.02) 4.85 (0.45) 4.46(1.16 0.64
LDL cholesterol-mmol/1 2.82 (0.91) 3.28 (0.36) 2.85 (0.98) 0.37
HDL cholesterol-mmol/1 1.21(0.29) 1.11 (0.22) 1.06 (0.26) 0.06
FMD-% change 3.31 (2.92) 3.72 (2.1) 4.11 (2.83) 0.46
GTN-% change 21.33 (7.67) 22.57 (7.27) 23.18(9.282) 0.55
Table 9.4c Endothelium-dependent and independent FMD and other CVD risk 
factors according to -871 6G/7G genotype in the Cambridge Young Adults Study 
cohort. No significant difference was observed between genotype and either blood 
pressure, cholesterol or endothelium-dependent or independent dilation (by One-Way 
ANOVA).
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9.4.4 Relationship between DDAH2 genotype and endothelial function in
women with normal pregnancies
9.4.4.1 Baseline demographics of the pregnancy cohort
The characteristics of the study cohort according to DDAH2 genotype are shown in 
tables 9.5a-c. No significant association was observed between genotype and age, 
blood pressure, cholesterol, gestational age or parity in this cohort (Tables 9.5a-c, 
P>0.05).
9.4.4.2 DDAH2 genotype and endothelial function
139 women with normal singleton pregnancies were genotyped for the DDAH2 -  
1020C/G, -1151 A/C and the -871 6G/7G polymorphisms and analysed for association 
between genotype and endothelial-dependent FMD. The results show both FMD 1 
minute after cuff deflation and the maximum FMD recorded. Genotyping was 
successful in 137 individuals for the -1020C/G polymorphism and 136 individuals for 
the -1151 A/C and -871 6G/7G polymorphism. No association was observed between 
DDAH2 genotype and endothelium-dependent FMD in this cohort (Table 9.5a-c, 
P>0.05).
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Genotype -1020C/G
CC
Mean (SD)
N=105
CG+GG
Mean (SD)
N=32
P
Age (Y ears) 32.02 (4.83) 33.16(4.36) 0.24
Systolic BP (mmHg) 115.0 (9.87) 117.0 (11.40) 0.32
Diastolic BP (mmHg) 69.48 (6.54) 78.5 (14.20) 0.87
Cholesterol (mmol/1) 5.11 (0.78) 5.12 (0.88) 0.94
Gestational age (weeks) 20.76 (11.66) 21.38(12.45) 0.79
Parity (N) 0.72 (0.82) 0.78(1.16) 0.73
FMD at 1 minute
(% change) 
FMD max
3.55 (0.56) 3.46 (0.45) 0.43
(% change) 9.36 (3.50) 9.31 (2.63) 0.94
Table 9.5a Endothelium-dependent FMD and other CVD risk factors according to -  
1020C/G genotype in the Pregnancy cohort. Due to the small number of GG individuals 
(N=3), CG+GG individuals were grouped together. No significant association was found 
between genotype and age, blood pressure, cholesterol, gestational age, parity or FMD (by 
Students t test).
Genotype -1151 A/C
AA AC CC P
Mean (SD) Mean (SD) Mean (SD)
N=58 N=65 N=13
Age (Years). 32.66 (4.82) 32.12(4.41) 31.31 (6.36) 0.62
Systolic BP (mmHg) 115.0 (8.5) 116.2 (11.81) 113.9 (9.723) 0.69
Diastolic BP (mmHg) 68.43 (13.7) 69.31 (7.30) 66.92 (5.88) 0.72
Cholesterol (mmol/1) 5.15 (0.81) 5.15(0.81) 4.60 (0.65) 0.06
Gestational age (weeks) 19.87 (12.27) 21.17(11.17) 21.44 (14.68) 0.80
Parity (N) 0.91 (1.08) 0.64 (0.78) 0.38(0.51) 0.09
FMD at 1 minute
(% change) 3.59 (0.66) 3.43 (0.43) 3.69 (0.35) 0.14
FMD max
(% change) 9.25(3.37) 9.64 (3.30) 8.63 (3.07) 0.56
Table 9.5b Endothelium-dependent FMD and other CVD risk factors according to -  
1151 A/C genotype in the Pregnancy cohort. No significant association was found between 
genotype and age, blood pressure, cholesterol, gestational age, parity or FMD (by One-Way 
ANOVA).
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Genotype-871 6G/7G
6G/6G 
Mean (SD)
N=132
6G/7G 
Mean (SD)
N=4
P
Age (Years) 32.41 (4.56) 27.75 (8.22) 0.05
Systolic BP (mmHg) 115.5(10.23) 113.9(13.49) 0.75
Diastolic BP (mmHg) 68.80(10.51) 68.75 (9.07) 0.99
Cholesterol (mmol/1) 5.10(0.81) 5.38 (0.63) 0.49
Gestational age (weeks) 20.75 (11.77) 23.13 (14.81) 0.69
Parity (N) 0.75 (0.92) 0.25 (0.50) 0.28
FMD at 1 minute
(% change) 
FMD max
3.52 (0.54) 3.84 (0.20) 0.32
(% change) 9.38 (3.33) 8.03 (2.71) 0.43
Table 9.5c Endothelium-dependent FMD and other CVD risk factors according to -871 
6G/7G genotype in the Pregnancy cohort. No 7G/7G homozygotes were identified in this 
cohort. No significant association was found between genotype and age, blood pressure, 
cholesterol, gestational age, parity or FMD (by Students t test).
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9.4.5 Relationship between DDAH2 genotype and endothelial function in the
EBCT cohort.
9.4.5.1 Baseline demographics of the EBCT cohort.
Demographic characteristics according to DDAH2 genotype of the EBCT cohort are 
shown in tables 9.6a and 9.6b. No significant association was found between DDAH2 
genotype and risk factors for cardiovascular disease including age, sex, smoking status, 
total cholesterol, HDL and blood pressure (P>0.05, tables 9.6a and 9.6b). However, a 
significant difference in allele distribution was observed between type I diabetics and 
non-diabetics for both the -1020C/G and -1151 A/C polymorphisms (Table 9.7). The 
rare allele G for the -1020 polymorphism was less frequent amongst diabetics 
(*P=0.0001), and the rare allele C for the -1151 polymorphism was found to be less 
frequent amongst non-diabetics (*P=0.0001).
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Genotype -1151 A/C
AA
Mean (SEM)
AC
Mean (SEM)
CC
Mean (SEM)
P
N=112 N=205 N=68
Age (Years) 38.0 (0.36) 37.8 (0.28) 37.9 (0.5) 0.83
Sex- Number (%) 0.30
Men
Women
63 (55.3) 
51 (44.74)
99 (48.3) 
106 (51.7)
30(44.12) 
38 (55.9)
Smoking status - Number (%) 0.40
Current
Past
Never
32 (28.1) 
23 (20.3) 
59 (51.8)
52 (25.4) 
52 (25.4) 
101 (49.3)
13(19.12) 
22 (32.4) 
33 (48.53)
Cholesterol (mmol/1) 
HDL (mmol/1) 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Calcification
5.5 (0.1)
1.7 (0.04)
118.5 (1.36) 
72.4 (0.89) 
48 (42.86)
5.5 (0.9)
1.8 (0.03) 
122.2 (0.96) 
74.0 (0.62) 
89 (44.28)
5.3 (0.13) 
1.8 (0.06) 
122.1 (1.81) 
72.7(1.16) 
29 (42.65)
0.46
0.17
0.07
0.27
0.96
Table 9.6a Demographic characteristics of the EBCT cohort according to -  
1X51 A/C genotype. Data are presented as mean (SEM). No significant association was 
found between genotype and age, sex, smoking status, cholesterol, blood pressure or 
coronary artery calcification (by One-Way ANOVA).
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Genotype -1020C/G
CC CG GG
Mean (SEM) Mean (SEM) Mean (SEM)
N=327 N=53 N=5
Age- Years 37.8 (0.22) 38.6 (0.6) 38.2(1.42) 0.31
Sex- Number (%) 0.65
Men 159(48.6) 29 (54.7) 2 (40.0)
Women 168 (51.4) 24 (45.3) 3 (60.0)
Smoking status - Number (%) 0.17
Current 79 (24.2) 18(34.0) 0 (0.00)
Past 83 (25.4) 10 (19.0) 3(60.0)
Never 165 (50.5) 25 (47.2) 2 (40.0)
Cholesterol -mmol/1 5.4 (0.07) 5.5 (0.15) 5.3 (0.39) 0.73
HDL -mmol/1 1.8(0.03) 1.9(0.05) 1.5 (0.11) 0.16
Systolic BP-mmHg 121.6 (0.79) 118.9(2.0) 117.2 (6.03) 0.36
Diastolic BP-mmHg 73.2 (0.5) 74.3 (1.33) 70.9(4.12) 0.60
Calcification 143 (43.7) 22(41.5) 2 (40.0) 0.97
Table 9.6b Demographic characteristics of the EBCT cohort according to -  
1020C/G genotype. Data are presented as mean (SEM). No significant association 
was observed between genotype and age, sex, smoking status, cholesterol, blood 
pressure or coronary artery calcification (by One-Way ANOVA).
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AA
n (%)
-1151A/C
AC
n(%)
CC
n (%)
CC
n (%)
-1020C/G
CG
n (%)
GG
n(%)
Diabetic 33 (17.37) 114(60.0) 43 (22.63) 175 (93.09) 12 (6.38) 1 (0.53)
Non-diabetic 81 (41.12) 91 (46.19) 25 (12.69) 152 (77.16) 41 (20.81) 4 (2.03)
Significance *P=0.0001 *P=0.0001
Table 9.7 Distribution of -1151 A/C and -1020C/G alleles according to diabetic status. The rare allele G for the -1020 
polymorphism was less frequent amongst diabetics compared to non-diabetics (*P=0.0001), and the rare allele C for the —1151 
polymorphism was found to be less frequent amongst non-diabetics (*P=0.0001).
9.4.5.2 DDAH2 genotype and endothelial function
385 individuals (188 type 1 diabetics, 197 controls) were genotyped for the DDAH2 -  
1151 A/C and -1020C/G polymorphisms and investigated for association between 
genotype and endothelium-dependent and independent vascular response as measured 
by venous occlusion plethysmography. Genotyping was successful in all 385 subjects 
for the -1020C/G polymorphism and the -1151 A/C polymorphism. Flow responses to 
incremental doses of ACh, BK (endothelium-dependent dilators), GTN (endothelium- 
independent dilator), LNMMA (endothelium-dependent constrictor) and NA 
(endothelium-independent constrictor) are shown in figures 9.1a and 9.1b according to 
DDAH2 -1020C/G and -1151 A/C genotype. Overall, no difference was observed in 
endothelium-dependent dilator responses between genotypes either before or after 
adjustment for age and sex (P>0.05, figures 9.1a and 9.1b). Neither was any significant 
difference in vascular function detected when subjects were divided by diabetic or 
smoking status (appendix 3, tables 1-4). A weak but statistically significant difference 
in endothelium-independent response (GTN mediated) was observed between - 1 151AA 
and -115ICC genotypes (*P=0.02, figure 9.1a). This was also observed when diabetics 
and non-smokers were analysed separately (P=0.02 and P=0.03 respectively, appendix 
3; table 1 and 3). A small but significant difference between genotypes was observed 
for LNMMA response between -1020 CC and GG diabetic subjects (*P=0.04, appendix 
3; table 2).
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Figure 9.1a Endothelium-dependent and independent vascular responses 
according to -1151 A/C genotype in the EBCT cohort. Data are presented as mean 
(SEM) % change in flow of infused/non-infused arm during drug treatment after 
adjustment for baseline flow. Genotypes AC and CC are compared to AA by multiple 
logistic regression and data are adjusted for age and sex. No significant difference in 
endothelium-dependent vascular response was observed between genotypes after 
infusion with acetylcholine (ACh) and bradykinin (BK) (P>0.05). A significant 
difference was observed between genotypes AA and CC for endothelium- independent 
response after infusion o f glyceryltrinitrate (GTN) (*P=0.02). No difference was 
observed in response to LNMMA or noradrenaline (NA) (P>0.05).
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Figure 9.1b Endothelium-dependent and independent vascular responses 
according to -1020C/G genotype in the EBCT cohort. Data are presented as mean 
(SEM) % change in flow of infused/non-infused arm in response to drug dosage. 
Genotypes CG and GG are compared to CC by multiple logistic regression and data are 
adjusted for age and sex. No significant difference in vascular response was observed 
between genotypes after infusion with acetylcholine (ACh), bradykinin (BK), 
glyceryltrinitrate (GTN), LNMMA or noradrenaline (NA) (P>0.05).
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9.5 Discussion
During this study the association between DDAH2 genotype and plasma NOx was 
investigated in a subset of healthy individuals selected form the NPHSII cohort. The 
relationship between DDAH2 genotype and endothelial function was also explored in a 
cohort of 264 healthy individuals from the Cambridge Young Adults Study, 139 women 
with normal pregnancies and a cohort comprising 188 type I diabetics and 197 control 
subjects. The relationship between DDAH2 genotype and other relevant risk factors for 
the development of CVD was also investigated in each cohort.
9.5.1 DDAH2 genotype and plasma concentrations of NOx in the NPHSII cohort
During this study an association was observed between the DDAH2 -1020C/G 
polymorphism and plasma NOx in subjects recruited from the Chesterfield clinic of the 
NPHSH cohort. However, failure to detect any association between genotype and NOx 
in the North Mymms clinic or when both clinics were combined indicates that this data 
needs to be interpreted with caution. These conflicting results could be due a lack of 
statistical power, differences in dietary NOx intake or undetected inflammatory 
processes, which would obscure any associations due to production of NO from other 
NOS isoforms. Alternatively, genetic variation within other genes that influence 
circulating NO may mask any association between DDAH2 genotype and plasma NOx. 
DDAH2 enzyme activity would be expected to affect NO synthesis indirectly via 
ADMA, therefore any influence of DDAH2 on NO levels may be masked by other 
factors that affect circulating ADMA such as PRMT activity and LDL cholesterol or 
renal function. Due to time constraints, the NPHSII cohort was not genotyped for the -
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871 6G/7G polymorphism, which in a lucuiferase promoter/reporter system 
demonstrated functionality when transfected into HUVEC (Chapter 7). Further studies 
to investigate the association between this variant (and differential DDAH2 expression) 
and plasma NOx in the NPHSH cohort are planned.
9.5.2 DDAH2 genotype and endothelial function
The second part of this study investigated the association between DDAH2 genotype 
and endothelial function. Endothelial dysfunction is an early marker of CVD and is 
thought to be a manifestation of deficient NO availability (Clarkson et al., 1997; Gaeta 
et al., 2000). Although no association was detected between DDAH2 genotype and 
ADMA concentration (Chapter 8), the hypothesis explored in this chapter was that 
DDAH2 polymorphisms effect local ADMA concentrations and through this, local NO 
availability and NO-dependent vasodilation. Three cohorts in whom endothelial 
function had been assessed previously were investigated. Firstly, no association was 
observed between DDAH2 genotype and NO-mediated endothelial function in a group 
of young healthy subjects from the Cambridge Young Adults Study cohort. This same 
cohort has previously been investigated for association between endothelial function 
and the eNOS Glu298Asp polymorphism. Overall, no association was observed 
between this variant and FMD (Leeson et al., 2002), however, FMD was lower in male 
smokers carrying the Asp allele, suggesting a potential eNOS genotype-environment 
interaction in this population, and supporting the potential for detecting gene effects on 
endothelial function in this group. In the present study, with a sample size of 264 
individuals, we had 80% power at 2P=0.05 to identify a 28% difference in FMD 
between groups.
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The second cohort studied were women with normal pregnancies. During normal 
pregnancy there is an increase in circulating blood volume and cardiac output and a 
decrease in blood pressure due to systemic vasodilation. Some evidence suggests that 
this vasodilation is due to an increase in NO availability (Nelson et al., 2000), and it has 
also been shown that the circulating levels of ADMA are significantly lower in pregnant 
women compared with non pregnant women, suggesting that systemic vasodilation 
during pregnancy maybe regulated by ADMA (Maeda et al., 2003). In keeping with 
this, ADMA levels are elevated in preeclampsia (Holden et al., 1998) and in women in 
early pregnancy prior to the development of preeclampsia (Sawidou et al., 2003). Also, 
ADMA concentrations in these women correlate with endothelial dysfunction 
(Sawidou et al., 2003). Therefore we tested the hypothesis that genetic variation in the 
DDAH2 gene, that alters DDAH2 transcription in vitro, may lead to differences in 
circulating ADMA levels, which, during pregnancy, might have an impact on maternal 
vascular endothelial function. However, during this study, no association was observed 
between DDAH2 genotype and endothelial function, which suggests genotype does not 
influence endothelial function in women with normal pregnancies. In addition genotype 
did not correlate with other parameters (such as cholesterol or blood pressure) that 
might influence FMD. The cause of elevated ADMA in these individuals is unknown 
but, as SDMA levels are unchanged, variation in DDAH2 expression or activity is a 
likely candidate. DDAH2 is highly expressed in the placenta and common genetic 
variation in the DDAH2 gene in this tissue may be important for differences in 
circulating levels of ADMA. Further work to characterise the expression of placental 
DDAH2 in women with preeclampsia and to determine the effects of DDAH2 variants 
in the susceptibility to preeclampsia is necessary.
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The final part of this study investigated the association between DDAH2 genotype and 
endothelial function in a cohort of diabetic patients and controls. A previous study in 
this cohort demonstrated dysfunction of endothelium-dependent vasodilation in diabetic 
subjects (Chan et al., 2003). However, the precise mechanisms behind endothelial 
dysfunction and increased risk of CVD seen in diabetics is still unknown. In this 
cohort, only -13%  of the variation in endothelial function could be explained by the 
presence of conventional CVD risk factors (Chan et al., 2001) suggesting, perhaps, that 
genetic and other influences may be important. However, during this study no 
association was observed between DDAH2 genotype and endothelium-dependent 
function either when the whole cohort was analysed or when diabetics and non-diabetics 
and smokers and non-smokers were analysed separately, suggesting that DDAH2 
genotype does not play a significant role in regulation of endothelial function in this 
cohort.
One interesting observation to emerge from this study was the difference in allele 
distribution between diabetics and non-diabetics for both the -1020C/G and -1151 A/C 
polymorphisms. However, this may be explained by the location of the DDAH2 gene 
within the MHC class HI region on chromosome 6, a region that has been strongly 
linked with typel diabetes in previous studies (Field, 2002). Therefore it is possible 
that these DDAH2 polymorphisms maybe acting as a marker for the presence of typel 
diabetes in this cohort.
In summary, no association was observed between DDAH2 genotype and endothelial 
function in young healthy subjects, in women with normal pregnancies or in a cohort of 
diabetic patients and controls. These data are in keeping with the findings of chapter 8
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in which no association was detected between DDAH2 genotype and ADMA 
concentration or ADMA/SDMA ratio. They are at odds however, with the findings of 
chapter 7 where in an in vitro reporter system, DDAH2 promoter genotype was found to 
alter promoter activity. Taken together, these observations indicate that, in the healthy 
state in vivof and despite the potential for DDAH2 genotype to modulate DDAH2 
transcription in vitro, it does not have a significant impact upon endothelial function. 
The reasons for this discrepancy between in vitro and in vivo observations are worthy of 
further investigation. Further research is also needed to ascertain whether DDAH2 
genotype is an important modulator of DDAH2 expression in the presence of other 
disorders or risk factors known to result in elevated circulating ADMA.
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CHAPTER 10 
GENERAL CONCLUSIONS
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Despite numerous scientific breakthroughs in the understanding of the complex nature of 
the cardiovascular system and its disorders, cardiovascular disease remains the UK’s 
biggest cause of mortality (BHF, 2003). It is fully recognized that environmental risk 
factors such as a diet rich in cholesterol, smoking and the presence of diseases such as 
diabetes and renal failure are major players in the cause of vascular disease. However a 
vast amount of evidence now implicates an individual’s genotype as a relevant determinant 
of disease development. Research into some rare monogenic disorders such as familial 
hypercholesterolaemia has helped to gain an insight into genes, which may be influential in 
the more complex multi-factorial vascular disease process. It is envisaged that each 
individual carries a complement of such common susceptibility alleles (‘a genetic load’) 
and that the interaction between susceptibility genes and the environment determines the 
development of cardiovascular disease.
A plethora of genes have been associated with carrying an increased risk of developing 
cardiovascular disease such as those involved in lipid metabolism, blood pressure 
regulation and coagulation (Nakai et al., 2002; Yamada et al., 2002). The essential role of 
the endothelium for the maintenance of a healthy vasculature has focused one area of the 
search on genes that are expressed by the endothelial cell. The discovery that one product 
of the endothelium, the simple gaseous molecule NO which, has many atheroprotective 
functions (Ignarro et al., 1987), has led to an explosion of research into the regulation of 
NO synthesis and degradation.
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During this study, genes encoding proteins in three different pathways implicated in the 
regulation of NO activity have been investigated. Firstly, inactivation of NO by 0 2‘ is 
thought to be one explanation for diminished endothelial function in some individuals 
(Kodja et al., 1999), and has prompted investigations into the enzymes responsible for 0 2' 
production such as NADPH oxidase. This study investigated the hypothesis that 
endothelium-dependent vaso-reactivity in healthy subjects would be dependent on genotype 
for the C242T polymorphism of the NADPH oxidase subunit - p22phox. The results 
demonstrated that a significant difference in endothelium-dependent vasodilation of the 
brachial artery does indeed exist between individuals of different genotype. Subjects who 
carried two copies of the 242T allele demonstrated augmented FMD of the brachial artery 
(an NO-dependent response) compared to subjects carrying the C allele. This implies that 
these individuals may have a preserved NO response due to decreased NADPH oxidase 
activity. A second study using venous occlusion plethysmography to assess endothelial 
function in the resistance arteries of the forearm, failed to reproduce this association in a 
case-control study of type 1 diabetic subjects. One potential explanation for this 
discrepancy is that endothelium-dependent vasodilation in resistance vessels is dependent 
more on the dilator substance EDHF than on NO.
The synthesis of NO from L-arginine requires BH4, an essential cofactor for the NOS 
enzymes. In a second study, the hypothesis that common genetic polymorphisms within 
the human GCH1 gene (the rate-limiting enzyme in the BH4 synthesis reaction) could 
influence pterin synthesis and endothelial function was explored. Three bi-allelic variants 
within the GCH1 promoter were identified, two of which correlated with plasma neopterin
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(an index of pterin pathway activity) in healthy subjects, suggesting the synthesis of the 
NOS cofactor BH4 is genetically determined. In addition, the finding that GCH1 genotype 
was associated with NO-mediated, endothelium-dependent vasodilation of the brachial 
artery supports further the hypothesis that GCH1 genotype can influence NO synthesis 
through the availability of BH4 . Future studies to investigate whether these GCH1 
promoter polymorphisms influence gene transcription, and therefore could account for the 
difference in neopterin seen in this study are needed. A system such as the luciferase 
reporter gene assay described in Chapter 7 will be used in this study.
Finally, the third series of investigations examined a pathway known to be involved in the 
regulation of NO synthesis through inhibition of NOS. The main objectives of this series 
of studies was to identify common polymorphisms in the DDAH2 gene and investigate the 
relationship between DDAH2 genotype and circulating levels of the NOS inhibitor ADMA. 
The relationship between DDAH2 genotype and conventional CVD risk factors including 
endothelial function was also explored. Elevated ADMA levels are a common feature in 
patients with vascular disease including diabetics, subjects with renal failure and 
preeclampsia. The identification of several polymorphisms within the DDAH2 promoter 
region, two of which are situated in transcription factor binding sequences, suggests that 
DDAH2 transcription could be genetically regulated. This hypothesis was explored by a 
promoter/reporter assay, which confirmed different promoter activities for the variant 
alleles at position -871. Disappointingly, the present study failed to identify any 
association between DDAH2 genotype and ADMA, ADMA/SDMA ratio or endothelial 
function, but given the rarity of the -871 variant among Caucasian subjects future large
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scale genotyping studies including a wide range of disease phenotypes may be required to 
fully test the hypothesis that this DDAH2 variant is an important determinant of vascular 
disease development.
To conclude, the findings of this study indicate that some, but not all, common genetic 
variation within genes involved in NO synthesis and inactivation are associated with 
differences in endothelial function that predates and predisposes to atherosclerosis. It is 
likely that a combination of polymorphisms in a wide variety of genes interact to compose 
the genetic element of CVD and these polymorphisms in turn are modulated by the 
environment. During this study the completion of the human genome project was 
announced, which together with advances in large-scale genotyping efforts makes the 
prospect of defining multiple gene-gene interactions and their impact on complex diseases a 
potentially realisable goal in the not too distant future.
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Appendix I
Hardy-Weinberg Principle
The relationship between the genotypic frequency and allelic frequency of a population was 
described by Godfrey Hardy and Wilhelm Heinberg in 1908, and became know as the 
Hardy-Weinberg principle. The principle states that after one generation o f random 
mating single locus genotypic frequencies can be represented as a function o f the allelic 
frequencies (Hardy, 1908). If a gene has two alleles designated A and a, then the frequency 
of these alleles in a population is p  and q respectively where p+q=l. If random mating 
occurs (i.e. random union of male and female gametes) then die frequency of the offspring 
will be as follows:
A (p)
Female gametes
A (q)
Male gametes 
A ip) a 0q)
AA (p2) Aa (pq)
Aa (pq) Aa (q2)
pz+2pq+q2=l
To determine whether the observed number of genotypes differs from those expected under 
the Hardy-Weinberg rule the Chi -square test (%2) is applied:
E
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Appendix II
Linkage disequilibrium
Two genes (or in the context of this thesis-polymorphisms) in relative close proximity on 
the same chromosome are said to be linked. The closer the polymorphisms are to one- 
another, the less likely genetic recombination between them during gamete formation.
Linkage disequilibrium (non-random association) between alleles of two polymorphisms 
was calculated by Chakravarti et al, 1984.
Two loci A and B each with two allelic variants A1A2 and B1B2 will result in the
production of gametes: A1B1, A1B2, A2B1, A2B2. The corresponding frequency of each
gamete will be; Pn=plql+A forA lBl
Pi2=plq2-A forAlB2
P2i=p2ql-A forA2Bl
P22=p2q2+A for A2B2
A measures the non-random association or linkage disequilibrium between alleles.
P_llP22rPl2P2}
A= V (Pll+Pl2)(P21+P22)(Pll+P2l)(Pl2+P22)
A values range between 0 and 1. The closer the A value is to 1 the more tightly linked the 
two loci. A negative A value indicates the rare allele at one loci is in complete linkage 
with the common allele at the second loci.
Appendix III
The difference in vascular responses between genotypes for Diabetics and non­
diabetics and smokers and non-smokers.
Genotype -1151 A/C 
Diabetics Non-Diabetics
AA versus 
AC
P coef(P)
AA versus 
CC
P coef (P)
AA versus 
AC
p coef(P)
AA versus 
CC
P coef (P)
Ach 0.08 (0.40) 0.12(0.29) 0.17(0.13) 0.15 (0.40)
BK -0.05 (0.45) -0.04 (0.60) -0.08 (0.36) -0.07 (0.61)
GTN -0.06 (0.29) -0.18 (0.02)* -0.01 (0.91) -0.13 (0.30)
NA 0.01 (0.78) -0.01 (0.8) 0.01 (0.80) 0.09 (0.18)
LNMMA 0.03 (0.34) -0.004 (0.91) -0.02 (0.48) -0.02 (0.70)
Table 1. Vascular response of Diabetic and Non-diabetic subjects according to -  
1151 A/C genotype. Vascular response in AA genotypes were compare with AC and CC 
genotypes. A significant difference in endothelium independent response was observed 
between individuals genotyped as AA compared to CC individuals in the diabetic patients 
only (*P=0.02). Data are adjusted for age and sex.
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Genotype -1020C/G
Diabetics Non-Diabetics
CC versus 
GC
P coef(P)
CC versus 
GG
P coef (P)
CC versus 
GC
p coef(P)
CC versus 
GG
p coef(P)
Ach -0.07 (0.63) -0.22 (0.52) 0.07 (0.56) -0.18(0.58)
BK -0.06 (0.57) -0.08 (0.75) 0.06 (0.48) -0.37(0.12)
GTN -0.04 (0.67) 0.22 (0.35) -0.00(0.98) -0.47 (0.02)*
NA 0.06 (0.35) -0.10(0.54) 0.00 (0.99) -0.07 (0.56)
LNMMA 0.03 (0.46) -0.19 (0.04)* 0.04(0.18) -0.01 (0.87)
Table 2. Vascular response of Diabetic and Non-diabetic subjects according to -
1020 C/G genotype. Vascular response in CC genotypes were compare with GC and GG 
genotypes. A significant difference in endothelium independent response was observed 
between individuals genotyped as CC compared to GG individuals in the Non-diabetic 
patients only (*P=0.02). A weak significance was also observed for LNMMA response 
between CC and GG diabetic subjects (*P=0.04). Data are adjusted for age and sex.
275
Genotype -1151 A/C
Smokers Non-Smokers
AA versus 
AC
p coef(P)
AA versus 
CC
p coef (P)
AA versus 
AC
p coef (P)
AA versus 
CC
p coef(P)
Ach 0.20 (0.19) 0.27 (0.23) 0.08 (0.29) 0.14(0.22)
BK 0.09 (0.36) 0.16(0.28) -0.12(0.06) -0.14(0.12)
GTN 0.06 (0.59) -0.15(0.32) -0.06 (0.25) -0.16(0.03)*
NA 0.08 (0.33) 0.13 (0.27) -0.002 (0.95) 0.01 (0.76)
LNMMA 0.01 (0.69) -0.02 (0.68) -0.01 (0.53) -0.001 (0.96)
Table 3. Vascular response of Smokers and Non-smokers according to -1151 
A/C genotype. Vascular response in AA genotypes were compare with AC and CC 
genotypes. A significant difference in endothelium independent response was observed 
between individuals genotyped as AA compared to CC individuals insmokers only 
(*P=0.03). Data are adjusted for age and sex.
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Genotype -1020C/G
Smokers Non-Smokers
CC versus 
CG
p coef(P)
CC versus 
GG
p coef(P)
CC versus 
CG
p coef(P)
CC versus 
GG
p coef(P)
Ach 0.24 (0.08) - -0.04 (0.69) -0.26 (0.24)
BK -0.05 (0.56) - 0.11 (0.22) -0.28 (0.12)
GTN -0.11 (0.23) - 0.06 (0.42) -0.22 (0.15)
NA 0.007 (0.92) - 0.03 (0.47) -0.09 (0.29)
LNMMA -0.01 (0.88) - 0.04 (0.15) -0.05 (0.38)
Table 4. Vascular response of Smokers and Non-smokers according to -1020 
C/G genotype. Vascular response in CC genotypes was compared with both GC and GG 
genotypes for Non-smokers. Vascular response of CC genotypes was compared to CG 
genotypes in smokers, no GG subjects were found among the smoking group. No 
difference in vascular response was observed between genotypes in either smokers or non- 
smokers. Data are adjusted for age and sex.
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